DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE

Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein-tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.

Description: DESCRIPTION DIABETES MELLΓTUS 37 DAUTOANTIGENPROTEIN-TYROSI EPHOSPHATASE BACKGROUND OF THE INVENTION Insulin-dependent diabetes mellitus (IDDM) is a disease resulting from the autoimmune destruction of the insulin-producing β-cells of the pancreas. Studies directed at identifying the autoantigen(s) responsible for β-cell destruction have generated several candidates, including poorly characterized islet cell antigens (ICA) (Bottazzo et al., Lancet 2 : 1279-83, 1974), insulin (Palmer et al. , Science 222 : 1337-39, 1983) , gluta ic acid decarboxylase (GAD) (Baekkeskov et al . , Nature 298 : 167- 69, 1982; Baekkeskov et al . , Nature 347: 151-56, 1990), and a 64 kD islet cell antigen that is distinct from GAD and that which yields 37 kD and 40 kD fragments upon trypsin-digestion (Christie et al. , Diabetes 41 : 782-87, 1992) . Detection of specific autoantigens in prediabetic individuals has been used as a predictive marker to identify, before clinical onset and significant β-cell loss has occurred, those at greater risk of developing IDDM (Gorsuch et al . , Lancet 2 : 1363-65, 1981; Baekkeskov et al. , J. Clin. Invest. 79: 926-34, 1987; Johnstone et al . , Diabetologia 32 : 382-86, 1989; Ziegler et al., Diabetes 38: 1320-25, 1989; Baekkeskov et al. , Nature (Lond) 347: 151-56, 1990; Bonifacio et al . , Lancet 335: 147-49, 1990; and Bingley et al . Diabetes 43 : 1304- 10, 1994) . Antibodies to the 40 kD, and more particularly the 37 kD, ICA fragments are detected when clinical onset of IDDM is imminent and are found to be closely associated with IDDM development (Christie et al . , Diabetes 41 : 782- 87, 1992) . Diabetic sera containing antibodies specific to the 40 kD fragment were recently found to bind to the intracellular domain of the protein tyrosine phosphatase, IA-2/ICA512 (Lu et al. , Biochem. Biophys. Res. Comm. 204 : 930-36, 1994; Lan et al . , DNA Cell Biol . 13: 505-14, 1994; Rabin et al . , J. Immunol . 152 : 3183-88, 1994; Payton et al . , J. Clinc. Invest. 96: 1506-11, 1995; and Passini et al., Proc. Natl . Acad. Sci. USA 92.: 9412-16, 1995) . Antibodies specific to the 37 kD fragment are thought to bind either to a posttranslational in vivo modification of IA-2/ICA512 or a different, but probably related, protein precursor (Passini et al . , ibid. ) . ICA 512 was initially isolated as an autoantigen from an islet cell cDNA library, and was subsequently shown to be related to the receptor-linked protein tyrosine phosphatase family (Rabin et al . , ibid. ) . ICA 512 was later found to be identical to a mouse and human protein tyrosine phosphatase, IA-2, isolated from brain and insulinoma cDNA libraries (Lu et al. , ibid . ; and Lan et al . , ibid. ) . Detection of diabetes-associated autoantigens, especially combinations of autoantigens, genotypes, such as HLA DR and HLA DQ, and loci, such as the polymorphic region in the 5' flanking region of the insulin gene; in prediabetic individuals have been shown to be useful predictive markers of IDDM, see for example, Bell et al . , (Diabetes 33 . :176-83, 1984) ; Sheehy et al., (J. Clin. Invest . .8_3:830-35, 1989) ; and Bingley et al. , (Diabetes 43 : 1304-10, 1994) . There is therefore a need in the art for autoantigens that would serve to improve detection and diagnosis of IDDM. The present invention fulfills this need by providing novel autoantigens as well as related compositions and methods. The autoantigens of the present invention represent a new β-cell antigen. The present invention also provides other, related advantages. SUMMARY OF THE INVENTION The present invention provides an isolated polynucleotide which forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM, comprising a DNA segment encoding a mammalian islet cell antigen polypeptide of SEQ ID NO: 16 from Leu, amino acid residue 636 to Gin, amino acid residue 1012. The invention also provides a mammalian islet cell antigen polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818. The invention also provides allelic variants of these polypeptides. Within one aspect of the invention, the isolated polynucleotide encodes a mammalian islet cell antigen polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818. Within another aspect of the invention, the isolated polynucleotide encodes a mammalian islet cell antigen polypeptide of SEQ ID NO:16 from Phe, amino acid residue 612, to Gin, amino acid residue 1012. The invention further provides allelic variants of these polypeptides. Within another aspect, the isolated polynucleotide encoding a polypeptide of SEQ ID NO: 16 from Ala, amino acid residue 1, to Gin, amino acid residue 1012. Within another aspect, the isolated polynucleotide encoding a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818. The invention further provides allelic variants of these polypeptides. Within another aspect, the isolated polynucleotide is a DNA molecule comprising a coding sequence corresponding to SEQ ID NO:21 from nucleotide 1325 to nucleotide 2455. In still another aspect, the DNA molecule comprises a coding sequence corresponding to SEQ ID NO:15 from nucleotide 1909 to nucleotide 3039. The invention also provides allelic variants of these molecules. The invention further provides complements of polynucleotide molecules which specifically hybridize to these molecules. In yet another aspect, the isolated polynucleotide is a DNA molecule comprising a coding sequence corresponding to SEQ ID N0:21 from nucleotide 1254 to nucleotide 2455. Within another aspect, the isolated polynucleotide is a DNA molecule comprising a coding sequence corresponding to SEQ ID NO:15 from nucleotide 1837 to nucleotide 3039. The invention also provides allelic variants of these molecules. The invention further provides complements of polynucleotide molecules which specifically hybridize to these molecules. In still another aspect, the DNA molecule comprises a coding sequence corresponding to SEQ ID NO: 15 from nucleotide 4 to nucleotide 3039. In still another aspect, the DNA molecule comprises a coding sequence corresponding to SEQ ID NO:21 from nucleotide 2 to nucleotide 2455.' The invention also provides allelic variants of these molecules. The invention further provides complements of polynucleotide molecules which specifically hybridize to these molecules. The invention also provides an isolated polynucleotide molecule which encodes a complete coding sequence of a mammalian islet cell antigen polypeptide comprising the sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. The invention also provides mammalian islet cell antigens that are primate islet cell antigens. The invention also provides DNA constructs comprising a first DNA segment encoding a human islet cell antigen polypeptide operably linked to additional DNA segments required for the expression of the first DNA segment. The invention further provides a first DNA segment that is an isolated polynucleotide molecule encoding a human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818. The invention also provides a first DNA segment that is an isolated polynucleotide molecule encoding a human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818. Within another aspect, the invention provides a first DNA segment that is an isolated polynucleotide molecule encoding a human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818. The invention further provides host cells containing such DNA constructs, as well as methods for producing human islet cell antigen polypeptides comprising the steps of culturing such host cell and isolating the human islet cell antigen polypeptide. The invention further provides isolated mammalian islet cell antigen polypeptides, wherein said isolated mammalian islet cell antigen polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818. The invention further provides isolated mammalian islet cell antigen polypeptides comprising the amino acid sequence of SEQ ID NO:16 from Leu, amino acid residue 636 to Gin, amino acid residue 1012. The invention also provides isolated polypeptides of SEQ ID NO:16 from Phe, amino acid residue 612 to Gin, amino acid residue 1012. The invention also provides isolated polypeptides of SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818. The invention further provides isolated polypeptides of SEQ ID NO: 16 from Ala, amino acid residue 1 to Gin, amino acid residue 1012. The invention also provides isolated polypeptides of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818. The invention further provides allelic variants of these polypeptides. The invention still further provides an isolated polypeptide which is a full length mammalian islet cell antigen protein comprising the sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. The invention also provides mammalian islet cell antigens that are primate islet cell antigens. Within yet another aspect of the invention is provided a method for determining the presence of an autoantibody to a human islet cell antigen polypeptide in a biological sample, comprising the steps of contacting the biological sample with the human islet cell antigen polypeptide, which comprises an amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof, under conditions conducive to immune complex formation, and detecting the presence of immune complex formation between the human islet cell antigen polypeptide and the autoantibody to a human islet cell antigen, thereby determining the presence of autoantibodies to the human islet cell antigen in the biological sample. The invention further provides human islet cell antigen polypeptides that are detectably labeled. Within a further embodiment the invention provides a method for predicting the clinical course of diabetes in a patient, comprising testing a biological sample from a patient for the presence of human islet cell antigen polypeptides comprising the amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof, wherein the polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM, and classifying the patient for clinical course of diabetes based on the presence or absence of human islet cell antigens in the sample. The invention further provides a method of predicting the clinical course of IDDM by testing one or more additional predictive markers associated with risk of or protection from IDDM. The invention provides methods of predicting the clinical course where the predictive marker is an autoantibody to an antigen selected from the group consisting of GAD65, IA-2/ICA512 or insulin. The invention also provides methods wherein the predictive marker is a genotype selected from the group consisting of HLA DR and HLA DQ. The invention also provides methods wherein the predictive marker is a polymorphic region in the 5' flanking region of a human insulin gene. The invention a mammalian islet cell antigen polypeptide comprising the amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof, that specifically binds a human islet cell antigen receptor on immature or mature T or B lymphocytes for use in preventing an autoimmune response to a human islet cell antigen polypeptide by inducing immunological tolerance. The invention also provides oligonucleotide probes of at least about 16 nucleotides, wherein which the oligonucleotide is at least 85% homologous to a sequence of the mammalian islet cell antigen DNA sequence of SEQ ID Nos:15 or 21. The invention further provides isolated antibodies which specifically bind to human islet cell antigen polypeptides which comprise the amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof. Within another aspect, the invention provides monoclonal antibodies. Within yet another aspect, the invention provides a hybridoma which produces the monoclonal antibody. The invention also provides a diagnostic kit for use in detecting autoantibodies to pancreatic β-islet cells, comprising a container containing an islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof, wherein the polypeptide forms an immune complex with autoantibodies from a patient at risk of or predisposed to develop IDDM, and one or more containers containing additional reagents. Within another embodiment of the invention is provided a pharmaceutical composition comprising an islet cell antigen comprising an amino acid sequence selected from the group consisting of a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 81, a polypeptide of SEQ ID NO:22 from Phe, amino acid residue 418 to Gin, amino acid residue 818, a polypeptide of SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818, and allelic variants thereof, in combination with a pharamceutically acceptable carrier or vehicle. Within a further embodiment of the invention is provided a method for monitoring the disease state in a patient comprising testing a biological sample from a patient for the presence of human islet cell antigen post- translationally modified polypeptides, determining the concentration of the peptides and correlating the peptide levels in the sample with the disease state in the patient. The invention provides that the human islet cell antigen post-translationally modified polypeptide comprises the sequence of SEQ ID NO:22 from His, amino acid residue 1 to Glu, amino acid residue 227. The invention further provides that the biological sample is plasma or serum. Within yet a further embodiment, the invention provides a method for monitoring the disease state in a patient comprising exposing T cells to islet cell antigen 1851 peptides, detecting T and correlating T cell reactivity with disease state. The invention provides that the T cells are from peripheral blood mononuclear cells from a prediabetic patient. The invention further provides that the disease state is conversion from prediabetes to diabetes. DETAILED DESCRIPTION OF THE INVENTION Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter: Allelic variant - Any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene. Biological sample - A sample that is derived from or contains cells, cell components or cell products, including, but not limited to, cell culture supernatants, cell lysates, cleared cell lysates, cell extracts, tissue extracts, blood plasma, serum, and fractions thereof, from a patient. Complements of polynucleotide molecules - Polynucleotide molecules having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3 ' is complementary to 5 ' CCCGTGCAT 3 ' . Immune Complex Formation - A noncovalently bound molecule formed between an antigen and an antibody specific for that antigen, resulting in an extensively cross-linked mass. Conditions conducive to complex formation are known in the art and easily adaptable by those skilled in art, for example, the degree of complex formation is in proportion to the relative amounts of available antigen and antibody. Such complexes can be used, for example, to identify and/or quantify the presence of either antigen or antibody in a biological sample, identify and characterize particular antibodies in tissues and cells, or to stimulate an immune response. Isolated - When applied to a protein the term "isolated" indicates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the proteins in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When applied to a polynucleotide molecule the term "isolated" indicates that the molecule is removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated and may include naturally occurring 5 ' and 3 ' untranslated regions such as promoters and terminators, the identification of such will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316 : 774-78, 1985) . Operably linked - Indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator. The DNA sequences encoding the polypeptides of the present invention were unexpectedly identified during screening of a primate islet cell cDNA library, and human insulinoma cDNA, for autoantigens toward human diabetic sera. Analysis of the macaque cDNA clones revealed a unique, previously unknown islet cell antigen which contained regions of homology to the protein tyrosine phosphatase family, especially the protein tyrosine phosphatase IA2/ICA512. This novel islet cell antigen has been designated 1851 or ICA512β. The present invention provides islet cell antigen polypeptides which are β-cell autoantigens. These autoantigens were reactive with human prediabetic and diabetic sera. The invention also provides methods for using the islet cell antigen polypeptides for the detection, diagnosis, and treatment of IDDM. Representative islet cell antigen polypeptides of the present invention comprise the amino acid sequences in SEQ ID NOs:4, 16 or 22 and/or are encoded by polynucleotide sequences comprising the sequences of SEQ ID N0s:3, 15 and 21 and form an immune complex with autoantibodies from a patient at risk of or predisposed to develop IDDM. The islet cell antigen polypeptides of the present invention are preferably from mammals, especially primates including humans. Preferred polypeptides of the present invention include isolated polypeptides selected from the group consisting of a polypeptide of SEQ ID NO:2 from Leu, amino acid residue 265, to Gin amino acid residue 641. The invention also provides polypeptides of SEQ ID NO:2 from Glu, amino acid residue 1, to Gin, amino acid residue 641. The invention further provides macaque polypeptides of SEQ ID NO:16 from Ala, amino acid residue 1 to Gin, amino acid residue 1012 and human polypeptides of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818 and SEQ ID NO:22 from His, amino acid residue 1 to Gin, amino acid residue 818. The invention further provides allelic variants and isolated sequences that are substantially identical to the representative polypeptide sequences of SEQ ID NOs :2, 16 and 22 and their species homologs. The term "substantially identical" is used herein to denote proteins having 50%, preferably 60%, more preferably 70%, and most preferably at least 80%, sequence identity to the representative sequences shown in SEQ ID NO:2, 16 or 22 or its species homologs. Within preferred embodiments, such proteins will be at least 90% identical, and most preferably 95% or more identical, to SEQ ID NO:2, 16 or 22 or their species homologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al. , Bull. Math. Bio. 48 : 603-616, 1986; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 8^:2444-2448, 1988; and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 8_9_:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 1 (amino acids are indicated by the standard one-letter codes) . The percent identity of the optimum alignment is then calculated as: V 10 15 20 Total number of identical matches x 100 [length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences] Substantially identical proteins are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 2) and other substitutions that do not significantly affect the folding or activity of the protein; small deletions, typically of one to about 30 amino acids; amidation of the amino- or carboxyl- terminal; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain. See, in general, Ford et al . , Protein Expression and Purification 2 . : 95-107, 1991, which is incorporated herein by reference. Table 2 Conservative amino acid substitutions Basic: arginine lysine histidine Acidic: glutamic acid aspartic acid Polar: glutamine asparagine Hydrophobic : leucine isoleucine valine Aromatic : phenylalanine tryptophan tyrosine Small : glycine alanine serine threonine methionine Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-85, 1989) . In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g. protein tyrosine phosphatase activity, Strueli et al . , EMBO J. : 2399-407, 1990, or binding to autoantibodies in prediabetic or diabetic sera) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al . , Science 255 :306-12 , 1992; Smith et al . , J. Mol. Biol . 224 . :899-904 , 1992; Wlodaver et al . , FEBS Lett. 301:59-64, 1992. Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-57, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA .86:2152-156, 1989) . Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a protein, selecting for functional protein, and then sequencing the mutagenized proteins to determine the spectrum of allowable substitutions at each position. These methods allow the rapid determination of the importance of individual amino acid residues in a protein of interest, and can be applied to proteins of unknown structure. The present invention further provides isolated polynucleotide molecules encoding islet cell antigen polypeptides which form immune complexes with autoantibodies from a patient at risk of or predisposed to develop IDDM. Useful polynucleotide molecules in this regard include mRNA, genomic DNA, cDNA and synthetic DNA. For production of recombinant islet cell antigen polypeptides, cDNA is preferred. The invention provides an isolated polynucleotide molecule wherein the molecule is a DNA molecule comprising a coding sequence corresponding to SEQ ID N0:1 from nucleotide 795 to nucleotide 1922. The invention also provides a DNA molecule comprising a coding sequence corresponding to SEQ ID NO:l from nucleotide 1 to nucleotide 2168. The invention also provides a DNA molecule comprising a coding sequence corresponding to nucleotide 4 to nucleotide 3039 of SEQ ID NO: 15. The invention also provides DNA molecules from nucleotide 1325 to nucleotide 2455, from nucleotide 1254 to nucleotide 2455 and from nucleotide 2 to nucleotide 2544 of SEQ ID NO-.21. The invention also provides allelic variants of the sequences shown in SEQ ID NOs:l, 15 or 21, and polynucleotide molecules that specifically hybridize to allelic variants. Such polynucleotide molecules will hybridize to the representative DNA sequences of SEQ ID N0s:l, 15, 21 or their allelic variants under stringent conditions (Sambrook et al . , Molecular Cloning: A Laboratory Manual. Second Edition, Cold Spring Harbor, NY, 1989) . As used herein, the term "stringent conditions" refers to hybridizing conditions that employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50 °C; employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% polyvinylpyrrolidone/50 mM sodium citrate at 42 °C; or employ 50% formamide, 5X SSC (0.75 M NaCl, 0.075M sodium pyrophosphate, 5X Denhardt ' s solution, sonicated salmon sperm DNA (50 g/ml) , 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42 °C in 0.2X SSC and 0.1% SDS. Such hybridizable polynucleotide molecules would include genetically engineered or synthetic variants of the representative islet cell antigen polynucleotide sequence, SEQ ID NO: 1, and polynucleotide molecules that encode one or more amino acid substitutions, deletions or additions, preferably of a minor nature, as discussed above. Genetically engineered variants may be obtained by using oligonucleotide-directed site-specific mutagenesis, by use of restriction endonuclease digestion and adapter ligation, polymerase chain reaction (PCR) , or other methods well established in the literature (see for example, Sambrook et al . , Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989, and Smith et al . , Genetic Engineering: Principles and Methods. Plenum Press, 1981; which are incorporated herein by reference) . In addition, hybridizable polynucleotide molecules may encompass sequences containing degeneracies in the DNA code wherein host- preferred codons are substituted for the analogous codons in the representative sequences of SEQ ID NOs: 1, 15 and 21. Analysis of the representative cDNA sequences of SEQ ID N0:1, 15 and 21 and their representative polypeptide sequences of SEQ ID NO:2, 16 and 22, show that they contain regions of homology to transmembrane protein tyrosine phosphatases . Comparison of the human protein tyrosine phosphatase IA-2/ICA512 cDNA and amino acid sequences with those of 1851 suggests that the coding region of macaque 1851 is missing amino-terminal sequence corresponding to approximately 1 amino acid and human 1851 is missing approximately 200 amino acid residues of the amino terminus. To recover the 5' region, cDNA libraries from different tissues can be screened to obtain a full length cDNA, which encodes a full length mammalian islet cell antigen polypeptides. Another option for obtaining the complete coding sequence comprises using 5' RACE (Rapid Amplification cDNA Ends) PCR. RACE is an art recognized PCR-based method for amplifying the 5' ends of incomplete cDNAs, a frequent occurrence in cDNA cloning. To obtain the 5 1 portion of a cDNA, PCR is carried out on specially prepared cDNA which contains unique anchor sequences, using anchor primers provided with the 5' RACE reagents available from, for example, Clontech, Palo Alto, CA and a 3' primer based on known sequence. The 5 ' -RACE-Ready cDNA can be purchased commercially (Clontech) , or prepared according to known methods. A secondary PCR reaction can then be carried out using the anchor primer and a nested 3' primer, according to known methods. Once a full- length cDNA is obtained, it is expressed and analyzed for overall structural similarity to known protein tyrosine phosphatases, and examined for features such as a continuous open reading frame flanked by translation initiation and termination sites and a potential signal sequence. Transmembrane, or receptor-linked, protein tyrosine phosphatases consist of a conserved cytoplasmic domain which may have one or two (tandemly duplicated) catalytic regions, a single transmembrane domain, a highly variable extracellular domain and a signal peptide. These structural features suggest that receptor-linked protein tyrosine phosphatases would be capable of binding ligand and transducing external signal, but no ligands as of yet have been identified. Based on the representative amino acid sequence of SEQ ID NOs:2 and 15, the macaque 1851 polypeptide has an approximately 611 amino acid extracellular domain, from Ala, amino acid residue 1 to Lys, amino acid residue 611 of SEQ ID NO: 16, containing a post translational modification dibasic site, at amino acid residue 423-424, or a tribasic site at amino acid residues 422-424; a 24 amino acid transmembrane domain comprising amino acid residue 241 to amino acid residue 265 of SEQ ID NO:2 or Phe, amino acid residue 612 to Cys, amino acid residue 635 of SEQ ID NO:16 and an approximately 375 amino acid cytoplasmic domain comprising the amino acid residue 265 to amino acid residue 640 of SEQ ID NO:2 or Leu, amino acid residue 636 to Gin, amino acid residue 1012 of SEQ ID NO:16. The representative amino acid sequence of the human islet cell antigen 1851 (SEQ ID NO:22) has 417 amino acids of an extracellular domain, from His, amino acid residue 1 to Lys, amino acid residue 417 of SEQ ID NO:22; a 24 amino acid residue transmembrane domain, from Phe, amino acid residue 418 to Cys, amino acid residue 441, of SEQ ID NO:22; and a 376 amino acid cytoplasmic domain, from Leu, amino acid residue 442 to Gin, amino acid residue 818 of SEQ ID NO:22. The cytoplasmic domain of 1851 contains many regions that are conserved between members of the protein tyrosine phosphatase family. Within the cytoplasmic domain of protein tyrosine phosphatases is a catalytic region of about 230 amino acids, which contains a highly conserved catalytic core segment of approximately 11 amino acid residues (VHCXAGXXRXG SEQ ID NO:13) where the first three X's are any amino acid, the fourth X is S or T, and the cysteine appears to be essential to the catalytic mechanism (Fischer et al . , Science 253 : 401- 06) . The catalytic core sequence of the representative macaque 1851 polypeptide sequences of SEQ ID Nos :2 and 16 and human 1851 polypeptide sequence represented by SEQ ID NO:22 differs from other members of the protein tyrosine phosphatase family in that alanine has been replaced by aspartic acid and the second variable amino acid (X) is alanine. 1851, like IA-2/ICA512, has a single catalytic region. Deletion of C-terminal amino acids from the intracellular domain of human islet cell antigen 1851 reduced reactivity with new onset IDDM sera, suggesting this region may play a role in defining an autoantibody epitope. Removal of the C-terminal 27 amino acids decreased reactivity from 19/53 sera (36%) to 10/53 sera (19%) , a 47% decrease. Removal of the C-terminal 80 amino acids decreased reactivity further to 9/53 sera (17%) , a 53% decrease, and removal of the C-terminal 160 amino acids abolished all recognition by all 53 new onset IDDM sera. This is similar to the reports of one of two described intracellular IA-2/ICA512 autoantibody epitopes (Bonifacio et al . , . Immunol. 155:5419-426, 1995) . That human islet cell antigens 1851 and human IA-2/ICA512 are each precipitated by sera that do not precipitate the other suggests that each antigen has unique autoantibody epitopes, which is consistent with previous findings regarding the 37kD and 40kD tryptic fragments (Payton et al . , J. Clin. Invest. S>6_:1506-11, 1995) . A comparison between the overall human and macaque islet cell antigen 1851 nucleotide and amino acid sequences shows a 96.2% nucleotide identity and a 94.6% amino acid identity, in particular there was 97% identity within the nucleotide sequence and 98.9% identity within the amino acid sequence of the corresponding cytoplasmic domains, 100% identity within the transmembrane domain. There is 77% amino acid identity within the cytoplasmic domain between the claimed human (SEQ ID NO:22) and macaque (SEQ ID NO:16) islet cell antigen 1851 sequences and the reported human IA-2/ICA512 sequences (Lan et al . , ibid. ; and Rabin et al., ibid. ) . Between the full length macaque islet cell antigen 1851 sequence (as represented in SEQ ID Nos: 15 and 16) and rat phogrin sequences (Wasmeier and Hutton, J. Biol. Chem. 271:18161-70, 1996) there was less homology, 75.5% identity within the nucleotide sequence and 69.9% identity within the amino acid sequence. In contrast, there is little homology in the extracellular regions of transmembrane protein tyrosine phosphatases. Some contain Ig-like and/or fibronectin type III repeats (Streuli et al . , J. Exp. Med. 168 : 1523, 1988; Hariharan et al. , Proc. Natl. Acad. Aci . USA 88 : 11266, 1991); others have glycosylated segments (Sap et al., Proc. Natl. Acad. Sci. USA 87:6112, 1990; and Krueger et al . , EMBO J. 9: 3241, 1990) and a conserved cysteine-rich region (Tonks et al . , J. Biol . Chem. 265 : 10674-80, 1990) (Lan et al . ibid.) . There is 31% identity between macaque islet cell antigen 1851 (as represented by SEQ ID NO:15) and IA-2/ICA512 (Lan et al . , ibid. ; and Rabin et al . , ibid. ) within the extracellular domain. The tissue distribution of human islet cell antigen 1851 is generally neuroendocrine. Northern analysis showed strong hybridization to human mRNA from brain and pancreas and weaker hybridization in spinal cord, thyroid, adrenal and GI tract. In si tu hybridization using macaque tissues further localized pancreatic and adrenal expression to islets and adrenal medulla, respectively. Northern blot analysis of rat phogrin showed expression in brain, pancreas and α and β cell tumor lines (Wasmeier and Hutton, ibid. ) ; mouse IA- 2β in brain, pancreas, stomach and in insulinoma and glucagomoma cell lines (Lu et al . , Proc. Natl. Acad. Sci. USA 93:2307-11, 1996) ; human IA-2 in brain, pituitary and pancreas, four insulinoma cell lines and a glioblastoma cell line (Lan et al. , ibid. ) ; and human ICA512, brain and pancreas (Rabin et al . , ibid. ) . Limited trypsinization of IA-2/ICA512 and human islet cell antigen 1851 yielded a 40 kD IA-2/ICA512 fragment and a 37 kD islet cell antigen 1851 fragment. These correspond to the 37 kD and 40 kD tryptic fragments described by Christie et al . (J. Exp. Med. 172 :789-94 , 1990) , Payton et al. (J. Clin. Invest. 96.:1506-11, 1995) , Bonifacio et al . (J. Immunol. 155 : 5419-26. 1995) , Lu et al. (Proc. Natl. Acad. Sci. USA 91:2307-11, 1996) and Wasmeier and Hutton {ibid. ) . Members of the protein tyrosine phosphatase family have been shown to display alternative mRNA splicing (Moeller et al . , WO 94/21800; Hall et al . , J. Immunol . 141: 2781-87, 1988; Johnson et al . , J. Biol . Chem. 264 : 6220-29, 1989; Streuli and Saito, EMBO J. 8_: 787-96, 1989; Matthews et al . , Proc. Natl. Acad. Sci. USA 87 : 4444-48, 1990; Walton and Dixon, Ann. Rev. Biochem. 62: 101-20, 1993; and Pan et al . , J. Biol. Chem. 268: 19284-91, 1993) . Alternative splicing may be important in autoantibody recognition; "inappropriate" splicing could lead to autoimmunity by activating T cells, for example. The invention provides isolated DNA molecules that are useful in producing recombinant islet cell antigens. As will be evident to one skilled in the art, each individual domain or combinations of the domains may be prepared synthetically or by recombinant DNA techniques for use in the present invention. Thus, the present invention provides the advantage that islet cell antigens are produced in high quantities that may be readily purified using methods known in the art (see generally; Scopes, Protein Purification. Springer-Verlag, NY, 1982) . Alternatively, the proteins of the present invention may be synthesized following conventional synthesis methods, such as the solid-phase synthesis method of Barany and Merrifield (in The Peptides. Analysis, Synthesis, Biology Vol. 2, Gross and Meienhofer, eds, Academic Press, NY, pp. 1-284, 1980) , by partial solid-phase techniques, by fragment condensation or by classical solution addition. DNA molecules of the present invention can be isolated using standard cloning methods such as those described by Maniatis et al . (Molecular Cloning: A Laboratory Manual . Cold Spring Harbor, NY, 1982; which is incorporated herein by reference) , Sambrook et al . , (Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor, NY, 1989) , or Mullis et al . (U.S. Patent No. 4,683,195) which are incorporated herein by reference. Alternatively, the coding sequences of the present invention can be synthesized using standard techniques that are well known in the art, such as by synthesis on an automated DNA synthesizer. The sequence of a polynucleotide molecule encoding a representative islet cell antigen polypeptide is shown in SEQ ID NOs: 1, 15 and 21 and the corresponding amino acid sequences are shown in SEQ ID NOs: 2, 16 and 22. Those skilled in the art will recognize that these sequences correspond to one allele of either the macaque or human gene, and that allelic variation is expected to exist. Allelic variants of the DNA sequence shown in SEQ ID NO: 1, 15 and 21 including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO: 2, 16 and 22. The macaque sequence disclosed herein is useful for isolating polynucleotide molecules encoding islet cell antigen polypeptides from other species ("species homologs") . In particular, the macaque cDNA was used to conduct a sequence search for a human homolog. A match was found as an expressed sequence tag (EST) from a human fetal brain library submitted to the Genbank database (GenBank ID: T0361, clone ID: HFBCV88) . This 127 amino acid polypeptide, SEQ ID NO:5, had homology to a region of the cytoplasmic domain of Ml.18.5.1 (SEQ ID NO:2) and was used to design PCR primers to clone a 1.1 kD cytoplasmic portion (SEQ ID NOs:6 and 7) of the human 1851 sequence, as described in the examples below. Other preferred species homologs include mammalian homologs such as bovine, canine, porcine, ovine, and equine proteins. Methods for using sequence information from a first species to clone a corresponding polynucleotide sequence from a second species are well known in the art. See, for example, Ausubel et al. , eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987. DNA molecules of the present invention or portions thereof may be used as probes, for example, to directly detect 1851 sequences in cells or biological samples. Such DNA molecules are generally synthetic oligonucleotides, but may be generated from cloned cDNA or genomic sequences and will generally comprise at least about 16 nucleotides, more often from about 17 nucleotides to about 25 or more nucleotides, sometimes 40 to 60 nucleotides, and in some instances a substantial portion or even the entire 1851 gene or cDNA. The synthetic oligonucleotides of the present invention have at least 85% identity to a representative macaque or human 1851 DNA sequence (SEQ ID Nos:l, 15 and 21) or their complements. For use as probes, the molecules are labeled to provide a detectable signal, such as with an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, paramagnetic particle, etc., according to methods known in the art. Probes of the present invention may also be used in diagnostic methods to detect autoantibodies in diabetic and prediabetic sera. DNA molecules used within the present invention may be labeled and used in a hybridization procedure similar to the Southern or dot blot. As will be understood by those skilled in the art, conditions that allow the DNA molecules of the present invention to hybridize to the representative DNA sequence of SEQ ID N0:1, 15 or 21 or their allelic variants may be determined by methods well known in the art (reviewed, for example, by Sambrook et al . Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; which is incorporated herein by reference) . Those skilled in the art will be capable of varying hybridization conditions (i.e. stringency of hybridization) of the DNA molecules as appropriate for use in the various procedures by methods well known in the literature (see, for example, Sambrook et al . , ibid. . , pages 11.45-11.53) . The higher the stringency of hybridization, the lower the number of mismatched sequences detected. Alternatively, lower stringency will allow related sequences to be identified. Alternatively, allelic variants may be identified using DNA molecules of the present invention and, for example, the polymerase chain reaction (PCR) (disclosed by Saiki et al. , Science 239: 487, 1987; Mullis et al., U.S. Patent 4,686,195; and Mullis et al . , U.S. Patent 4,683,202) to amplify DNA sequences, which are subsequently detected by their characteristic size on agarose gels or which may be sequenced to detect sequence abnormalities. DNA molecules encoding the islet cell antigen polypeptides of the present invention may be inserted into DNA constructs. As used within the context of the present invention a DNA construct is understood to refer to a DNA molecule, or a clone of such a molecule, either single- or double-stranded, which has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner that would not otherwise exist in nature. DNA constructs of the present invention comprise a first DNA segment encoding an islet cell antigen polypeptide operably linked to additional DNA segments required for the expression of the first DNA segment. Within the context of the present invention, additional DNA segments will generally include promoters and transcription terminators, and may further include enhancers and other elements. One or more selectable markers may also be included. DNA constructs useful for expressing cloned DNA segments in a variety of prokaryotic and eukaryotic host cells can be prepared from readily available components or purchase from commercial suppliers. In general, a DNA sequence encoding a protein of the present invention is operably linked to a transcription promoter and terminator within a DNA construct. The construct will commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers. In one embodiment the first DNA segment is an isolated polynucleotide molecule encoding a mammalian islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID N0:4, wherein the polypeptide forms an immune complex with autoantibodies from a patient at risk of or predisposed to IDDM. In another embodiment, the first DNA segment is an isolated polynucleotide encoding a polypeptide of SEQ ID NO:2 from Leu, amino acid residue 265 to Gin, amino acid residue 641. In another embodiment, the first DNA segment is an isolated polynucleotide encoding a polypeptide of SEQ ID NO:2 from Ser, amino acid residue 1, to Gin, amino acid residue 641. Within yet another embodiment, the first DNA segment is an isolated polynucleotide encoding a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818. In another embodiment, the first DNA segment is an isolated polynucleotide encoding a polypeptide of SEQ ID NO:16 from Ala, amino acid residue 1 to Gin, amino acid residue 1012. The proteins of the present invention can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al . , Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al . , ibid. . , which are incorporated herein by reference. To direct a protein of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence is joined to the DNA sequence encoding a protein of the present invention in the correct reading frame . Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the protein of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al . , U.S. Patent No. 5,037,743; Holland et al . , U.S. Patent No. 5,143,830) . The secretory signal sequence may be that normally associated with a protein of the present invention, or may be from a gene encoding another secreted protein. Cultured mammalian cells are also preferred hosts within the present invention. A preferred vector system for use in the present invention is the pZCEP vector system as disclosed by Jelineck et al . , Science, 259 : 1615-16, 1993. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate- mediated transfection (Wigler et al . , Cell !4.:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7 . = 60 , 1981: Graham and Van der Eb, Virology 52 . :456, 1973), electroporation (Neumann et al . , EMBO J. 1:841-845, 1982) , DEAE-dextran mediated transfection (Ausubel et al . , eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987) , and cationic lipid transfection using commercially available reagents including the Boehringer Mannheim Transfection-Reagent (N- [1- (2,3-Dioleoyloxy)propyl] -N,N,N-trimethyl ammoniummethylsulfate; Boehringer Mannheim, Indianapolis, IN) or LIPOFECTIN- reagent (N- [1- (2, 3-Dioleyloxy)propyl] - N,N,N-trimethylammonium chloride and dioeleoyl phosphatidylethanolamine; GIBCO-BRL, Gaithersburg, MD) using the manufacturer-supplied directions, which are incorporated herein by reference. The production of recombinant proteins in cultured mammalian cells is disclosed, for example, by Levinson et al . , U.S. Patent No. 4,713,339; Hagen et al . , U.S. Patent No. 4,784,950; Palmiter et al . , U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632) , BHK 570 (ATCC No. CRL 10314) , 293 (ATCC No. CRL 1573; Graham et al . , J. Gen. Virol. 3_6 :59-72, 1977) and Chinese hamster ovary (e.g. CH0-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. Prokaryotic cells can also serve as host cells for use in carrying out the present invention. Particularly preferred are strains of the bacteria Escherichia coli , although Bacillus and other genera are also useful. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al . , ibid. . ) . When expressing the proteins in bacteria such as E. coli , the protein may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate. The denatured protein is then refolded by diluting the denaturant. In the latter case, the protein can be recovered from the periplasmic space in a soluble form. Fungal cells are also suitable as host cells. For example, Sa ccharomγces ssp., Hansenula pol vmorpha , Schizosaccharomyces pombe, Kl uyveromγces lactis, Kl uwero vces fraαilis, Ustilaαo maγdis , Pichia vastoris , Pichia Quillermondii . Pichia methanolica , and Candida mal tosa transformation systems are known in the art. See, for example, Kawasaki, U.S. Patent No. 4,599,311, Kawasaki et al . , U.S. Patent No. 4,931,373, Brake, U.S. Patent No. 4,870,008; Welch et al . , U.S. Patent No. 5,037,743; and Murray et al . , U.S. Patent No. 4,845,075, Gleeson et al . , J. Gen. Microbiol . 132 :3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279. Asverαillus cells may be utilized according to the methods of McKnight et al . , U.S. Patent No. 4,935,349, which is incorporated herein by reference. Methods for transforming Acremonium chrvsocrenum are disclosed by Sumino et al . , U.S. Patent No. 5,162,228, which is incorporated herein by reference. Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign proteins therein is disclosed by Guarino et al . , U.S. Patent No. 5,162,222 and Bang et al . , U.S. Patent No. 4,775,624, which are incorporated herein by reference. The use of Aaroba c t eri urn rhizoαenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al . , J. Biosci. (Bangalore) 11 :47- 58, 1987. Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as " ransfectants" . Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin- type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. The recombinant islet cell antigen polypeptides expressed using the methods described herein are isolated and purified by conventional procedures, including separating the cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulfate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography or affinity chromatography, or the like. Methods of protein purification are known in the art (see generally, Scopes, R. , Protein Purification, Springer- Verlag, NY (1982) , which is incorporated herein by reference) and may be applied to the purification of the recombinant proteins of the present invention. Substantially pure recombinant islet cell antigen polypeptides of at least about 50% is preferred, at least about 70-80% more preferred, and 95-99% or more homogeneity most preferred, particularly for pharmaceutical uses. Once purified, partially or to homogeneity, as desired, the recombinant islet cell antigen polypeptides may then be used diagnostically, therapeutically, etc. as further described below. Recombinant 1851 polypeptides can also be produced by expressing islet cell antigen DNA fragments, such as fragments generated by digesting an islet cell antigen cDNA at convenient restriction sites. The isolated recombinant polypeptides or cell-conditioned media are then assayed for activity as described in the examples below. Alternatively, the proteins of the present invention may be synthesized following conventional synthesis methods such as the solid-phase synthesis using the method of Barany and Merrifield (in The Peptides. Analysis, Synthesis, Biology Vol. 2, Gross and Meienhofer, eds, Academic Press, NY, pp. 1-284, 1980, which are incorporated herein by reference) , by partial solid-phase techniques, by fragment condensation or by classical solution addition. Short polypeptide sequences, or libraries of overlapping peptides, usually from about 6 up to about 35 amino acids, which correspond to selected islet cell antigen polypeptide regions can be readily synthesized and then screened in screening assays designed to identify peptides having a desired activity, such as domains which are responsible for or contribute to binding activity, immunodominant epitopes (particularly those recognized by autoantibodies) , and the like. Although the use of recombinant 1851 polypeptides is preferred within the methods of the present invention, 1851 polypeptides may also be prepared from cells that naturally produce 1851 protein (such as islet cells) . For example, 1851 polypeptides may be prepared from islet cells by isolation of a membrane fraction. This 1851-enriched fraction is then used to detect autoantibodies to 1851 in prediabetic and diabetic sera. Islet cell antigen polypeptides produced according to the present invention can be used diagnostically, in the detection and quantitation of autoantibodies in a biological sample, that is, any sample derived from or containing cells, cell components or cell products, including, but not limited to, cell culture supernatants, cell lysates, cleared cell lysates, cell extracts, tissue extracts, blood plasma, serum, and fractions thereof. By means of having islet cell antigen polypeptides which specifically bind to autoantibodies in prediabetic and diabetic sera, the presence or absence of such autoantibodies can be determined, and the concentration of such autoantibodies in an individual can be measured. This information can then be used to monitor the progression or regression of the potentially harmful autoantibodies in individuals at risk of, or with a predisposition to develop IDDM, and would be useful for predicting the clinical course of the disease in a patient. The assay results can also find use in monitoring the effectiveness of therapeutic measures for treatment of IDDM or related diseases. As will be recognized by those skilled in the art, numerous types of immunoassays are available for use in determining the presence of autoantibodies. For instance, direct and indirect binding assays, competitive assays, sandwich assays, and the like, as are generally described in, e.g., U.S. Pat. Nos . 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, N.Y., 1988, each incorporated herein by reference. In one assay format, autoantibodies directed to the polypeptides of the present invention are quantified directly by measuring the binding of autoantibodies in a biological sample to recombinant or synthetic islet cell antigen polypeptides. The biological sample is contacted with at least one islet cell antigen polypeptide of the invention under conditions conducive to immune complex formation. The immune complexes formed between the islet cell antigen polypeptide and the antibodies are then detected, and the presence and quantity of autoantibodies can then be used to diagnose or direct treatment of IDDM. The immune complexes can be detected by means of antibodies that bind to the islet cell antigen of the present invention or by labeling the polypeptide as described below. Separation steps (e.g., washes) may be necessary in some cases to distinguish specific binding over background. In another format, the serum level of a patient's autoantibodies to the islet cell antigen polypeptides in serum can be measured by competitive binding with labeled or unlabeled antibodies to the islet cell antigen polypeptides of the present invention. Unlabeled 1851 polypeptides can be used in combination with labeled antibodies that bind to human antibodies or to islet cell antigens. Alternatively, the islet cell antigen polypeptide can be directly labeled. A wide variety of labels can be employed, such as radionuclides, particles (e.g., gold, ferritin, magnetic particles, red blood cells) , fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens) , chemiluminescers, biotin and other compounds that provide for the detection of the labeled polypeptide or protein. For example, an 1851 polypeptide can be radiolabeled using conventional methods such as in vi tro transcription and translation. Radiolabeled 1851 polypeptide is combined with patient serum under conditions suitable for immune complex formation. Immune complexes are then separated, such as by binding to protein A. Precipitated 1851 polypeptides are then quantitated by conventional methods, such as gel electrophoresis, fluorography, densitometry or by direct counting of immunoprecipitated, radiolabeled antigen. The amount of 1851 polypeptide precipitated by test sera can be statistically compared to mean counts precipitated by healthy control sera, each measured separately. In an alternative format, an 1851 polypeptide antigen, labeled with biotin, is combined with patient serum under conditions suitable for immune complex formation. The serum is then transferred to a protein A-coated container, such as a well of an assay plate, and the container is allowed to stand so that immune complexes can form. The container is then washed, and streptavidin, conjugated to a suitable enzyme (e.g. alkaline phosphatase) , is added. A chromogenic substrate is then added, and the presence of 1851 polypeptide autoantibodies in the sample is indicated by a color change. Additional assay formats will be evident to those skilled in the art. Thus, autoantibodies to islet cell antigen polypeptides can be identified and, if desired, extracted from a patient's serum by binding to 1851 polypeptides of the present invention. The islet cell antigen polypeptides may be attached, e.g., by adsorption, to an insoluble or solid support, such as ELISA microtiter well, microbead, filter membrane, insoluble or precipitable soluble polymer, etc. to function as an affinity resin. The captured autoantibodies can then be identified by several methods. For example, antisera or monoclonal antibodies to the antibodies can be used. These antisera or monoclonal antibodies are typically non-human in origin, such as rabbit, goat, mouse, etc. These anti-antibodies can be detected directly if attached to a label such as 125 I, enzyme, biotin, etc., or can be detected indirectly by a labeled secondary antibody made to specifically detect the anti-antibody. The diagnostic methods of the present invention can be used in conjunction with other known assays and diagnostic techniques (see for example, WO 95/07464, incorporated herein by reference in its entirety) . Such other assays and techniques include measurement of body mass index (BMI) , defined as the quotient of the patient ' s weight in kg divided by the square of height in meters; C-peptide level (Heding, Diabetologia 11 : 541-548 (1975) ; Landin-Olsson et al . , Diabetologia 33 : 561-568 (1990)) ; or one or more additional diabetes-associated autoantibodies, genotypes or loci. A low BMI (i.e. less than about 25) in combination with other indicators is suggestive of type I diabetes. BMI is thus a useful indicator for distinguishing type I from type II diabetes. C-peptide level can be measured using standard methods, such as that of Heding (ibid.) , in which insulin and proinsulin are removed from serum and C-peptide is measured in the resulting insulin-free fraction radioimmunologically. The islet cell antigen polypeptides of the current invention can also be used to assess T cell reactivity, as a method for monitoring the disease state in a patient. Mammalian islet cell antigen 1851 peptides will generally comprise at least about 12 amino acids, and more often from about 15 amino acids to about 20 or more amino acids. In some instances, a substantial portion or domain or even the entire 1851 protein, can be used to assess T cell reactivity in peripheral blood mononuclear cells (PBMNCs) from prediabetics. Methods for detecting such in vi tro activity are known in the art, including a proliferation assay measuring 3 H- thymidine incorporation, analysis of activation markers, such as CD69, or measuring cytokine production, such as IL-2. Correlations can be drawn between T cell reactivity to islet cell antigen 1851 and conversion from prediabetes to diabetes. This correlation would be consistent with the appearance of autoantibodies to islet cell antigen peptides late in prediabetes (Christie et al., Diabetes 43:1254-59, 1994) . Mammalian cells, such as COS cells or L cells, may also be transfected with appropriate Class I or Class II alleles specific for the islet cell antigen of the present invention. Such MHC molecules may be soluble or membrane bound, and the 1851 antigenic polypeptide may be recombinantly tethered to the N-terminal region of the α or β chain using a flexible linker containing, for example, repeating glycine residues separated by a serine residue, such that the antigenic peptide binds to the MHC molecule and is properly presented to the T cell. Alternatively, the antigenic peptide may be exogenously loaded into the MHC peptide binding grove. The MHC- antigenic peptide complex can then be used to assess the reactivity of peripheral blood T cells derived from prediabetic or diabetic patients. This reactivity may be assessed by methods known in the art, such as 3 H thymidine incorporation, cytokine production or cytolysis. Alternatively, islet cell antigen expressed in microorganisms can be "fed" to peripheral blood mononuclear cells (PBMN) . The antigen-fed cells can then be used to stimulate peripheral blood T cells derived from diabetics or prediabetics . The islet cell antigen polypeptides are also contemplated to be advantageous for use as immunotherapeutics to induce immunological tolerance or nonresponsiveness (anergy) to 1851 polypeptide autoantigens in patients predisposed or already mounting an immune response to 1851 polypeptide autoantigens of the islet β-cells. This therapy can take the form of autoantigenic 1851 peptides bound to an appropriate MHC Class I or Class II molecule as described above. The therapy can also be in the form of oral tolerance (Weiner et al., Nature 376 : 177-80, 1995) , or IV tolerance, for example. The use of polypeptide antigens in suppression of autoimmune disease is disclosed by Wraith, et al . , (Cell 59: 247-55, 1989) . Tolerance can be induced in patients, although conditions for inducing such tolerance will vary according to a variety of factors. In a neonate, tolerance can be induced by parenteral injection of an islet cell antigenic polypeptide, either with recombinant polypeptide or synthetic antigen, or more conveniently by oral administration in an appropriate formulation. The precise amount of administration, its mode and frequency of dosages will vary. To induce immunological tolerance to the islet cell autoantigens in an adult susceptible to or already suffering from a islet cell antigen related disease such as IDDM, the precise amounts and frequency of administration will also vary, for adults about 1 to 1,000 mg/kg can be administered by a variety of routes, such as parenterally, orally, by aerosols, intradermal injection, etc. For neonates the doses will generally be higher than those administered to adults; e.g. 100 to 1, 000 mg/kg. The islet cell antigen 1851 polypeptides will typically be more tolerogenic when administered in a soluble form rather than an aggregrated or particulate form. Persistence of an islet cell antigen polypeptide of the invention is generally needed to maintain tolerance in an adult, and thus may require more frequent administration of the antigen, or its administration in a form which extends the half-life of the islet cell antigen. See for example, Sun et al. (Proc. Natl. Acad. Sci. USA 91: 10795-99, 1994) . The islet cell antigen polypeptides described herein are also contemplated to be advantageous for use as immunotherapeutics in treating longer term IDDM patients that have been identified by autoantibody testing at the time of clinical non-insulin dependent diabetes mellitus (NIDDM) diagnosis. Intervention in these patients may be especially effective, perhaps due to the slowly progressive nature of their β cell destruction. Since the numbers of such patients is nearly the same as those with classical childhood IDDM, there is a need for such therapeutic intervention (Hagopian et al . , J. Clin. Invest. 9_1:368-74; 1993; Harris and Robbins, Diabetes Care 3/7:1337-40, 1994; and Kobayashi et al . , Diabetes 45:622-26, 1996) . The N-terminal domain of islet cell antigen 1851 is expected to be inside the insulin secretory granule. The islet cell antigen polypeptides of the current invention contain post translational modification sites within the N-terminal domain. A dibasic site or tribasic site at amino acid residues 228-230 (Arg-Lys- Lys) in SEQ ID NO:22 and amino acid residues 422-424 (Arg-Lys-Lys) in SEQ ID NO:16 could result in cleavage of a 420 amino acid post-translationally modified mammalian islet cell antigen polypeptide from the islet cell antigen 1851 polypeptide. All or part of this cleaved polypeptide may be released from the β cell via either the constitutive secretory pathway for granule halo components, or via the regulated pathway involved in insulin release. Detection and quantitation of post translationally modified polypeptides in a biological sample (that is, any sample derived from or containing cells, cell components or cell products, including, but not limited to, cell culture supernatants, cell lysates, cleared cell lysates, cell extracts, tissue extracts, blood plasma, serum, and fractions thereof) can be used diagnostically to monitor disease state in a patient. The presence or absence of such polypeptides in prediabetic and diabetic sera can be determined, for example by radioimmunoassay, and the concentration of such polypeptides in such an individual serum sample can be measured. This information can then be used, for example, to monitor insulin secretory activity, such as β cell insulin secretory rates; or to indicate altered β cell physiology associated with cellular stress as in an immune attack. Peptide levels could be an indicator of β cell distress or β cell death, and would be useful for predicting the disease state in a patient. Alternatively, the peptides herein function serve in paracrine or endocrine signaling to other islet cells or remote cells in other organs. The assay results can also find use in monitoring the effectiveness of therapeutic measures for treatment of IDDM or related diseases . In a preferred embodiment, a post-translationally modified mammalian islet cell antigen polypeptide comprises the sequence of SEQ ID NO:22 from His, amino acid residue 1 to Glu, amino acid residue 227. In another preferred embodiment the biological sample is blood. The present invention also relates to a pharmaceutical composition comprising an islet cell antigen polypeptide of the present invention, together with a pharmaceutically acceptable carrier or vehicle, such as saline, buffered saline, water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed. , Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference. Therapeutic doses will generally be in the range of 0.1 to 100 μg/kg of patient weight, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. In general, a therapeutically effective amount of an islet cell antigen polypeptide of the present invention is an amount sufficient to produce a clinically significant reduction in β-cell loss or a delay of clinical onset of IDDM. In a related aspect, the present invention provides diagnostic kits for use with the recombinant or synthetic islet cell antigen polypeptides of the present invention, in detecting autoantibodies to pancreatic β- islet cells. Thus, 1851 polypeptides may be provided, usually in lyophilized form, in a container, either alone or in conjunction with additional reagents, such as 1851- specific antibodies, labels, and /or anti-human antibodies and the like. The 1851 polypeptides and antibodies, which may be conjugated to a label or unconjugated, are included in the kits with buffers, such as Tris phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., serum albumin, and the like. Frequently it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% of the total composition. Where an antibody capable of binding to the islet cell antigen polypeptide autoantibody or to the recombinant or synthetic 1851 polypeptide is employed in an assay, this will typically be present in a separate vial. Within one aspect of the present invention, islet cell antigen polypeptides, including derivatives thereof, as well as portions or fragments of these polypeptides, are utilized to prepare antibodies for diagnostic or therapeutic uses which specifically bind to islet cell antigen polypeptides. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')2 and Fab fragments, as well as recombinantly produced binding partners. These binding partners incorporate the variable regions from a gene which encodes a specifically binding monoclonal antibody. Antibodies are defined to be specifically binding if they bind to the islet cell antigen polypeptides with a K a of greater than or equal to 10 7 /M. The affinity of a monoclonal antibody or binding partner may be readily determined by one of ordinary skill in the art (see, Scatchard, Ann. NY Acad. Sci. 51: 660-72, 1949) . Methods for preparing polyclonal and monoclonal antibodies have been well described in the literature (see for example, Sambrook et al . , Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., Monoclonal Hvbridoma Antibodies: Techniques and Applications. CRC Press, Inc., Boca Raton, FL, 1982, which is incorporated herein by reference) . As would be evident to one of ordinary skill in the art, polyclonal antibodies may be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, for example. The immunogenicity of the islet cell antigen polypeptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. A variety of assays known to those skilled in the art may be utilized to detect antibodies which specifically bind to an islet cell antigen. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.) , Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme- linked immuno-sorbent assays, dot blot assays, inhibition or competition assays, and sandwich assays. Additional techniques for the preparation of monoclonal antibodies may be utilized to construct and express recombinant monoclonal antibodies. Briefly, mRNA is isolated from a B cell population and used to create heavy and light chain immunoglobulin cD A expression libraries in a suitable vector such as the λlMMUΝOZAP (H) and λlMMUΝOZAP (L) vectors, which may be obtained from Stratogene Cloning Systems (La Jolla, CA) . These vectors are then screened individually or are co-expressed to form Fab fragments or antibodies (Huse et al . , Science 246 : 1275-81, 1989; Sastry et al. , Proc. Νatl . Acad. Sci . USA 86 : 5728-32, 1989) . Positive plaques are subsequently converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments in E . col i . Binding partners such as those described above may also be constructed utilizing recombinant DΝA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody. The construction of these proteins may be readily accomplished by one of ordinary skill in the art (see for example, Larrick et al . , Biotechnology 1_ : 934-38, 1989; Reichmann et al . , Nature 322 : 323-27, 1988 and Roberts et al . Nature 328 : 731-34, 1987) . Once suitable antibodies or binding partners have been obtained, they may be isolated or purified by many techniques well described in the literature (see for example, Antibodies: A Laboratory Manual, ibid. ) . Suitable techniques include protein or peptide affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns or any combination of these techniques. Within the context of the present invention, the term "isolated" as used to define antibodies or binding partners means "substantially free of other blood components . " Antibodies of the present invention may be produced by immunizing an animal, a wide variety of warm¬ blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats can be used, with a recombinant or synthetic islet cell antigen polypeptide or a selected portion thereof (e.g., a peptide) . For example, by selected screening one can identify a region of the islet cell antigen polypeptide such as that predominantly responsible for recognition by anti-islet cell antigen polypeptide antibodies, or a portion which comprises an epitope of a islet cell antigen polypeptide variable region, which may thus serve as a islet cell antigen polypeptide-specific marker. Antibody producing cells obtained from the immunized animals are immortalized and screened, or screened first for, e.g., the production of antibody which inhibits the interaction of the anti-islet cell antigen polypeptide autoantibody with the islet cell antigen polypeptide and then immortalized. As the generation of human monoclonal antibodies to a human antigen, such as an 1851 polypeptide, may be difficult with conventional immortalization techniques, it may be desirable to first make non-human antibodies and then transfer via recombinant DNA techniques the antigen binding regions of the non-human antibodies, e.g. the F(ab')2 or hypervariable regions, to human constant regions (Fc) or framework regions to produce substantially human molecules. Such methods are generally known in the art and are described in, for example, U.S. Patent No. 4,816,397, and EP publications 173,494 and 239,400, which are incorporated herein by reference. Alternatively, one may isolate DNA sequences which encode a human monoclonal antibody or portions thereof that specifically bind to islet cell antigen polypeptides by screening a DNA library from human B cells according to the general protocol outlined by Huse et al . , Science 246 : 1275-81, 1989, incorporated herein by reference, and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity. In another aspect of the invention, the mammalian islet cell antigen polypeptides can be used to clone T cells which have specific receptors for the islet cell antigen polypeptide. Once the islet cell antigen polypeptide specific T cells are isolated and cloned using techniques generally available to the skilled artisan, the T cells or membrane preparations thereof can be used to immunize animals to produce antibodies to the islet cell antigen polypeptide receptors on T cells. The antibodies can be polyclonal or monoclonal. If polyclonal, the antibodies can be murine, lagomorph, equine, ovine, or from a variety of other mammals. Monoclonal antibodies will typically be murine in origin, produced according to known techniques, or human, as described above, or combinations thereof, as in chimeric or humanized antibodies. The anti-islet cell antigen polypeptide receptor antibodies thus obtained can then be administered to patients to reduce or eliminate T cell subpopulations which recognize and participate in the immunological destruction of islet cell antigen polypeptide bearing cells in an individual predisposed to or already suffering from a disease, such as IDDM. Further, the islet cell antigen polypeptide T cell receptors can thus be identified, cloned and sequenced, and receptor polypeptides synthesized which bind to the islet cell antigen polypeptides and block recognition of the islet cell antigen polypeptide-bearing cells, thereby impeding the autoimmune response against host islet cells. Howell et al . (Science 246 : 668-70, 1989) have demonstrated that T cell receptor peptides can block the formation of the tri-molecular complex between T cells, autoantigen and major histocompatibilty complex in an autoimmune disease model . Antibodies and binding partners of the present invention may be used in a variety of ways. The tissue distribution of the islet cell antigen, for example, may be determined by incubating tissue slices with a labeled monoclonal antibody which specifically binds to the islet cell antigen polypeptides, followed by detection of the presence of the bound antibody. Labels suitable for use within the present invention are well known in the art and include, among others, fluorescein, isothiocyanate, phycoerythrin, horseradish peroxidase, and colloidal gold. The antibodies of the present invention may also be used for the purification of the islet cell antigen polypeptides of the present invention. The coupling of antibodies to solid supports and their use in purification of proteins is well known in the literature (see for example, Methods in Molecular Biology, Vol. 1, Walker (Ed.) , Humana Press, New Jersey, 1984, which is incorporated by reference herein in its entirety) . Antibodies of the present invention may be used as a marker reagent to detect the presence of islet cell antigen polypeptides on cells or in solution. Such antibodies are also useful for western analysis or immunoblotting, particularly of purified cell secreted material. Polyclonal, affinity purified polyclonal, monoclonal and single chain antibodies are suitable for use in this regard. In addition, proteolytic and recombinant fragments and epitope binding domains can be used herein. Chimeric, humanized, veneered, CDR- replaced, reshaped or other recombinant whole or partial antibodies are also suitable. The following examples are offered by way of illustration, not by way of limitation. EXAMPLES Example 1 Synthesis of Macaque Islet Cell cDNA and Preparation of a Macaque Islet Cell cDNA Library Islets of Langerhans (~100,000) were isolated by collagenase digestion and Ficoll density gradient centrifugation from pancreas of Macaca nemestrina (obtained from the University of Washington Primate Center, Seattle, WA) . These cells were then flash frozen in liquid nitrogen and stored at -80 °C until use. Total RNA from the islets was isolated according to the method of Chirgwin et al. , Biochemistry 18 : 52-94, 1994, incorporated herein by reference, using polytron homogenization in guanidinium thiocynate and LiCl centrifugation. Poly(A) + RNA was isolated using oligo d(T) cellulose chromatography (Aviv and Leder, Proc . Natl. Acad. Sci. USA 69: 1408-12, 1972) . First strand cDNA was synthesized from two-time poly d(T) -selected liver poly(A) + RNA. Ten microliters of a solution containing 10 μg of liver poly(A) + RNA was mixed with 2 μl of 20 pmole/μl first strand primer ZC3747 (SEQ ID NO: 8) and 4 μl of diethylpyrocarbonate-treated water. The mixture was heated at 65°C for 4 minutes and cooled by chilling on ice. The first strand cDNA synthesis was initiated by the addition of 8 μl of 5X SUPERSCRIPT buffer (GIBCO BRL, Gaithersburg, Md. ) , 4 μl of 100 mM dithiothreitol, and 2.0 μl of a deoxynucleotide triphosphatate solution containing 10 mM each of dATP, dGTP, dTTP and 5-methyl- dCTP (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) to the RNA-primer mixture. The reaction mixture was incubated at 45°C for 4 minutes. After incubation, 10.0 μl of 200 U/μl SUPERSCRIPT reverse transcriptase (GIBCO BRL) was added. The efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 μCi of 32 P-αdCTP to a 5 μl aliquot of the reaction mixture to label the reaction products. The first strand synthesis reaction mixtures were incubated at 45°C for 45 minutes followed by a 15 minute incubation at 50°C. Unincorporated nucleotides were removed from each reaction by precipitating the cDNA in the presence of 8 μg of glycogen carrier, 2.5 M ammonium acetate and 2.5 volume ethanol . The unlabeled cDNA was resuspended in 50 μl water and used for the second strand synthesis. The length of first strand cDNA was assessed by resuspending the labeled cDNA in 20 μl water and determining the cDNA size by agarose gel electrophoresis. Second strand synthesis was performed on the RNA-DNA hybrid from the first strand synthesis reaction under conditions that promoted first strand priming of second strand synthesis resulting in DNA hairpin formation. A reaction mixture was prepared containing 20.0 μl of 5X polymerase I buffer (100 mM Tris, pH 7.4, 500 mM KCl, 25 mM MgCl 2 , 50 mM (NH ) 2 S0 4 ) , 1.0 μl of 100 mM dithiothreitol, 2.0 μl of a solution containing 10 mM of each deoxynucleotide triphosphate, 3.0 μl 5 mM β-NAD, 1.0 μl of 3 U/μl E . coli DNA ligase (New England Biolabs, Inc., Beverly, MA) , 5.0 μl of 10 U/μl E . col i DNA polymerase (Gibco BRL) and 50.0 μl of the unlabeled first strand DNA. A parallel reaction in which a 10 μl aliquot of the second strand synthesis was labeled by the addition of 10 μCi of 32 P-αdCTP was used to monitor the efficiency of second strand synthesis. The reaction mixtures were incubated at room temperature for 5 minutes followed by the addition of 1.5 μl of 2 U/μl RNase H (Gibco BRL) to each reaction mixture. The reactions were incubated at 15°C for 2 hours and 15 minutes, followed by a 15 minute incubation at room temperature . The reactions were each terminated by serial phenol/chloroform and chloroform/isoamylalcohol extractions. The DNA from each reaction was precipitated in the presence of ethanol and 2.5 M ammonium acetate. The DNA from the unlabeled reaction was resuspended in 100 μl water. The labeled DNA was resuspended and electrophoresed as described above. The single-stranded DNA in the hairpin structure was cleaved using mung bean nuclease. The reaction mixture contained 20 μl of 10X Mung Bean Nuclease Buffer (Stratagene Cloning Systems, La Jolla, CA) , 16 μl of 100 mM dithiothreitol, 54 μl water, 100 μl of the second strand cDNA, and 10 μl of a 1:10 dilution of Mung Bean Nuclease, final concentration 10.5 U/μl (Promega Corp., Madison, WI) in Stratagene MB dilution Buffer (Stratagene Cloning Systems) . The reaction was incubated at 37 °C for 15 minutes, and the reaction was terminated by the addition of 20 μl of Tris-HCl, pH 8.0 followed by sequential extractions with phenol/chloroform and chloroform/isoamylalcohol . Following the extractions, the DNA was precipitated in ethanol and resuspended in water. The resuspended cDNA was blunt-ended with T4 DNA polymerase. The cDNA, which was resuspended in a volume of 50 μl of water, was mixed with 50 μl of 5X T4 DNA polymerase buffer (250 mM Tris-HCl, pH 8.0, 250 mM KCl, 25 mM MgCl 2 ), 3 μl of 100 mM dithiothreitol, 3 μl of a solution containing 10 mM of each deoxynucleotide triphosphate, and 4 μl of 1.0 U/μl T4 DNA polymerase (Boehringer Mannheim, Indianapolis, IN) . After an incubation at 10 °C for 60 minutes, the reaction was terminated by serial phenol/chloroform and chloroform/isoamylalcohol extractions. The cDNA fragments less than 400 bp in length were removed by chromatography on a Clontech TE400 spin column (Clontech, Palo Alto, CA) . The DNA was ethanol precipitated and resuspended in 9 μl of water. Based on the incorporation of 32p_ c jcτ , the yield of cDNA was estimated to be 4 μg from a starting mRNA template of 10 μg. Eco RI adapters (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) were added to the cDNA prepared above to facilitate the cloning of the cDNA into a mammalian expression vector. A 9 μl aliquot of the cDNA and 975 pmole of the adapter (15 μl) were mixed with 3 μl 10X ligase buffer (Promega Corp.) , 1 μl 10 mM ATP, and 20 Units (2 μl) , of T4 DNA ligase (Promega Corp.) . The reaction was incubated for 16 hours at a temperature gradient of 4 °C to 15 °C. The reaction was terminated by the addition of 185 μl water, 25 μl REACT 2 buffer (Gibco BRL) followed by an incubation at 65 °C for between 30 and 60 minutes. After incubation, the reaction was terminated by serial phenol/chloroform and chloroform/isoamylalcohol extractions and ethanol precipitation as described above. Following centrifugation, the DNA pellet was washed with 70% ethanol and was air dried. The pellet was resuspended in 89 μl of water. To facilitate the directional insertion of the cDNA into a mammalian expression vector, the cDNA was digested with Xho I, resulting in a cDNA having a 5' Eco RI adhesive end and a 3' Xho I adhesive end. The Xho I restriction site at the 3 ' end of the cDNA was introduced through the ZC3747 primer (SEQ ID NO:8) . The restriction digestion was terminated by serial phenol/chloroform and chloroform/isoamylalcohol extractions. The cDNA was ethanol precipitated, and the resulting pellet was washed with 70% ethanol and air-dried. The pellet was resuspended in IX loading buffer (10 mM phosphate buffer, pH 8.8, 5% glycerol, 0.125% bromphenol blue) . The resuspended cDNA was heated to 65 °C for 10 minutes, cooled on ice and electrophoresed on a 0.8% low melt agarose gel (Seaplaque GTG Low Melt Agarose, FMC Corp., Rockland, ME) using a 1 Kb ladder (Gibco BRL) as size markers. The contaminating adapters and by-product fragments below 600 bp in size were excised from the gel. The electrodes were reversed, and the cDNA was electrophoresed until concentrated near the lane origin. The area of the gel containing the concentrated DNA was excised, placed in a microfuge tube, and the approximate volume of the gel slice was determined. An aliquot of TE (10 mM Tris HCl pH 7.4, 1 mM disodium ethylenediaminetetraacetate.2 H 2 0 (EDTA) ) equivalent to half the volume of the gel slice was added to the tube, and the agarose was melted by heating to 65 °C for fifteen minutes. Following equilibration of the sample to 42 °C, approximately 5 units of β-Agarase I (New England Biolabs, Inc.) was added. The sample was incubated for 2 hours to digest the agarose. After incubation, a 0. IX volume of 3M sodium acetate was added to the sample, and the mixture was incubated on ice for fifteen minutes. After incubation, the sample was centrifuged at 14,000 x g for 10 minutes to remove the undigested agarose. The cDNA in the supernatant was ethanol precipitated. The cDNA pellet was washed with 70% ethanol, air dried and resuspended in 37 μl of water. The cDNA recovered from the agarose gel was phosphorylated using T4 polynucleotide kinase. The reaction consisted of 37 μl cDNA, 5 μl 10X Stratagene Ligase Buffer (Stratagene Cloning Systems) . Following a 5 minute incubation at 65 °C, the reaction was cooled to room temperature where 5 μl 10 mM ATP (Pharmacia) and 3 μl T4 DNA polymerase (10 U/μl, Stratagene) were added. The reaction was incubated at 37 °C for 45 minutes and at 65 °C for 10 minutes. The reaction was terminated by serial phenol/chloroform extractions. The samples were chromatographed through a Clontech TE400 spin column and were precipitated in the presence of 2.5 M ammonium acetate. The cDNA was resuspended in 15 μl of 2.5 mM Tris-HCl, pH 8.0, 0.25 mM EDTA. The resulting Eco Rl-Xho I cDNA library was cloned into the E. coli vector pZCEP (Jelinek et al . , Science 259: 1614-16, 1993) . Eco Rl-Xho I linearized pZCEP was ligated with the Eco Rl-Xho I cDNA library. The resulting plasmids were electroporated into the E . coli strain DH10B ELECTROMAX- (Gibco BRL) . The library was plated to obtain >5 x 10^ independent colonies and aliquoted into 120 pools to give approximately 5,000 colonies per pool. An aliquot of the cells from each pool was removed for use in preparing plasmid DNA. The remaining cell mixtures were brought to a final concentration of 15% glycerol, aliquoted and frozen at - 80 °C. Plasmid DNA was prepared from each pool and the resulting plasmid DNA was digested with RNAse (Boehringer Mannheim) according to the manufacturer's instructions. The RNAse reaction was terminated by a phenol/chloroform/isoamylalcohol (24:24:1) extraction, and the DNA was ethanol precipitated. The pools were systematically screened as described in the examples below. Example 2 Transfection of Macaque DNA into COS-7 Cells Macaque DNA from each pool was transfected into COS-7 cells (African Green Monkey Kidney cells, ATCC CRL 1651) using the method essentially described by McMahan et al. (EMBO J. 10: 2821-32, 1991; which is incorporated by reference herein in its entirety) . Briefly, one day prior to transfection approximately 2 x 10^ COS-7 cells in 2 ml growth medium containing 10% fetal bovine serum (Dulbecco's modified Eagle's medium (DMEM) , 1% L- glutamine, 1% PNS antibiotic mix (Gibco BRL) , 25 mM Hepes, and 1 mM NaPyruvate) were plated on sterile, single-chamber slides (Nunc AS, Roskilde, Denmark) that had been coated with 10 μg/ml of human fibronectin in PBS for 30 minutes at 37 °C and washed with phosphate buffered saline (PBS) . For each pool to be tested, 1-2 μg of macaque islet cell library pooled DNA was added into 100 μl of serum free medium (SFM, F/DV medium, 10 mg/1 transferrin, 2 μg/1 selenium, 10 mg/1 fetuin, 5 mg/1 insulin, 1% L-glutamine, 25 mM Hepes, 1 mM NaPyruvate, and 0.1 mM NEAA) . To each DNA sample was added 100 μl SFM containing 12 μl LipofectAMINE- (Gibco BRL) . The transfection solution was mixed by pipetting up and down and kept at room temperature for 15 to 45 minutes. To each mix was added 0.8 ml SFM which was then gently added to the COS-7 cells which had been washed once with SFM. The cells were incubated at 37 °C, 5% C0 2 for 4-5 hours. One milliliter of growth medium containing 20% FBS was added to each slide. Slides were incubated overnight at 37 °C, 5% C0 2 . The spent medium was removed and replaced with 2 ml growth medium containing 10% FBS and the cells incubated for 24 to 48 hours, preferably 48 hours, at 37 °C, 5% C0 2 . Example 3 Diabetic Sera Sera from two prediabetic subjects, EmWi and JoGr, were selected for screening the islet cell cDNA library. Sera from both subjects were characterized for autoantibodies to known β-cell antigens using techniques known in the art. The sera were tested for GAD65 autoantibodies using an in vi tro transcription/translation assay (Grubin et al., Diabetologia 37: 344-50, 1994) followed by immunoprecipitation using radiolabeled recombinant human GAD65 according to Hagopian et al. , J. Clin. Invest. 91 : 368-74, 1993. Recombinant radiolabeled GAD was expressed in the presence of 35 S Methionine (Amersham Corp., Arlington Heights, IL) using the Sp6 bacteriophage promoter and the TNT reticulocyte lysate kit (Promega) , according to manufacturer's direction. 35 S Methionine incorporation was determined by precipitation using trichloroacetic acid (TCA) , and 25% or more incorporation was considered acceptable. Radiolabeled antigen was stored at -80 °C until use. Radiolabeled antigen was diluted 1:10 in immunoprecipitation buffer (150 mM NaCl, 1% v/v Triton X- 114 (Sigma Chemical Co., St. Louis, MO) , 0.05% Bovine serum albumin (Sigma) , 10 mM benzamidine (Sigma) , and 10 mM HEPES pH 7.4) . The antigen was incubated for preclearing for 4 hours at 4 °C with 50 μl normal human serum. Immunoglobulin was removed using 200 μl Protein A Sepharose beads (Pharmacia LKB Biotechnology Inc.) for 45 minutes. The cleared supernatant was diluted to 50,000 TCA-precipitable counts per minute (cpm) per 400 μl immunoprecipitation buffer. Four microliters of serum from diabetic or control patients was separately incubated in duplicate with 400 μl diluted antigen at 4 °C overnight with mixing by gentle rotation. Antigen- antibody complexes were precipitated by 16 μl Protein A Sepharose, and the pellet was washed 5 times in ice-cold wash buffer which consisted of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.05% BSA, and 0.25% Triton X-114. Antigen was dissociated from the pellet by boiling in the presence of 2% SDS and 5% β-mercaptoethanol, and counted by scintillation counting in scintillation fluid. Counts per minute reflect the level of autoantibodies present in the sera to capture the antigen. Autoantibodies to the protein tyrosine phosphatase IA-2/ICA512 were detected as above using a radiolabeled cytoplasmic domain of human IA-2/ICA512 (Lan et al . , DNA Cell Biology 13 : 505-14, 1994; and Hagopian et al . , Autoimmunity 21 : 61, 1995) . The complete cytoplasmic domain of human IA-2 was isolated by RT-PCR from U87MG glioblastoma cells (ATCC M85) . Briefly, total RNA was prepared from 5 x 10 7 glioblastoma cells which were homogenized in 3.5 ml guanidine/LiCl followed by CsCl centrifugation. First strand cDNA was synthesized using a Superscript- Preamplification System (GIBCO BRL) according to the manufacturer's directions. One and one half microliters of a solution containing 5 μg total U87MG RNA was mixed with 1 μl oligo dT solution and 11.5 μl diethylpyrocarbonate-treated water. The mixture was heated at 70 °C for 10 minutes and cooled by chilling on ice. First strand cDNA synthesis was initiated by the addition of 2 μl Superscript- II buffer, 2 μl 0.1 M dithiothreitol, 1 μl deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP, and dCTP, and 1 μl of 200 U/μl Superscript- II reverse transcriptase to the RNA-primer mixture. The reaction was incubated at room temperature for 10 minutes followed by an incubation at 42 °C for 50 minutes, then 70 °C for 15 minutes, then cooled on ice. The reaction was terminated by addition of 1 μl RNase H which was incubated at 37 °C for 20 minutes, then cooled on ice. A 100 μl PCR reaction mixture was then prepared containing 20 μl of first strand template, 8 μl 10X synthesis buffer, 3.3 μM ZC8802 (SEQ ID NO:9, contains 5' Xho I site and ATG) , 5.4 μM ZC8803 (SEQ ID NO:10, contains Eco RI site following stop codon) , 65 μl dH 2 0 and 1 wax bead (AmpliWax-, Perkin-Elmer Cetus, Norwalk, CT) . Following an initial cycle of 95 °C for 2 minutes, 4 °C for 10 minutes, 5 U Taq polymerase was added, and the reaction was amplified for 30 cycles of 1 minute at 95 °C, 2 minutes at 55 °C and 3 minutes at 72 °C.. The reaction mixture was then stored at 4 °C. The resulting 1.2 kb fragment (SEQ. ID. No.30) was digested with Eco Rl-Xho I, treated with RNAse, then isolated by low melt agarose gel electrophoresis and ligated into Eco Rl-Xho I linearized pZCEP. Sera were screened for IA-2/ICA512 autoantibodies as described above for GAD autoantibodies. Both E Wi and JoGr sera showed reactivity to IA-2/ICA512. The sera were titered for IA-2/ICA512 reactivity on vector only transfected COS-7 cells using techniques known in the art, see for example, Greenbaum et al . (Diabetes 41 : 1570-1574, 1992) . The sera were separately adsorbed with porcine insulin (Hoechst, 10 mg/ml) and GAD (1 mg/ml) until reactivity was abolished in the respective antibody assays . These sera were then retitered for IA-2/ICA512 as above. JoGr had IA-2/ICA512 reactivity of 280 JDFU (Juvenile Diabetes Foundation Units) which persisted at >130 JDFU after adsorption. EmWi had IA-2/ICA512 reactivity of 140 JDFU which persisted at >130 JDFU after adsorption. EmWi had the lowest background staining and was therefore used for primary screening. Twenty milliliters of EmWi was diluted 1:1 in 0.1 M NaP0 4 buffer, pH 8.0 and incubated with an equal volume of Protein A covalently linked to Sepharose beads (Zy ed, South San Francisco, CA) for affinity purification. After gentle mixing for 45 minutes at 4 °C, the slurry was loaded onto a column and washed with 10 column volumes of 0.1 M NaP0 4 buffer, pH 8.0 and one column volume of 0.01 M NaP0 4 buffer, pH 8.0, before elution of immunoglobulins with 0.05 M Na citrate buffer, pH 3.5. Eluted immunoglobulins were immediately neutralized to pH 7.0 with 2 M Tris, pH 8.0. Eluted fractions were evaluated by spectrophotometric absorption at 280 nM, and peak fractions were pooled, aliquoted and flash frozen for storage at -80 °C. Typically the concentration was 4 mg/ml IgG. C0S-7 cells were grown to confluence in 150 ml T-flasks, washed with PBS, fixed in 4% paraformaldehyde, and permeabilized by freeze/thaw. The pooled sera were diluted to 1 mg/ml in PBS and incubated with the permeabilized COS-7 cell lysate overnight at 4 °C. Supernatant was cleared at 100,000 x g and aliquotted for storage at -80 °C for use in the binding assay. Example 4 Binding Assay The macaque DNA transformed COS-7 cells on single chamber slides, from Example 2, were prepared for assay by removing spent medium from the slides and washing the cells 3 times in PBS at room temperature. The cells were fixed with 1 ml 50% ETOH/50% acetone for 5 minutes at room temperature followed by two washes in PBS and two washes in 1% bovine serum albumin (BSA) in PBS. The precleared serum (EmWi) was diluted to 0.2 mg/ml in a 5% BSA in PBS solution, and 500 μl was added to each of the slides which were then covered, wrapped in plastic wrap, and rocked gently on a rocker overnight at room temperature. The slides were then washed three times in a 1% BSA/PBS solution, three minutes for each wash. Following the final wash, the slides were blocked for 10 minutes with 1 ml 5% BSA/4% normal goat serum (Sigma) in PBS at room temperature. The blocking buffer was removed, and 500 μl of 0.02 mg/ml biotinylated Protein A (Amersham Corp., Arlington Heights, IL) in 5% BSA/4% normal goat serum/PBS was added, followed by a 30 minute incubation at room temperature. The slides were washed three times with 1% BSA/PBS, three minutes for each wash, then 500 μl streptavidin-gold (Amersham) diluted 1:50 in 5% BSA/4% normal goat serum/PBS was added to each slide. Following a 60 minute incubation at room temperature the slides were washed three times in 1% BSA/PBS and one final time in PBS. The slides were then fixed by adding 0.5 ml of 9% formaldehyde/45% acetone in PBS for 30 seconds followed by three, 3 minute washes in dH 2 0. An equal volume of silver enhancement solution and initiator (IntenSE- M Silver Enhancement Kit, Amersham) were mixed in a 15 ml conical tube, and 0.5 ml was added to each slide. The slides were allowed to develop for 20 minutes or until the desired color intensity was achieved. The slides were then rinsed twice for five minutes in dH 2 0 and air dried. A single positive pool (#18) containing approximately 5,000 clones was found out of approximately 50 pools screened using EmWi sera. To isolate the positive clone (s) from pool #18, one 150 mm plate was plated to give approximately 10,000 colonies from the #18 pool. Filter lifts were prepared using the methods essentially described by Hanahan and Meselson (Gene 10: 63, 1980) and Maniatis et al . (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, 1982) , which are incorporated herein by reference in their entirety. The hybridization probe was obtained by PCR amplification of plasmid DNA from pool #18. Briefly, an aliquot of the plasmid DNA from pool #18 was subjected to PCR amplification using oligonucleotides ZC8802 and ZC8803 (SEQ ID NOS : 9 and 10, respectively) . A 50 μl reaction mixture was prepared containing 0.05 μg of the plasmid DNA from pool #18; 20 pmole of ZC 8802 and ZC 8803 (SEQ ID NOS: 9 and 10, respectively) ; 10 nmoles of each deoxynucleotide triphosphate (Pharmacia) ; 4 μl 10X synthesis buffer (Boehringer Mannheim), and 2.5 U Taq polymerase (Boehringer Mannheim) . The PCR reaction was run for 24 cycles (1 minute at 94°C, 1 minute at 56°C, and 1 minute at 72°C) . An approximately 1.1 Kb band was isolated on a low melt agarose gel electrophoresis and random primed using the MEGAPRIME- Kit (Amersham) according to the manufacturer' s instructions. The filter was hybridized in a solution containing 6X SSC, 0.1% SDS, 5X Denhardt's, 200 μg/ml denatured, sheared salmon sperm DNA, and 1 x 10 5 cpm/ml of 32 P-labeled PCR fragment. The filter was hybridized overnight at 65°C. The excess label was removed by two, 15 minute washes with 2X SSC, 0.1% SDS at 65°C. The filter was exposed to film overnight at -80°C with two screens . Eighteen positive colonies were detected. Six of these colonies were cultured and subjected to a second round of filter lifts as described above, and from this two positive clones were identified. Restriction endonuclease analysis showed that both contained an approximate 2 Kb insert. One clone, designated Ml.18.5.1, was sequenced, revealing a 2,170 bp coding region which contained regions of homology to the protein tyrosine phosphatase family, especially IA-2/ICA512. Comparison of the full length human protein tyrosine phosphatase IA-2/ICA512 with Ml.18.5.1 suggests that the coding region of Ml.18.5.1 is missing amino terminal sequence corresponding to approximately 400 amino acids. The partial nucleic acid sequence and deduced amino acid sequence of Ml.18.5.1 is shown in SEQ ID NO 1 and SEQ ID N0:2. Ml.18.5.1 was re-transfected into COS-7 cells and assayed as described above. In addition to the EmWi sera, the JoGr sera, which had a high titer to IA-2, was added to the screen and both detected Ml.18.5.1. Example 5 Isolation of Human Islet Cell Antigen 1851 The 2,170 nucleotide sequence from Ml.18.5.1 (SEQ ID NO 1) was used to conduct a sequence search for a human homolog. A match was found in the GenBank database (GenBank ID: T0361, clone ID: HFBCV88) submitted by The Institute of Genomic Research, Gaithersburg, MD, as an expressed sequence tag (EST) from a human fetal brain library (Stratagene Cloning Systems) . HFBCV88 (EST24415.seq) , a 127 amino acid polypeptide, SEQ ID NO:5, had homology to a region of the cytoplasmic domain of Ml.18.5.1. The closest human DNA sequence to HFBCV88 is HSICA512, islet cell antigen ICA-512. An oligonucleotide primer (ZC10,011 SEQ ID NO:11) was made to a conserved region between 1851 and HFBCV88 which differed from the corresponding sequence of mouse and human IA-2/ICA512 in that an arginine was substituted for a methionine. Combined with a 128 fold degenerate primer (ZC10,019 SEQ ID NO: 14, AARGCNACNGTNGAYAAY, wherein R is A or G, N is A, C, T, or G, and Y is C or T) which lies just upstream of the transmembrane domain, in the extracellular domain, a portion of the human homologue of Ml.18.5.1 was identified in human insulinoma cDNA by PCR. Briefly, a PCR reaction was performed in a 100 μl final volume using 12.5 ng Marathon-ready human insulinoma cDNA prepared according to manufacturer's instruction (Marathon- cDNA Amplification Kit, Clontech) , 20 pmoles each of primers ZC 10,011 (SEQ ID NO:ll) and ZC 10,019 (SEQ ID NO:14) , and the reagents provided in the Marathon- PCR kit (Clontech) according to the manufacturer's instructions. The reaction was amplified for 30 cycles (1 minute at 94 °C, 30 seconds at 60 °C, 5 minutes at 68 °C) followed by a 10 minute extension at 72 °C. An 800 bp (WK11111, SEQ ID NO:32) and a 1,200 bp (WK121315, SEQ ID NO:34) fragment were isolated by low melt agarose gel electrophoresis. A 3'RACE Marathon PCR was also performed in a 50 μl final volume using 12.5 ng Marathon-ready human insulinoma cDNA, 10 pmoles each of primers ZC 10,177 (SEQ ID NO:12) the complement to ZC 10,011, and AP-1 (adaptor primer, supplied with kit) , and the reagents provided in the 3 'RACE Marathon- PCR kit (Clontech) , according to the manufacturer's instructions. The reaction was amplified for 30 cycles (30 seconds at 94 °C, 30 seconds at 68 °C) . A 900 bp and a 2,000 bp (WK121111, SEQ ID NO:33) fragment were isolated by low melt agarose electrophoresis. The 800 bp, (SEQ ID NO:32) 1,200 bp, (SEQ ID NO:34) and 2,000 bp (SEQ ID NO:33) PCR fragments were independently subcloned into pCRl (Invitrogen Inc., San Diego, CA) , using the TA Cloning Kit (Invitrogen Inc.) according to the manufacturer's instructions. The resulting plasmids (11.1.1, 11.1.2, and 11.1.3, respectfully) were used to transform E . col i XL-1 cells. Transformants were screened for presence of insert, followed by sequencing of the insert. Example 6 Detection of Human Islet Cell Antigen Autoantibodies An approximately 1.1 kb (SEQ ID NO: 6) Eco RI- Hind III cytoplasmic fragment of human islet cell antigen 1851 cDNA was inserted into the vector pcDNAII (Invitrogen, San Diego, CA) , and designated IL1851-3. The resultant polypeptide was transcribed and translated in vi tro using a TNT Coupled Reticulocyte Lysate System (Promega) , according the manufacturer's instructions. The labeled, synthesized cytoplasmic portion of human islet cell antigen 1851 was used to screen diabetic sera from six patients, for the presence of autoantibodies. Protein A-Sepharose immunoprecipitation, as described above, showed that sera from all six reacted positively with the in vi tro synthesized, human islet cell antigen, and indicated that the major autoepitope is likely present on this polypeptide. Additional immunoprecipitation assays were performed with a spectrum of serum samples, including 91 healthy control sera (median age 22 years, range 1-49 years, 49% males and 51% females) ; 183 newly diagnosed IDDM patients sampled at onset (median age 11 years, 51% males and 49% females) ; and 60 first degree relatives of type I diabetic patients sampled a mean of 2.0 years before onset (median age 12 years, 58% males and 42% females) . Parallel autoantibody assays used the intracellular domain of IA-2/ICA512. Immunoprecipitation assays were as described above. Briefly, 4 μl of serum from diabetic or control patients were separately incubated in duplicate with 400 μl 35 S radiolabeled antigen (cytoplasmic portion of human islet cell antigen 1851, SEQ ID NO: 6, in immunoprecipitation buffer (lOmM Hepes, 0.05% BSA, 150mM NaCl, lOmM benzamidine, and 1% Triton X114)) at 4 °C overnight with mixing by gentle rotation (Hagopian et al. , J. Clinc. Invest. 91 :368-74 , 1995) . Antigen-antibody complexes were precipitated using 20 μl Protein A Sepharose, and the pellet was washed 3 times in ice-cold wash buffer (which consisted of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.25% BSA, and 0.25% Triton X-114) and one cold water wash. Antigen was dissociated from the pellet by boiling in the presence of 2% SDS and 5% β-mercaptoethanol, counted by scintillation counting in scintillation fluid, and the results expressed as islet cell antigen 1851 index (Hagopian et al . , Diabetes 4_2:631-36, 1993) . Counts per minute reflect the level of autoantibodies present in the sera that can capture the antigen. Assay cutoff was an index of 0.04, determined as the mean +3 standard deviations of 91 control sera. Assay sensitivity, specificity, and positive predictive value were calculated (Hagopian et al. , ibid. , 1995) . Immunoprecipitation assays revealed autoantibodies in 56/183 (30.6%) newly diagnosed IDDM patients, 28/60 (46.7%) first degree relatives later progressing to clinical diabetes, but only 1/91 (1.1%) healthy control subject groups. For first degree relatives, this represents a positive predictive value of 58% and a sensitivity of 48%. Of sera from 153 newly diagnosed patients, 83 (54%) recognized IC-2/ICA512 and 48 (31%) recognized islet cell antigen 1851. Only 1/48 (2%) from the sera recognizing islet cell antigen 1851 did not precipitate IA-2/ICA512, but 35/83 (42%) from the sera reactive with IA-2/ICA512 did not bind islet cell antigen 1851. Of those positive for both antigens, reactivity to IA- 2/ICA512 was generally stronger than that to islet cell antigen 1851. The intracellular domains of human islet cell antigen 1851 and IA-2/ICA512 were expressed and radiolabeled by in vi tro transcription and translation using a TNT Coupled Reticulocyte Lysate System (Promega) , according the manufacturer's instructions, as described above. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography of the resulting radiolabeled polypeptide revealed, for human islet cell antigen 1851, a major band of 46 kD and a minor band at 33 kD, both immunoprecipitated by IDDM sera. Limited trypsin digest of the radiolabeled immunoprecipitated intracellular fragment of macaque and human islet cell antigen 1851 and IA-2/ICA512 was done using the method of Christie et al . (J. Exp. Med. 172:789-94, 1990) , followed by SDS-PAGE and autoradiography, which revealed a 37 kD product from both macaque and human islet cell antigen 1851. This product was distinct from the 40 kD product produced by limited trypinization of the intracellular domain of IA-2/ICA512. In order to test whether IA-2/ICA512 autoantibodies recognized only epitopes shared with islet cell antigen 1851, the intracellular domain of IA- 2/ICA512 was expressed in baby hamster kidney cells (BHK cells) . The 1.2 kb IA-2/ICA512 intracellular fragment (SEQ ID NO:30) from Example 3 was ligated into pZEM219b under the SV40 promoter (Busby et al . , J. Biol. Chem. 266 :15286-92, 1991) and cellular expression was determined by immunocytochemistry using rabbit polyclonal antiserum to IA-2/ICA512 (Rabin et al . , J. Immunol . 152:3183-88, 1994) . IA-2/ICA512-transfected BHK cells were homogenized in homogenization buffer (0.25% Triton X-114, 10 mM benzamidine) . Using Western blotting, the concentration of recombinant intracellular IA-2/ICA512 was estimated at 7 μg/ml of cell extract. Immunoprecipitation assays, as described above, were done using radiolabeled islet cell antigen 1851 in the presence of 0.5 μg of unlabeled IA-2/ICA512 per microliter of islet cell antigen 1851 positive sera, as a competitor. Islet cell antigen 1851 autoantibodies not fully blocked by this amount of IA-2/ICA512 were subjected to repeated immunoprecipitation assays using a 2.5 fold increase of unlabeled IA-2/ICA512 as a competitor. As a control, extracts from non-transfected BHK cells were used. Recombinant intracellular IA- 2/ICA512 fully blocked islet cell antigen 1851 reactivity in 29/53 islet cell antigen 1851 positive sera, while a median of 21.4% (range 3%-55%) of original immunoreactivity was retained in 24/53 sera. Increasing the IA-2/ICA512 concentration did not reduce this residual immunoreactivity, suggesting that unique islet cell antigen 1851 epitopes are being recognized in certain sera. Example 7 Cloning the Remaining 5 ' Sequence of Macaque and Human Islet Cell Antigen 1851 cDNA To obtain the remaining 5 ' macaque cDNA sequence one pool (#12) from the macaque library described in Example 1 was plated at 10,000 colonies/150 mm plate. Filter lifts were prepared (Maniatis et al . (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, 1982) and denatured with 0.5 M NaOH for four minutes, neutralized with 1 M Tris pH8.0 for 2 minutes followed by renaturation with 1 M Tris pH 8.0/1.5 M NaCl for 2 minutes. Filters were cross linked in a UV Stratalinker (1200 μj) (Stratagene Cloning Systems, La Jolla, CA) . The filters were prehybridized in 20 ml hybridization buffer (6X SSC, 0.5% SDS, 5X Denhardts and 0.2 mg/ml boiled salmon sperm DNA) overnight at 65°C. The filters were then hybridized in 20 ml hybridization buffer containing 1 x 10 6 cpm/ml γ32 P-ATP labeled hybridization probe (ZC10504 SEQ ID NO:18) overnight at 65°C. The labeled hybridization probe was prepared by adding to a 5 μl final volume 30 pmol oligo ZC10504 (SEQ ID N0:18) , T4 polynucleotide kinase buffer, 37.5 pmol γ32 P- ATP and 10 U T4 polynucleotide kinase The reaction was incubated for 1 hour at room temperature and unincorporated ATP was removed using a Stratagene push column according the manufacturer's instructions (Stratagene Cloning Systems, La Jolla, CA) . Following the hybridization, excess unbound label was removed from the filters with eight washes in 2X SSC/0.1% SDS (2 times with 20 ml, 5 times with 30 ml and a final wash in 100 ml) for 5 to 10 minutes at 65°C. The filters were exposed to film overnight at -80°C. Several positive colonies were detected. One of these colonies was cultured from a replica plated colony and subjected to sequence analysis. The clone, 12.10504.1, contained 2,736 bp coding region (SEQ ID NO:23) , containing the cytoplasmic and transmembrane domains and extending the 5 ' end of the macaque extracellular domain sequence (SEQ ID N0:1) by 609 bp. 5 ' RACE PCR was used to generate the remaining 5' cDNA fragments of macaque islet cell antigen 1851. To a 50 μl final volume was added 5 pmol of a vector- specific oligonucleotide primer (ZC11197, SEQ ID NO:29) , 5 pmol of a macaque specific primer (ZC11654, SEQ ID NO:28) , 1 ng macaque islet cell cDNA library from Example 1, 40 mM dNTPs, TAQ Polymerase buffer and 1.25 U TAQ Polymerase. A one minute denaturation at 94°C was followed by 30 amplification cycles (30 seconds at 94 °C, 1 minute at 60 °C, 2 minutes at 72 °C) followed by a 6 minute extension at 72 °C) . Four independent 5 'RACE PCR reactions were run, each using a different pool from the macaque library as template. Four fragments were obtained, a 738 bp fragment (SEQ. ID. No. 24) extending the 5' end by 246 bp; a 932 bp fragment (SEQ ID NO:25) extending the 5' end by 193 bp; a 999 bp fragment (SEQ ID NO:26) extending the 5' end by 68 bp and a 1011 bp fragment (SEQ ID NO:27) which contained the remaining 5 ' sequence with the exception of the start methionine. The fragments were isolated by agarose electrophoresis, excised and separated from the agarose using the Qiagen Qiaquick Gel Extraction System (Qiagen, Inc., Chatsworth, CA) according to manufacturer's instruction. The fragments were subcloned into pGEM-T (Promega Corp., Madison, Wi. ) , using the TA Cloning Kit (Promega Corp.) according to the manufacturer's instructions. The resulting plasmids pJML8, 7, 9 and 10 respectfully, were used to transform E. col i DH10B cells. Transformants were screened for presence of insert, followed by sequencing of the insert. The 5' RACE fragments (SEQ ID Nos:23, 24, 25, 26 and 27) contain overlapping segments and were aligned with the macaque islet cell antigen 1851 sequence of SEQ ID NO:l to give a full length macaque islet cell antigen 1851 DNA sequence as represented in SEQ ID NO:15. Comparison of the human protein tyrosine phosphatase IA- 2/ICA512 cDNA and amino acid sequences with those of the macaque islet cell antigen 1851 cDNA and amino acid sequences (SEQ ID NOs: 15 and 16) suggests that the coding region is missing the start methionine. A vector containing the full length macaque sequence can be created using PCR. The macaque 5' RACE fragments (SEQ ID NOs: 23, 24, 25, 26 and 27) can be joined using PCR. A clone shown to possess the complete coding sequence can then be digested with convenient restriction sites and subcloned into a vector of choice. Clones can be screened for correct insertion of the full length sequence and subjected to DNA sequence analysis. PCR using macaque derived primers was done to identify remaining 5' cDNA sequence for the human islet cell antigen 1851 (SEQ ID NO:6) . To a 50 μl final volume was added 5 pmol each of two gene-specific oligonucleotide primers ZC10504, SEQ ID NO:18 and ZC11653, SEQ ID NO:17, 1 ng Marathon-ready insulinoma cDNA, prepared according to manufacturer's instruction (Marathon- cDNA Amplification Kit, Clontech) , 40 mM dNTPs, TAQ Polymerase buffer and 1.25 U TAQ Polymerase. The reaction was denatured at 94 °C for one minute, amplified for 30 cycles (30 seconds at 94 °C, 1 minute at 63 °C, 2 minutes at 72 °C) , followed by a 6 minute extension at 72 °C) . A 1263 bp fragment (SEQ ID NO: 31) was isolated by agarose electrophoresis. The isolated fragment was then excised and subcloned into pGEM-T using the TA Cloning Kit (Promega, Corp.), as described above. The clones were then analyzed for the presence of insert, and those containing insert were subjected to DNA sequence analysis. The human islet cell antigen 1851 fragments can be joined using PCR to give the human sequence as represented in SEQ ID NO:21. Clones can be screened for correct insertion of the fragments and subjected to DNA sequence analysis. Comparison of the human protein tyrosine phosphatase IA-2/ICA512 cDNA with that of the human islet cell antigen 1851 sequences (SEQ ID NO:21 and 22) suggests that the coding region is missing 5' sequence corresponding to approximately 600 bp. Including the 3' untranslated region, but not the 5' untranslated region, the estimated mRNA size for the human sequence is 5 kb, which is consistent with the 5.5 kb mRNA observed in Northern blots discussed below. To obtain the remaining 5' human islet cell antigen 1851 cDNA sequence, additional PCR or 5' RACE PCR reactions can be performed as described above. Example 8 Tissue Distribution Human Multiple Tissue Northern Blots (MTN I, MTN II, and MTN III; Clontech, Palo Alto, CA) were probed to determine the tissue distribution of human islet cell antigen 1851 expression. A 38 nucleotide oligonucleotide sequence just external to the transmembrane region of human islet cell antigen 1851, which is distinct from the corresponding sequence of IA-2/ICA512 (SEQ ID NO: 18) was radioactively labeled with γ32p using a T4 nucleotide kinase (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's specifications. ExpressHyb- (Clontech) solution was used for prehybridization and as a hybridizing solution for the Northern blots. Hybridization took place overnight at 37°C using 5 x 10 6 cpm/ml of labeled probe. The blots were then washed three times at room temperature, once at 50°C for 30 minutes, once at 60°C, in 6X SSC, 0.1% SDS. A final wash at 68 °C with 2X SSC, 0.05% SDS for 20 minutes was done prior to autoradiography. Two transcript sizes were detected. A strong 5.5 kb band and a weaker 3.3 kb band were detected in brain, pancreas and prostate, with lesser signals in spinal cord, thyroid, adrenal and GI tract. With the exception of prostate, this represents the expected neuroendocrine distribution. In order to define tissue localization further, in si tu hybridization was performed on macaque pancreas, adrenal gland and muscle. The 38 nucleotide islet cell antigen 1851 oligonucleotide (SEQ ID NO:18) , a 38 bp IC- 2/ICA512 oligonucleotide (SEQ ID NO: 19) and a 30 bp insulin β-chain probe for pancreatic islets (Petersen et al., Diabetes 42.:484-95, 1993) (SEQ ID NO:20) were end- labeled with 33 P-dATP (New England Nuclear, Boston, MA) using terminal deoxytransferase (GIBCO BRL) according to manufacturer's instructions. Frozen sections (14 μm) from macaque pancreas, adrenal, pituitary and muscle were fixed in 4% paraformaldehyde, followed by acetylation with acetic anhydride and then delipidated in chloroform prior to use. Labeled probes (2 pmol/ml) were incubated on the sections overnight and then washed in two changes of IX SSC at 60 °C for 30 minutes, followed by dehydration in ethanol and apposition to autoradiography film (Hyperfilm Betamax, Amersham Corp., Arlington Heights, IL) for 2 to 6 days. The slides were then coated with NTB2 Track emulsion (Eastman Kodak, Rochester, NY) and exposed for 12-18 days before development and counterstain with cresyl violet . Images were captured using a Dage 72 CCD camera and a MCID M2 imaging system (Imaging Research, Ontario, Canada) . Strong hybridization was detected in pancreatic islets and adrenal medulla but not in muscle. The IA-2/ICA512 and the insulin β chain probes hybridized to islets. From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims . SEQUENCE LISTING (1) GENERAL INFORMATION (1) APPLICANT: ZymoGenetics. Inc. 1201 Eastlake Avenue East Seattle WA USA 98102 University of Washington Seattle WA USA 98195 (11) TITLE OF THE INVENTION: ISLET CELL ANTIGEN 1851 (ill) NUMBER OF SEQUENCES: 34 (i ) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Zy oGenetics, Inc. (B) STREET: 1201 Eastlake Avenue East (C) CITY: Seattle (D) STATE: WA (E) COUNTRY: USA (F) ZIP: 98102 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ for Windows Version 2.0 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (viii) AHORNEY/AGENT INFORMATION: (A) NAME: Lingenfelter. Susan (B) REGISTRATION NUMBER: P-41,156 (C) REFERENCE/DOCKET NUMBER: 95-36 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 206-442-6675 (B) TELEFAX: 206-442-6678 (C) TELEX: (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2171 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...1923 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GAA TTC GGC ACG AGC GGA GTT CAG GAC GAC GAT GAC AGA CTT TAC CAA 48 Glu Phe Gly Thr Ser Gly Val Gin Asp Asp Asp Asp Arg Leu Tyr Gin 1 5 10 15 GAG GTC CAT CGT CTG AGT GCC ACA CTC GGG GGC CTC CTG CAG GAC CAC 96 Glu Val His Arg Leu Ser Ala Thr Leu Gly Gly Leu Leu Gin Asp His 20 25 30 GGG TCT CGA CTC TCG CCT GGA GCC CTC CCC TFT GCA AAG CCC CTC AAA 144 Gly Ser Arg Leu Ser Pro Gly Ala Leu Pro Phe Ala Lys Pro Leu Lys 35 40 45 ATG GAG AGG AAG AAA TCC GAG CGC CCT GAG GCT TCC CTG TCT TCA GAA 192 Met Glu Arg Lys Lys Ser Glu Arg Pro Glu Ala Ser Leu Ser Ser Glu 50 55 60 GAG GAG ACT GCC GGA GTG GAG AAC GTC AAG AGC CAG ACG TAT TCC AAA 240 Glu Glu Thr Ala Gly Val Glu Asn Val Lys Ser Gin Thr Tyr Ser Lys 65 70 75 80 GAC CTG CTG GGG CAG CAG CCG CAT TCG GAG CCC GGG GCA GGC GCG TTT 288 Asp Leu Leu Gly Gin Gin Pro His Ser Glu Pro Gly Ala Gly Ala Phe 85 90 95 GGG GAG CTC CAA AAC CAG ATG CCT GGG CCC TCG GAG GAG GAG CAG AGC 336 Gly Glu Leu Gin Asn Gin Met Pro Gly Pro Ser Glu Glu Glu Gin Ser 100 105 110 CTT CCA GCG GGT GCT CAG GAG GCC CTC GGC GAC GGC CTG CAA TTG GAA 384 Leu Pro Ala Gly Ala Gin Glu Ala Leu Gly Asp Gly Leu Gin Leu Glu 115 120 125 GTC AAG CCT TCC GAG GAA GAG GCA CGG TGC TAC ATC GTG ACA GAC AGA 432 Val Lys Pro Ser Glu Glu Glu Ala Arg Cys Tyr He Val Thr Asp Arg 130 135 140 GAC CCC CTG CGC CCC GAG GAA GGA AGG CAG CTG GTG GAG GAC GTC GCC 480 Asp Pro Leu Arg Pro Glu Glu Gly Arg Gin Leu Val Glu Asp Val Ala 145 150 155 160 CGC CTC CTG CAG ATG CCC AGC AGC ACA TTC GCC GAC GTG GAG GTT CTC 528 Arg Leu Leu Gin Met Pro Ser Ser Thr Phe Ala Asp Val Glu Val Leu 165 170 175 GGA CCA GCA GTG ACC TTC AAA GTG GGC GCC AAT GTC CAG AAC GTG ACC 576 Gly Pro Ala Val Thr Phe Lys Val Gly Ala Asn Val Gin Asn Val Thr 180 185 190 ACT GCG GAT GTG GAG AAG GCC ACA GTT GAC AAC AAA GAC AAA CTG GAG 624 Thr Ala Asp Val Glu Lys Ala Thr Val Asp Asn Lys Asp Lys Leu Glu 195 200 205 GAA ACC TCT GGA CTG AAA ATT CTT CAA ACC GGA GTC GGG TCG AAA AGC 672 Glu Thr Ser Gly Leu Lys He Leu Gin Thr Gly Val Gly Ser Lys Ser 210 215 220 AAA CTC AAG TTC CTG CCT CCT CAG GCG GAG CAA GAA GAC TCA ACC AAG 720 Lys Leu Lys Phe Leu Pro Pro Gin Ala Glu Gin Glu Asp Ser Thr Lys 225 230 235 240 πC ATC GCG CTC ACC CTG GTC TCC CTC GCC TGC ATC CTG GGC GTC CTC 768 Phe He Ala Leu Thr Leu Val Ser Leu Ala Cys He Leu Gly Val Leu 245 250 255 CTG GCC TCT GGC CTC ATC TAC TGC CTA CGC CAT AGC TCT CAG CAC AGG 816 Leu Ala Ser Gly Leu He Tyr Cys Leu Arg His Ser Ser Gin His Arg 260 265 270 CTG AAG GAG AAG CTC TCG GGA CTA GGG CGC GAC CCA GGT GCA GAT GCC 864 Leu Lys Glu Lys Leu Ser Gly Leu Gly Arg Asp Pro Gly Ala Asp Ala 275 280 285 ACC GCC GCC TAC CAG GAG CTG TGC CGC CAG CGT ATG GCC ACG CGG CCA 912 Thr Ala Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met Ala Thr Arg Pro 290 295 300 CCA GAC CGG CCC GAG GGC CCG CAC ACA TCC CGC ATC AGC AGC GTC TCG 960 Pro Asp Arg Pro Glu Gly Pro His Thr Ser Arg He Ser Ser Val Ser 305 310 315 320 TCC CAG πC AGC GAC GGG CCG ATG CCC AGC CCC TCC GCA CGC AGC AGC 1008 Ser Gin Phe Ser Asp Gly Pro Met Pro Ser Pro Ser Ala Arg Ser Ser 325 330 335 GCC TCG TCC TGG TCC GAG GAG CCC GTG CAG TCC AAC ATG GAC ATC TCC 1056 Ala Ser Ser Trp Ser Glu Glu Pro Val Gin Ser Asn Met Asp He Ser 340 345 350 ACC GGC CAC ATG ATC CTG TCC TAC ATG GAG GAC CAC CTG AAG AAC AAG 1104 Thr Gly His Met He Leu Ser Tyr Met Glu Asp His Leu Lys Asn Lys 355 360 365 AAC CGG CTG GAG AAG GAG TGG GAG GCG CTG TGT GCC TAC CAG GCG GAG 1152 Asn Arg Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala Tyr Gin Ala Glu 370 375 380 CCC AAC AGC TCA CTT GTG GCC CAG AAG GAG GAG AAT GTG CCC AAG AAC 1200 Pro Asn Ser Ser Leu Val Ala Gin Lys Glu Glu Asn Val Pro Lys Asn 385 390 395 400 CGC TCC CTG GCC GTG CTG ACC TAT GAC CAC TCC CGG GTC CTA CTG AAG 1248 Arg Ser Leu Ala Val Leu Thr Tyr Asp His Ser Arg Val Leu Leu Lys 405 410 415 GCG GAG AAC AGC CAC AGC CAC TCG GAC TAC ATC AAC GCC AGC CCC ATC 1296 Ala Glu Asn Ser His Ser His Ser Asp Tyr He Asn Ala Ser Pro He 420 425 430 ATG GAT CAC GAC CCG AGG AAC CCC GCG TAC ATC GCC ACC CAG GGA CCG 1344 Met Asp His Asp Pro Arg Asn Pro Ala Tyr He Ala Thr Gin Gly Pro 435 440 445 CTG CCC GCC ACC GTG GCC GAC TTT TGG CAG ATG GTG TGG GAG AGC GGC 1392 Leu Pro Ala Thr Val Ala Asp Phe Trp Gin Met Val Trp Glu Ser Gly 450 455 460 TGC GTG GTG ATC GTC ATG CTG ACA CCC CTC ACA GAG AAC GGC GTC CGG 1440 Cys Val Val He Val Met Leu Thr Pro Leu Thr Glu Asn Gly Val Arg 465 470 475 480 CAG TGC TAC CAC TAC TGG CCA GAT GAA GGC TCC AAC CTC TAC CAC ATC 1488 Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn Leu Tyr His He 485 490 495 TAT GAG GTG AAC CTG GTC TCC GAG CAC ATC TGG TGC GAG GAC CTG 1536 Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys Glu Asp Phe Leu 500 505 510 GTG AGG AGC TTC TAT CTG AAG AAC CTG CAG ACC AAC GAG ACG CGC ACC 1584 Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn Glu Thr Arg Thr 515 520 525 GTG ACC CAG TTC CAC TTC CTG AGT TGG TAT GAC CGA GGA GTC CCC TCC 1632 Val Thr Gin Phe His Phe Leu Ser Trp Tyr Asp Arg Gly Val Pro Ser 530 535 540 TCC TCA AGA TCC CTC CTG GAC TTC CGC AGA AAA GTA AAC AAG TGC TAC 1680 Ser Ser Arg Ser Leu Leu Asp Phe Arg Arg Lys Val Asn Lys Cys Tyr 545 550 555 560 AGG GGC CGT TCT TGT CCA ATA ATT GTT CAT TGC AGT GAC GGT GCA GGC 1728 Arg Gly Arg Ser Cys Pro He He Val His Cys Ser Asp Gly Ala Gly 565 570 575 CGG AGC GGC ACC TAC GTC CTG ATC GAC ATG GTT CTC AAC AAG ATG GCC 1776 Arg Ser Gly Thr Tyr Val Leu He Asp Met Val Leu Asn Lys Met Ala 580 585 590 AAA GGT GCT AAA GAG Aπ GAT ATC GCA GCA ACC CTG GAG CAC TTG AGG 1824 Lys Gly Ala Lys Glu He Asp He Ala Ala Thr Leu Glu His Leu Arg 595 600 605 GAC CAG AGA CCC GGC ATG GTC CAG ACG AAG GAG CAG TTT GAG TTC GCG 1872 Asp Gin Arg Pro Gly Met Val Gin Thr Lys Glu Gin Phe Glu Phe Ala 610 615 620 CTG ACA GCC GTG GCT GAA GAG GTG AAT GCC ATC CTC AAG GCC CTT CCC 1920 Leu Thr Ala Val Ala Glu Glu Val Asn Ala He Leu Lys Ala Leu Pro 625 630 635 640 CAG TGAGCAGCGG CCTCGGGGCC TCGGGGGAGC CCCCACCCCC CGGATGTCGT CAGGAA 1979 Gin TCGTGATCTG ACTTTAATTG TGTGTCTTCT ATTATAACTG CATAGTAATA GGGCCCTTAG 2039 CTCTCCCGTA GTCAGCGCAG TTTAGCAGTT AAGCAGTTAA AATGTGTATT TTTGTTTAAT 2099 CCAACAATAA TAAAGAGAGA TTTGTGGAAA AATCCCAAAA AAAAAAAAAA AAAAAAAAAA 2159 AAAAAACTCG AG 2171 (2) INFORMATION FOR SEQ ID NO:2: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 641 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2: Glu Phe Gly Thr Ser Gly Val Gin Asp Asp Asp Asp Arg Leu Tyr Gin 1 5 10 15 Glu Val His Arg Leu Ser Ala Thr Leu Gly Gly Leu Leu Gin Asp His 20 25 30 Gly Ser Arg Leu Ser Pro Gly Ala Leu Pro Phe Ala Lys Pro Leu Lys 35 40 45 Met Glu Arg Lys Lys Ser Glu Arg Pro Glu Ala Ser Leu Ser Ser Glu 50 55 60 Glu Glu Thr Ala Gly Val Glu Asn Val Lys Ser Gin Thr Tyr Ser Lys 65 70 75 80 Asp Leu Leu Gly Gin Gin Pro His Ser Glu Pro Gly Ala 85 90 Gly Glu Leu Gin Asn Gin Met Pro Gly Pro Ser Glu Glu 100 105 Leu Pro Ala Gly Ala Gin Glu Ala Leu Gly Asp Gly Leu 115 120 125 Val Lys Pro Ser Glu Glu Glu Ala Arg Cys Tyr He Val 130 135 140 Asp Pro Leu Arg Pro Glu Glu Gly Arg Gin Leu Val Glu 145 150 155 Arg Leu Leu Gin Met Pro Ser Ser Thr Phe Ala Asp Val 165 170 Gly Pro Ala Val Thr Phe Lys Val Gly Ala Asn Val Gin 180 185 Thr Ala Asp Val Glu Lys Ala Thr Val Asp Asn Lys Asp 195 200 205 Glu Thr Ser Gly Leu Lys He Leu Gin Thr Gly Val Gly 210 215 220 Lys Leu Lys Phe Leu Pro Pro Gin Ala Glu Gin Glu Asp 225 230 235 Phe He Ala Leu Thr Leu Val Ser Leu Ala Cys He Leu 245 250 Leu Ala Ser Gly Leu He Tyr Cys Leu Arg His Ser Ser 260 265 Leu Lys Glu Lys Leu Ser Gly Leu Gly Arg Asp Pro Gly 275 280 285 Thr Ala Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met Ala 290 295 300 Pro Asp Arg Pro Glu Gly Pro His Thr Ser Arg He Ser 305 310 315 Ser Gin Phe Ser Asp Gly Pro Met Pro Ser Pro Ser Ala 325 330 Ala Ser Ser Trp Ser Glu Glu Pro Val Gin Ser Asn Met 340 345 Thr Gly His Met He Leu Ser Tyr Met Glu Asp His Leu 355 360 365 Asn Arg Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala Tyr 370 375 380 Pro Asn Ser Ser Leu Val Ala Gin Lys Glu Glu Asn Val 385 390 395 Arg Ser Leu Ala Val Leu Thr Tyr Asp His Ser Arg Val 405 410 Ala Glu Asn Ser His Ser His Ser Asp Tyr He Asn Ala 420 425 (2) INFORMATION FOR SEQ ID NO 3: (i) SEQUENCE CHARACTERISTICS" (A) LENGTH: 894 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY linear (n) MOLECULE TYPE: cDNA (ix) FFATURE: (A) NAME/KEY. Coding Sequence (B) LOCATION. 1...894 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3: CGC CAT AGC TCT CAG CAC AGG CTG AAG GAG AAG CTC TCG GGA CTA GGG 48 Arg His Ser Ser Gin His Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly 1 5 10 15 GGC GAC CCA GGT GCA GAT GCC ACT GCC GCC TAC CAG GAG CTG TGC CGC 96 Gly Asp Pro Gly Ala Asp Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg 20 25 30 CAG CGT ATG GCC ACG CGG CCA CCA GAC CGA CCT GAG GGC CCG CAC ACG 144 Gin Arg Met Ala Thr Arg Pro Pro Asp Arg Pro Glu Gly Pro His Thr 35 40 45 TCA CGC ATC AGC AGC GTC TCA TCC CAG TTC AGC GAC GGG CCG ATC CCC 192 Ser Arg He Ser Ser Val Ser Ser Gin Phe Ser Asp Gly Pro He Pro 50 55 60 AGC CCC TCC GCA CGC AGC AGC GCC TCA TCC TGG TCC GAG GAG CCT GTG 240 Ser Pro Ser Ala Arg Ser Ser Ala Ser Ser Trp Ser Glu Glu Pro Val 65 70 75 80 CAG TCC AAC ATG GAC ATC TCC ACC GGC CAC ATG ATC CTG TCC TAC ATG 288 Gin Ser Asn Met Asp He Ser Thr Gly His Met He Leu Ser Tyr Met 85 90 95 GAG GAC CAC CTG AAG AAC AAG AAC CGG CTG GAG AAG GAG TGG GAA GCG 336 Glu Asp His Leu Lys Asn Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala 100 105 110 CTG TGC GCC TAC CAG GCG GAG CCC AAC AGC TCG TTC GTG GCC CAG AGG 384 Leu Cys Ala Tyr Gin Ala Glu Pro Asn Ser Ser Phe Val Ala Gin Arg 115 120 125 GAG GAG AAC GTG CCC AAG AAC CGC TCC CTG GCC GTG CTG ACC TAT GAC 432 Glu Glu Asn Val Pro Lys Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp 130 135 140 CAC TCC CGG GTC CTG CTG AAG GCG GAG AAC AGC CAC AGC CAC TCA GAC 480 His Ser Arg Val Leu Leu Lys Ala Glu Asn Ser His Ser His Ser Asp 145 150 155 160 TAC ATC AAC GCT AGC CCC ATC ATG GAT CAC GAC CCG AGG AAC CCC GCG 528 Tyr He Asn Ala Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala 165 170 175 TAC ATC GCC ACC CAG GGA CCG CTG CCC GCC ACC GTG GCT GAC TGG 576 Tyr He Ala Thr Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp 180 185 190 CAG ATG GTG TGG GAG AGC GGC TGC GTG GTG ATC GTC ATG CTG ACA CCC 624 Gin Met Val Trp Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro 195 200 205 CTC GCG GAG AAC GGC GTC CGG CAG TGC TAC CAC TAC TGG CCG GAT GAA 672 Leu Ala Glu Asn Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu 210 215 220 GGC TCC AAT CTC TAC CAC ATC TAT GAG GTG AAC CTG GTC TCC GAG CAC 720 Gly Ser Asn Leu Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His 225 230 235 240 ATC TGG TGT GAG GAC TTC CTG GTG AGG AGC TTC TAT CTG AAG AAC CTG 768 He Trp Cys Glu Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu 245 250 255 CAG ACC AAC GAG ACG CGC ACC GTG ACG CAG TTC CAC TTC CTG AGT TGG 816 Gin Thr Asn Glu Thr Arg Thr Val Thr Gin Phe His Phe Leu Ser Trp 260 265 270 TAT GAC CGA GGA GTC CCT TCC TCC TCA AGG TCC CTC CTG GAC TTC CGC 864 Tyr Asp Arg Gly Val Pro Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg 275 280 285 AGA AAA GTA AAC AAG TGC TAC AGG GGC CGT 894 Arg Lys Val Asn Lys Cys Tyr Arg Gly Arg 290 295 (2) INFORMATION FOR SEQ ID N0:4: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 298 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION SEQ ID N0:4 Arg His Ser Ser Gin His Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly 1 5 10 15 Gly Asp Pro Gly Ala Asp Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg 20 25 30 Gin Arg Met Ala Thr Arg Pro Pro Asp Arg Pro Glu Gly Pro His Thr 35 40 45 Ser Arg He Ser Ser Val Ser Ser Gin Phe Ser Asp Gly Pro He Pro 50 55 60 Ser Pro Ser Ala Arg Ser Ser Ala Ser Ser Trp Ser Glu Glu Pro Val 65 70 75 80 Gin Ser Asn Met Asp He Ser Thr Gly His Met He Leu Ser Tyr Met 85 90 95 Glu Asp His Leu Lys Asn Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala 100 105 110 Leu Cys Ala Tyr Gin Ala Glu Pro Asn Ser Ser Phe Val Ala Gin Arg 115 120 125 Glu Glu Asn Val Pro Lys Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp 130 135 140 His Ser Arg Val Leu Leu Lys Ala Glu Asn Ser His Ser His Ser Asp 145 150 155 160 Tyr He Asn Ala Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala 165 170 175 Tyr He Ala Thr Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp 180 185 190 Gin Met Val Trp Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro 195 200 205 Leu Ala Glu Asn Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu 210 215 220 Gly Ser Asn Leu Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His 225 230 235 240 He Trp Cys Glu Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu 245 250 255 Gin Thr Asn Glu Thr Arg Thr Val Thr Gin Phe His Phe Leu Ser Trp 260 265 270 Tyr Asp Arg Gly Val Pro Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg 275 280 285 Arg Lys Val Asn Lys Cys Tyr Arg Gly Arg 290 295 (2) INFORMATION FOR SEQ ID NO:5 (l) SEQUENCE CHARACTERISTICS- (A) LENGTH 127 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Ala Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala Tyr He Ala 1 5 10 15 Thr Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp Gin Met Val 20 25 30 Trp Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro Leu Ala Glu 35 40 45 Asn Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn 50 55 60 Leu Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys 65 70 75 80 Glu Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn 85 90 95 Glu Thr Arg Thr Val Thr Gin Phe Pro Leu Ser Xaa Trp Tyr Asp Arg 100 105 110 Xaa Val Pro Ser Phe Leu Lys Val Pro aa Trp Thr Ser Ala Glu 115 120 125 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1163 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 27...1154 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: AAGCTATGCA TCAAGCTTCC ACCATG CGC CAT AGC TCT CAG CAC AGG CTG AAG 53 Arg His Ser Ser Gin His Arg Leu Lys 1 5 GAG AAG CTC TCG GGA CTA GGG GGC GAC CCA GGT GCA GAT GCC ACT GCC 101 Glu Lys Leu Ser Gly Leu Gly Gly Asp Pro Gly Ala Asp Ala Thr Ala 10 15 20 25 GCC TAC CAG GAG CTG TGC CGC CAG CGT ATG GCC ACG CGG CCA CCA GAC 149 Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met Ala Thr Arg Pro Pro Asp 30 35 40 CGA CCT GAG GGC CCG CAC ACG TCA CGC ATC AGC AGC GTC TCA TCC CAG 197 Arg Pro Glu Gly Pro His Thr Ser Arg He Ser Ser Val Ser Ser Gin 45 50 55 πC AGC GAC GGG CCG ATC CCC AGC CCC TCC GCA CGC AGC AGC GCC TCA 245 Phe Ser Asp Gly Pro He Pro Ser Pro Ser Ala Arg Ser Ser Ala Ser 60 65 70 TCC TGG TCC GAG GAG CCT GTG CAG TCC AAC ATG GAC ATC TCC ACC GGC 293 Ser Trp Ser Glu Glu Pro Val Gin Ser Asn Met Asp He Ser Thr Gly 75 80 85 CAC ATG ATC CTG TCC TAC ATG GAG GAC CAC CTG AAG AAC AAG AAC CGG 341 His Met He Leu Ser Tyr Met Glu Asp His Leu Lys Asn Lys Asn Arg 90 95 100 105 CTG GAG AAG GAG TGG GAA GCG CTG TGC GCC TAC CAG GCG GAG CCC AAC 389 Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala Tyr Gin Ala Glu Pro Asn 110 115 120 AGC TCG πC GTG GCC CAG AGG GAG GAG AAC GTG CCC AAG AAC CGC TCC 437 Ser Ser Phe Val Ala Gin Arg Glu Glu Asn Val Pro Lys Asn Arg Ser 125 130 135 CTG GCC GTG CTG ACC TAT GAC CAC TCC CGG GTC CTG CTG AAG GCG GAG 485 Leu Ala Val Leu Thr Tyr Asp His Ser Arg Val Leu Leu Lys Ala Glu 140 145 150 AAC AGC CAC AGC CAC TCA GAC TAC ATC AAC GCT AGC CCC ATC ATG GAT 533 Asn Ser His Ser His Ser Asp Tyr He Asn Ala Ser Pro He Met Asp 155 160 165 CAC GAC CCG AGG AAC CCC GCG TAC ATC GCC ACC CAG GGA CCG CTG CCC 581 His Asp Pro Arg Asn Pro Ala Tyr He Ala Thr Gin Gly Pro Leu Pro 170 175 180 185 GCC ACC GTG GCT GAC Tπ TGG CAG ATG GTG TGG GAG AGC GGC TGC GTG 629 Ala Thr Val Ala Asp Phe Trp Gin Met Val Trp Glu Ser Gly Cys Val 190 195 200 GTG ATC GTC ATG CTG ACA CCC CTC GCG GAG AAC GGC GTC CGG CAG TGC 677 Val He Val Met Leu Thr Pro Leu Ala Glu Asn Gly Val Arg Gin Cys 205 210 215 TAC CAC TAC TGG CCG GAT GAA GGC TCC AAT CTC TAC CAC ATC TAT GAG 725 Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn Leu Tyr His He Tyr Glu 220 225 230 GTG AAC CTG GTC TCC GAG CAC ATC TGG TGT GAG GAC πC CTG GTG AGG 773 Val Asn Leu Val Ser Glu His He Trp Cys Glu Asp Phe Leu Val Arg 235 240 245 AGC πC TAT CTG AAG AAC CTG CAG ACC AAC GAG ACG CGC ACC GTG ACG 821 Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn Glu Thr Arg Thr Val Thr 250 255 260 265 CAG πC CAC πC CTG AGT TGG TAT GAC CGA GGA GTC CCT TCC TCC TCA 869 Gin Phe His Phe Leu Ser Trp Tyr Asp Arg Gly Val Pro Ser Ser Ser 270 275 280 AGG TCC CTC CTG GAC πC CGC AGA AAA GTA AAC AAG TGC TAC AGG GGC 917 Arg Ser Leu Leu Asp Phe Arg Arg Lys Val Asn Lys Cys Tyr Arg Gly 285 290 295 CGT TCT TGT CCA ATA Aπ Gπ CAT TGC AGT GAC GGT GCA GGC CGG AGC 965 Arg Ser Cys Pro He He Val His Cys Ser Asp Gly Ala Gly Arg Ser 300 305 310 GGC ACC TAC GTC CTG ATC GAC ATG Gπ CTC AAC AAG ATG GCC AAA GGT 1013 Gly Thr Tyr Val Leu He Asp Met Val Leu Asn Lys Met Ala Lys Gly 315 320 325 GCT AAA GAG Aπ GAT ATC GCA GCG ACC CTG GAG CAC πG AGG GAC CAG 1061 Ala Lys Glu He Asp He Ala Ala Thr Leu Glu His Leu Arg Asp Gin 330 335 340 345 AGA CCC GGC ATG GTC CAG ACG AAG GAG CAG Tπ GAG πC GCG CTG ACA 1109 Arg Pro Gly Met Val Gin Thr Lys Glu Gin Phe Glu Phe Ala Leu Thr 350 355 360 GCC GTG GCT GAG GAG GTG AAC GCC ATC CTC AAG GCC CTG CCC CAG TGAGA 1159 Ala Val Ala Glu Glu Val Asn Ala He Leu Lys Ala Leu Pro Gin 365 370 375 AπC 1163 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Arg His Ser Ser Gin His Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly 1 5 10 15 Gly Asp Pro Gly Ala Asp Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg 20 25 30 Gin Arg Met Ala Thr Arg Pro Pro Asp Arg Pro Glu Gly Pro His Thr 35 40 45 Ser Arg He Ser Ser Val Ser Ser Gin Phe Ser Asp Gly Pro He Pro 50 55 60 Ser Pro Ser Ala Arg Ser Ser Ala Ser Ser Trp Ser Glu Glu Pro Val 65 70 75 80 Gin Ser Asn Met Asp He Ser Thr Gly His Met He Leu Ser Tyr Met 85 90 95 Glu Asp His Leu Lys Asn Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala 100 105 110 Leu Cys Ala Tyr Gin Ala Glu Pro Asn Ser Ser Phe Val Ala Gin Arg 115 120 125 Glu Glu Asn Val Pro Lys Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp 130 135 140 His Ser Arg Val Leu Leu Lys Ala Glu Asn Ser His Ser His Ser Asp 145 150 155 160 Tyr He Asn Ala Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala 165 170 175 Tyr He Ala Thr Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp 180 185 190 Gin Met Val Trp Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro 195 200 205 Leu Ala Glu Asn Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu 210 215 220 Gly Ser Asn Leu Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His 225 230 235 240 He Trp Cys Glu Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu 245 250 255 Gin Thr Asn Glu Thr Arg Thr Val Thr Gin Phe His Phe Leu Ser Trp 260 265 270 Tyr Asp Arg Gly Val Pro Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg 275 280 285 Arg Lys Val Asn Lys Cys Tyr Arg Gly Arg Ser Cys Pro He He Val 290 295 300 His Cys Ser Asp Gly Ala Gly Arg Ser Gly Thr Tyr Val Leu He Asp 305 310 315 320 Met Val Leu Asn Lys Met Ala Lys Gly Ala Lys Glu He Asp He Ala 325 330 335 Ala Thr Leu Glu His Leu Arg Asp Gin Arg Pro Gly Met Val Gin Thr 340 345 350 Lys Glu Gin Phe Glu Phe Ala Leu Thr Ala Val Ala Glu Glu Val Asn 355 360 365 Ala He Leu Lys Ala Leu Pro Gin 370 375 (2) INFORMATION FOR SEQ ID N0:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other (vii) IMMEDIATE SOURCE: (B) CLONE: ZC3747 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GGGAATAACA TGTGAATGAC AAAATAAAAT GATAGCπGC GCTπTGCG 49 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE. Other (vn) IMMEDIATE SOURCE- (B) CLONE. ZC8802 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9 GCGCCTCGAG CCACCATGCA GCATGCGCGG CAGCAAGAC 39 (2) INFORMATION FOR SEQ ID NO:10: (l) SEQUENCE CHARACTERISTICS- (A) LENGTH: 31 base pairs (B) TYPE, nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY, linear (n) MOLECULE TYPE: Other (vil) IMMEDIATE SOURCE. (B) CLONE- ZC8803 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GCGCGAAπC TCACTGGGGC AGGGCCπGA G 31 (2) INFORMATION FOR SEQ ID NO-11. (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS. single (D) TOPOLOGY linear (n) MOLECULE TYPE Other (vii) IMMEDIATE SOURCE- (B) CLONE: ZC10011 (xi) SEQUENCE DESCRIPTION SEQ ID NO:11. TGTACGCGGG GπCCTC 17 (2) INFORMATION FOR SEQ ID NO:12 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 25 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY linear (n) MOLECULE TYPE Other (vii) IMMEDIATE SOURCE (B) CLONE ZC10177 (xi) SEQUENCE DESCRIPTION SEQ ID NO 12 GAGGAACCCC GCGTACATCG CCACC 25 (2) INFORMATION FOR SEQ ID NO 13 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 11 amino acids (B) TYPE amino acid (C) STRANDEDNESS single (D) TOPOLOGY linear (n) MOLECULE TYPE peptide (ix) FEATURE (xi) SEQUENCE DESCRIPTION SEQ ID NO 13 Val His Cys Xaa Ala Gly Xaa Xaa Arg Xaa Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO 14 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 18 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY linear (xi) SEQUENCE DESCRIPTION SEQ ID NO 14 AARGCNACNG TNGAYAAY 18 (2) INFORMATION FOR SEQ ID NO 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 4...3039 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: AGG GCG CTC CCG CTG CTG πG CTG CTA CTG CTG CTG CTG CCG CCA CGC 48 Ala Leu Pro Leu Leu Leu Leu Leu Leu Leu Leu Leu Pro Pro Arg 1 5 10 15 GTC CTG CCT GCC GCC CCC TCG TCC GTC CCC CAC GGC CGG CAG CTC CCG 96 Val Leu Pro Ala Ala Pro Ser Ser Val Pro His Gly Arg Gin Leu Pro 20 25 30 GGG CGC CTG GGC TGC CTA CTC GAG GAG GGC CTC TGC GGA GCG TCC GAG 144 Gly Arg Leu Gly Cys Leu Leu Glu Glu Gly Leu Cys Gly Ala Ser Glu 35 40 45 GCC TGT GTG AAC GAT GGA GTG Tπ GGA AGG TGC CAG AAG Gπ CCG GCA 192 Ala Cys Val Asn Asp Gly Val Phe Gly Arg Cys Gin Lys Val Pro Ala 50 55 60 ATG GAC Tπ TAC CGC TAC GAG GTG TCG CCC GTG GCC CTG CAG CGC CTG 240 Met Asp Phe Tyr Arg Tyr Glu Val Ser Pro Val Ala Leu Gin Arg Leu 65 70 75 CGC GTG GCT πG CAG AAA CTC TCC GGC ACA GGT πC ACG TGG CAG GAT 288 Arg Val Ala Leu Gin Lys Leu Ser Gly Thr Gly Phe Thr Trp Gin Asp 80 85 90 95 GAC TAT ACT CAG TAT GTG ATG GAC CAG GAA Cπ GCA GAC CTC CCC AAA 336 Asp Tyr Thr Gin Tyr Val Met Asp Gin Glu Leu Ala Asp Leu Pro Lys 100 105 110 ACC TAC CTG AGG CAT CCT GAA GCG TCC GGC CCA GCC AGG CCC TCA AAA 384 Thr Tyr Leu Arg His Pro Glu Ala Ser Gly Pro Ala Arg Pro Ser Lys 115 120 125 CAC AGC Aπ GGC AGT GAG AGG AGG TAC AGT CGG GAG GGC GGC GCT GCC 432 His Ser He Gly Ser Glu Arg Arg Tyr Ser Arg Glu Gly Gly Ala Ala 130 135 140 CTG GCC AAG GCC πC CGA CGC CAC CTG CCC πC CTG GAG GCC CTG TCC 480 Leu Ala Lys Ala Phe Arg Arg His Leu Pro Phe Leu Glu Ala Leu Ser 145 150 155 CAG GCC CCA GCT TCA GAC GCG CTC GCC AGG ACC CGG ATG GCG CAG GAC 528 Gin Ala Pro Ala Ser Asp Ala Leu Ala Arg Thr Arg Met Ala Gin Asp 160 165 170 175 AGA CCC CGT GCT GAG GGT GAC GAC CGC πC TCC AAG AGC ATC CTG ACC 576 Arg Pro Arg Ala Glu Gly Asp Asp Arg Phe Ser Lys Ser He Leu Thr 180 185 190 TAT GTG GCC CAC ACG TCT GTG CTG ACC TAC CCT CCC GGG CCC CAG GCC 624 Tyr Val Ala His Thr Ser Val Leu Thr Tyr Pro Pro Gly Pro Gin Ala 195 200 205 CAG CTC CCC GAG GAC CTC CTG CCA CGG ACC CTC AGC CAG CTC CAG CCA 672 Gin Leu Pro Glu Asp Leu Leu Pro Arg Thr Leu Ser Gin Leu Gin Pro 210 215 220 GAC GAG CTC AGC CCT AAG GTG GAC AGC AGT GTG GAG AGA CAC CAT CTG 720 Asp Glu Leu Ser Pro Lys Val Asp Ser Ser Val Glu Arg His His Leu 225 230 235 ATG GCA GCC CTC AGT GCC TAT GCT GCC CAG AGG CCC CCA GCT CCC CCT 768 Met Ala Ala Leu Ser Ala Tyr Ala Ala Gin Arg Pro Pro Ala Pro Pro 240 245 250 255 GGG AAG GGC AGC CTG GAG CCG CAG TAC Cπ CTG CGC GCC CCG TCC AGA 816 Gly Lys Gly Ser Leu Glu Pro Gin Tyr Leu Leu Arg Ala Pro Ser Arg 260 265 270 ATG CCC AGG CCC πG πG TCG CCA GCC GTC CCC CAG AAG TGG CCT TCA 864 Met Pro Arg Pro Leu Leu Ser Pro Ala Val Pro Gin Lys Trp Pro Ser 275 280 285 CCT CTG GGA GAT CCT GAA GAC CCC CCC AGC ACA GGG GAA GGA GCA CGG 912 Pro Leu Gly Asp Pro Glu Asp Pro Pro Ser Thr Gly Glu Gly Ala Arg 290 295 300 Aπ CAC ACT CTC CTG AAG GAC CTG CAG AGG CAG CCG GCT GAG GCG AGG 960 He His Thr Leu Leu Lys Asp Leu Gin Arg Gin Pro Ala Glu Ala Arg 305 310 315 GGC CTG AGT GAC CTG GAG CTG GAC AGC ATG GCC GAG CTG ATG GCT GGC 1008 Gly Leu Ser Asp Leu Glu Leu Asp Ser Met Ala Glu Leu Met Ala Gly 320 325 330 335 CTG ATG CAA GGC ATG GAC CAC AGA GGA GCT CTA GGC GGC CCT GGG AAA 1056 Leu Met Gin Gly Met Asp His Arg Gly Ala Leu Gly Gly Pro Gly Lys 340 345 350 GCG GCC CTG GGA GAG TCT GGA GAA CAG GCG GAT GGC CCC AAG GCC GCC 1104 Ala Ala Leu Gly Glu Ser Gly Glu Gin Ala Asp Gly Pro Lys Ala Ala 355 360 365 CTC CGT GGG GAA AGC Tπ CCA GAT GAC GGA Gπ CAG GAC GAC GAT GAC 1152 Leu Arg Gly Glu Ser Phe Pro Asp Asp Gly Val Gin Asp Asp Asp Asp 370 375 380 AGA Cπ TAC CAA GAG GTC CAT CGT CTG AGT GCC ACA CTC GGG GGC CTC 1200 Arg Leu Tyr Gin Glu Val His Arg Leu Ser Ala Thr Leu Gly Gly Leu 385 390 395 CTG CAG GAC CAC GGG TCT CGA CTC TCG CCT GGA GCC CTC CCC Tπ GCA 1248 Leu Gin Asp His Gly Ser Arg Leu Ser Pro Gly Ala Leu Pro Phe Ala 400 405 410 415 AAG CCC CTC AAA ATG GAG AGG AAG AAA TCC GAG CGC CCT GAG GCT TCC 1296 Lys Pro Leu Lys Met Glu Arg Lys Lys Ser Glu Arg Pro Glu Ala Ser 420 425 430 CTG TCT TCA GAA GAG GAG ACT GCC GGA GTG GAG AAC GTC AAG AGC CAG 1344 Leu Ser Ser Glu Glu Glu Thr Ala Gly Val Glu Asn Val Lys Ser Gin 435 440 445 ACG TAT TCC AAA GAC CTG CTG GGG CAG CAG CCG CAT TCG GAG CCC GGG 1392 Thr Tyr Ser Lys Asp Leu Leu Gly Gin Gin Pro His Ser Glu Pro Gly 450 455 460 GCA GGC GCG πT GGG GAG CTC CAA AAC CAG ATG CCT GGG CCC TCG GAG 1440 Ala Gly Ala Phe Gly Glu Leu Gin Asn Gin Met Pro Gly Pro Ser Glu 465 470 475 GAG GAG CAG AGC Cπ CCA GCG GGT GCT CAG GAG GCC CTC GGC GAC GGC 1488 Glu Glu Gin Ser Leu Pro Ala Gly Ala Gin Glu Ala Leu Gly Asp Gly 480 485 490 495 CTG CAA πG GAA GTC AAG CCT TCC GAG GAA GAG GCA CGG TGC TAC ATC 1536 Leu Gin Leu Glu Val Lys Pro Ser Glu Glu Glu Ala Arg Cys Tyr He 500 505 510 GTG ACA GAC AGA GAC CCC CTG CGC CCC GAG GAA GGA AGG CAG CTG GTG 1584 Val Thr Asp Arg Asp Pro Leu Arg Pro Glu Glu Gly Arg Gin Leu Val 515 520 525 GAG GAC GTC GCC CGC CTC CTG CAG ATG CCC AGC AGC ACA πC GCC GAC 1632 Glu Asp Val Ala Arg Leu Leu Gin Met Pro Ser Ser Thr Phe Ala Asp 530 535 540 GTG GAG Gπ CTC GGA CCA GCA GTG ACC πC AAA GTG GGC GCC AAT GTC 1680 Val Glu Val Leu Gly Pro Ala Val Thr Phe Lys Val Gly Ala Asn Val 545 550 555 CAG AAC GTG ACC ACT GCG GAT GTG GAG AAG GCC ACA Gπ GAC AAC AAA 1728 Gin Asn Val Thr Thr Ala Asp Val Glu Lys Ala Thr Val Asp Asn Lys 560 565 570 575 GAC AAA CTG GAG GAA ACC TCT GGA CTG AAA Aπ Cπ CAA ACC GGA GTC 1776 Asp Lys Leu Glu Glu Thr Ser Gly Leu Lys He Leu Gin Thr Gly Val 580 585 590 GGG TCG AAA AGC AAA CTC AAG πC CTG CCT CCT CAG GCG GAG CAA GAA 1824 Gly Ser Lys Ser Lys Leu Lys Phe Leu Pro Pro Gin Ala Glu Gin Glu 595 600 605 GAC TCA ACC AAG πC ATC GCG CTC ACC CTG GTC TCC CTC GCC TGC ATC 1872 Asp Ser Thr Lys Phe He Ala Leu Thr Leu Val Ser Leu Ala Cys He 610 615 620 CTG GGC GTC CTC CTG GCC TCT GGC CTC ATC TAC TGC CTA CGC CAT AGC 1920 Leu Gly Val Leu Leu Ala Ser Gly Leu He Tyr Cys Leu Arg His Ser 625 630 635 TCT CAG CAC AGG CTG AAG GAG AAG CTC TCG GGA CTA GGG CGC GAC CCA 1968 Ser Gin His Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly Arg Asp Pro 640 645 650 655 GGT GCA GAT GCC ACC GCC GCC TAC CAG GAG CTG TGC CGC CAG CGT ATG 2016 Gly Ala Asp Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met 660 665 670 GCC ACG CGG CCA CCA GAC CGG CCC GAG GGC CCG CAC ACA TCC CGC ATC 2064 Ala Thr Arg Pro Pro Asp Arg Pro Glu Gly Pro His Thr Ser Arg He 675 680 685 AGC AGC GTC TCG TCC CAG πC AGC GAC GGG CCG ATG CCC AGC CCC TCC 2112 Ser Ser Val Ser Ser Gin Phe Ser Asp Gly Pro Met Pro Ser Pro Ser 690 695 700 GCA CGC AGC AGC GCC TCG TCC TGG TCC GAG GAG CCC GTG CAG TCC AAC 2160 Ala Arg Ser Ser Ala Ser Ser Trp Ser Glu Glu Pro Val Gin Ser Asn 705 710 715 ATG GAC ATC TCC ACC GGC CAC ATG ATC CTG TCC TAC ATG GAG GAC CAC 2208 Met Asp He Ser Thr Gly His Met He Leu Ser Tyr Met Glu Asp His 720 725 730 735 CTG AAG AAC AAG AAC CGG CTG GAG AAG GAG TGG GAG GCG CTG TGT GCC 2256 Leu Lys Asn Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala 740 745 750 TAC CAG GCG GAG CCC AAC AGC TCA Cπ GTG GCC CAG AAG GAG GAG AAT 2304 Tyr Gin Ala Glu Pro Asn Ser Ser Leu Val Ala Gin Lys Glu Glu Asn 755 760 765 GTG CCC AAG AAC CGC TCC CTG GCC GTG CTG ACC TAT GAC CAC TCC CGG 2352 Val Pro Lys Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp His Ser Arg 770 775 780 GTC CTA CTG AAG GCG GAG AAC AGC CAC AGC CAC TCG GAC TAC ATC AAC 2400 Val Leu Leu Lys Ala Glu Asn Ser His Ser His Ser Asp Tyr He Asn 785 790 795 GCC AGC CCC ATC ATG GAT CAC GAC CCG AGG AAC CCC GCG TAC ATC GCC 2448 Ala Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala Tyr He Ala 800 805 810 815 ACC CAG GGA CCG CTG CCC GCC ACC GTG GCC GAC TTT TGG CAG ATG GTG 2496 Thr Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp Gin Met Val 820 825 830 TGG GAG AGC GGC TGC GTG GTG ATC GTC ATG CTG ACA CCC CTC ACA GAG 2544 Trp Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro Leu Thr Glu 835 840 845 AAC GGC GTC CGG CAG TGC TAC CAC TAC TGG CCA GAT GAA GGC TCC AAC 2592 Asn Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn 850 855 860 CTC TAC CAC ATC TAT GAG GTG AAC CTG GTC TCC GAG CAC ATC TGG TGC 2640 Leu Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys 865 870 875 GAG GAC Tπ CTG GTG AGG AGC πC TAT CTG AAG AAC CTG CAG ACC AAC 2688 Glu Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn 880 885 890 895 GAG ACG CGC ACC GTG ACC CAG πC CAC πC CTG AGT TGG TAT GAC CGA 2736 Glu Thr Arg Thr Val Thr Gin Phe His Phe Leu Ser Trp Tyr Asp Arg 900 905 910 GGA GTC CCC TCC TCC TCA AGA TCC CTC CTG GAC πC CGC AGA AAA GTA 2784 Gly Val Pro Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg Arg Lys Val 915 920 925 AAC AAG TGC TAC AGG GGC CGT TCT TGT CCA ATA Aπ Gπ CAT TGC AGT 2832 Asn Lys Cys Tyr Arg Gly Arg Ser Cys Pro He He Val His Cys Ser 930 935 940 GAC GGT GCA GGC CGG AGC GGC ACC TAC GTC CTG ATC GAC ATG Gπ CTC 2880 Asp Gly Ala Gly Arg Ser Gly Thr Tyr Val Leu He Asp Met Val Leu 945 950 955 AAC AAG ATG GCC AAA GGT GCT AAA GAG ATT GAT ATC GCA GCA ACC CTG 2928 Asn Lys Met Ala Lys Gly Ala Lys Glu He Asp He Ala Ala Thr Leu 960 965 970 975 GAG CAC πG AGG GAC CAG AGA CCC GGC ATG GTC CAG ACG AAG GAG CAG 2976 Glu His Leu Arg Asp Gin Arg Pro Gly Met Val Gin Thr Lys Glu Gin 980 985 990 Tπ GAG πC GCG CTG ACA GCC GTG GCT GAA GAG GTG AAT GCC ATC CTC 3024 Phe Glu Phe Ala Leu Thr Ala Val Ala Glu Glu Val Asn Ala He Leu 995 1000 1005 AAG GCC Cπ CCC CAG TGAGCAGCGG CCTCGGGGCC TCGGGGGAGC CCCCACCCCC C 3080 Lys Ala Leu Pro Gin 1010 GGATGTCGTC AGGAATCGTG ATCTGACTπ AAπGTGTGT CπCTAπAT AACTGCATAG 3140 TAATAGGGCC CπAGCTCTC CCGTAGTCAG CGCAG TAG CAGπAAGCA GπAAAATGT 3200 GTAπiTTGT πAATCCAAC AATAATAAAG AGAGATπGT GGAAAAATCC CAAAAAAAAA 3260 AAAAAAAAAA AAAAAAAAAA ACTCGAG 3287 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1012 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16- Ala Leu Pro Leu Leu Leu Leu Leu Leu Leu Leu Leu Pro Pro Arg Val 1 5 10 15 Leu Pro Ala Ala Pro Ser Ser Val Pro His Gly Arg Gin Leu Pro Gly 20 25 30 Arg Leu Gly Cys Leu Leu Glu Glu Gly Leu Cys Gly Ala Ser Glu Ala 35 40 45 Cys Val Asn Asp Gly Val Phe Gly Arg Cys Gin Lys Val Pro Ala Met 50 55 60 Asp Phe Tyr Arg Tyr Glu Val Ser Pro Val Ala Leu Gin Arg Leu Arg 65 70 75 80 Val Ala Leu Gin Lys Leu Ser Gly Thr Gly Phe Thr Trp Gin Asp Asp 85 90 95 Tyr Thr Gin Tyr Val Met Asp Gin Glu Leu Ala Asp Leu Pro Lys Thr 100 105 110 Tyr Leu Arg His Pro Glu Ala Ser Gly Pro Ala Arg Pro Ser Lys His 115 120 125 Ser He Gly Ser Glu Arg Arg Tyr Ser Arg Glu Gly Gly Ala Ala Leu 130 135 140 Gin Leu Glu Val Lys Pro Ser Glu Glu Glu Ala Arg Cys Tyr He Val 500 505 510 Thr Asp Arg Asp Pro Leu Arg Pro Glu Glu Gly Arg Gin Leu Val Glu 515 520 525 Asp Val Ala Arg Leu Leu Gin Met Pro Ser Ser Thr Phe Ala Asp Val 530 535 540 Glu Val Leu Gly Pro Ala Val Thr Phe Lys Val Gly Ala Asn Val Gin 545 550 555 560 Asn Val Thr Thr Ala Asp Val Glu Lys Ala Thr Val Asp Asn Lys Asp 565 570 575 Lys Leu Glu Glu Thr Ser Gly Leu Lys He Leu Gin Thr Gly Val Gly 580 585 590 Ser Lys Ser Lys Leu Lys Phe Leu Pro Pro Gin Ala Glu Gin Glu Asp 595 600 605 Ser Thr Lys Phe He Ala Leu Thr Leu Val Ser Leu Ala Cys He Leu 610 615 620 Gly Val Leu Leu Ala Ser Gly Leu He Tyr Cys Leu Arg His Ser Ser 625 630 635 640 Gin His Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly Arg Asp Pro Gly 645 650 655 Ala Asp Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met Ala 660 665 670 Thr Arg Pro Pro Asp Arg Pro Glu Gly Pro His Thr Ser Arg He Ser 675 680 685 Ser Val Ser Ser Gin Phe Ser Asp Gly Pro Met Pro Ser Pro Ser Ala 690 695 700 Arg Ser Ser Ala Ser Ser Trp Ser Glu Glu Pro Val Gin Ser Asn Met 705 710 715 720 Asp He Ser Thr Gly His Met He Leu Ser Tyr Met Glu Asp His Leu 725 730 735 Lys Asn Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala Tyr 740 745 750 Gin Ala Glu Pro Asn Ser Ser Leu Val Ala Gin Lys Glu Glu Asn Val 755 760 765 Pro Lys Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp His Ser Arg Val 770 775 780 Leu Leu Lys Ala Glu Asn Ser His Ser His Ser Asp Tyr He Asn Ala 785 790 795 800 Ser Pro He Met Asp His Asp Pro Arg Asn Pro Ala Tyr He Ala Thr 805 810 815 Gin Gly Pro Leu Pro Ala Thr Val Ala Asp Phe Trp Gin Met Val Trp 820 825 830 Glu Ser Gly Cys Val Val He Val Met Leu Thr Pro Leu Thr Glu Asn 835 840 845 Gly Val Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn Leu 850 855 860 Tyr His He Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys Glu 865 870 875 880 Asp Phe Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn Glu 885 890 895 Thr Arg Thr Val Thr Gin Phe His Phe Leu Ser Trp Tyr Asp Arg Gly 900 905 910 Val Pro Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg Arg Lys Val Asn 915 920 925 Lys Cys Tyr Arg Gly Arg Ser Cys Pro He He Val His Cys Ser Asp 930 935 940 Gly Ala Gly Arg Ser Gly Thr Tyr Val Leu He Asp Met Val Leu Asn 945 950 955 960 Lys Met Ala Lys Gly Ala Lys Glu He Asp He Ala Ala Thr Leu Glu 965 970 975 His Leu Arg Asp Gin Arg Pro Gly Met Val Gin Thr Lys Glu Gin Phe 980 985 990 Glu Phe Ala Leu Thr Ala Val Ala Glu Glu Val Asn Ala He Leu Lys 995 1000 1005 Ala Leu Pro Gin 1010 (2) INFORMATION FOR SEQ ID NO 17 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 28 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY linear (n) MOLECULE TYPE Other (vil) IMMEDIATE SOURCE (B) CLONE ZC11653 (xi) SEQUENCE DESCRIPTION SEQ ID NO 17 CGGAAπCCT CTGTGGTCCA TGCCπGC 28 (2) INFORMATION FOR SEQ ID NO 18 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 38 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18 GCGCCATGAA CπGGTGGAG TCπcπGCT CCGCCTGA 38 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE- nucleic acid (C) STRANDEDNESS- single (D) TOPOLOGY- linear (n) MOLECULE TYPE. cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AGCTGCCTCC TCCCTCTGTC CCACTCCTGT CTGCAAGA 38 (2) INFORMATION FOR SEQ ID N0:20- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY- linear (ii) MOLECULE TYPE. cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20 CπGGGTGTG TAGAAGAAGC CACGπCCCC 30 (2) INFORMATION FOR SEQ ID NO.21: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2464 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY- linear (n) MOLECULE TYPE- cDNA ( i x) FEATURE : (A) NAME/KEY: Coding Sequence (B) LOCATION: 2...2455 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: T CAC ACG TCT GTG CTG ACC TAC CCT CCC GGG CCC CGG ACC CAG CTC CAC 49 His Thr Ser Val Leu Thr Tyr Pro Pro Gly Pro Arg Thr Gin Leu His 1 5 10 15 GAG GAC CTC CTG CCA CGG ACC CTC GGC CAG CTC CAG CCA GAT GAG CTC 97 Glu Asp Leu Leu Pro Arg Thr Leu Gly Gin Leu Gin Pro Asp Glu Leu 20 25 30 AGC CCT AAG GTG GAC AGT GGT GTG GAC AGA CAC CAT CTG ATG GCG GCC 145 Ser Pro Lys Val Asp Ser Gly Val Asp Arg His His Leu Met Ala Ala 35 40 45 CTC AGT GCC TAT GCT GCC CAG AGG CCC CCA GCT CCC CCC GGG GAG GGC 193 Leu Ser Ala Tyr Ala Ala Gin Arg Pro Pro Ala Pro Pro Gly Glu Gly 50 55 60 AGC CTG GAG CCA CAG TAC Cπ CTG CGT GCA CCC TCA AGA ATG CCC AGG 241 Ser Leu Glu Pro Gin Tyr Leu Leu Arg Ala Pro Ser Arg Met Pro Arg 65 70 75 80 CCT πG CTG GCA CCA GCC GCC CCC CAG AAG TGG CCT TCA CCT CTG GGA 289 Pro Leu Leu Ala Pro Ala Ala Pro Gin Lys Trp Pro Ser Pro Leu Gly 85 90 95 GAT TCC GAA GAC CCC TCT AGC ACA GGC GAT GGA GCA CGG Aπ CAT ACC 337 Asp Ser Glu Asp Pro Ser Ser Thr Gly Asp Gly Ala Arg He His Thr 100 105 110 CTC CTG AAG GAC CTG CAG AGG CAG CCG GCT GAG GTG AGG GGC CTG AGT 385 Leu Leu Lys Asp Leu Gin Arg Gin Pro Ala Glu Val Arg Gly Leu Ser 115 120 125 GGC CTG GAG CTG GAC GGC ATG GCT GAG CTG ATG GCT GGC CTG ATG CAA 433 Gly Leu Glu Leu Asp Gly Met Ala Glu Leu Met Ala Gly Leu Met Gin 130 135 140 GGC GTG GAC CAT GGA GTA GCT CGA GGC AGC CCT GGG AGA GCG GCC CTG 481 Gly Val Asp His Gly Val Ala Arg Gly Ser Pro Gly Arg Ala Ala Leu 145 150 155 160 GGA GAG TCT GGA GAA CAG GCG GAT GGC CCC AAG GCC ACC CTC CGT GGA 529 Gly Glu Ser Gly Glu Gin Ala Asp Gly Pro Lys Ala Thr Leu Arg Gly 165 170 175 GAC AGC πT CCA GAT GAC GGA GTG CAG GAC GAC GAT GAT AGA Cπ TAC 577 Asp Ser Phe Pro Asp Asp Gly Val Gin Asp Asp Asp Asp Arg Leu Tyr 180 185 190 CAA GAG GTC CAT CGT CTG AGT GCC ACA CTC GGG GGC CTC CTG CAG GAC 625 Gin Glu Val His Arg Leu Ser Ala Thr Leu Gly Gly Leu Leu Gin Asp 195 200 205 CAC GGG TCT CGA CTC πA CCT GGA GCC CTC CCC Tπ GCA AGG CCC CTC 673 His Gly Ser Arg Leu Leu Pro Gly Ala Leu Pro Phe Ala Arg Pro Leu 210 215 220 GAC ATG GAG AGG AAG AAG TCC GAG CAC CCT GAG TCT TCC CTG TCT TCA 721 Asp Met Glu Arg Lys Lys Ser Glu His Pro Glu Ser Ser Leu Ser Ser 225 230 235 240 GAA GAG GAG ACT GCC GGA GTG GAG AAC GTC AAG AGC CAG ACG TAT TCC 769 Glu Glu Glu Thr Ala Gly Val Glu Asn Val Lys Ser Gin Thr Tyr Ser 245 250 255 AAA GAT CTG CTG GGG CGG CAG CCG CAT TCG GAG CCC GGG GCC GCT GCG 817 Lys Asp Leu Leu Gly Arg Gin Pro His Ser Glu Pro Gly Ala Ala Ala 260 265 270 TTT GGG GAG CTC CAA AAC CAG ATG CCT GGG CCC TCG AAG GAG GAG CAG 865 Phe Gly Glu Leu Gin Asn Gin Met Pro Gly Pro Ser Lys Glu Glu Gin 275 280 285 AGC Cπ CCA GCG GGT GCT CAG GAG GCC CTC AGC GAC GGC CTG CAA πG 913 Ser Leu Pro Ala Gly Ala Gin Glu Ala Leu Ser Asp Gly Leu Gin Leu 290 295 300 GAG GTC CAG CCT TCC GAG GAA GAG GCG CGG GGC TAC ATC GTG ACA GAC 961 Glu Val Gin Pro Ser Glu Glu Glu Ala Arg Gly Tyr He Val Thr Asp 305 310 315 320 GGA GAC CCC CTG CGC CCC GAG GAA GGA AGG CGG CTG GTG GAG GAC GTC 1009 Gly Asp Pro Leu Arg Pro Glu Glu Gly Arg Arg Leu Val Glu Asp Val 325 330 335 GCC CGC CTC CTG CAG GTG CCC AGC AGC GCG πC GCT GAC GTG GAG Gπ 1057 Ala Arg Leu Leu Gin Val Pro Ser Ser Ala Phe Ala Asp Val Glu Val 340 345 350 CTC GGA CCA GCA GTG ACC πC AAA GTG AGC GCC AAT GTC CAA AAC GTG 1105 Leu Gly Pro Ala Val Thr Phe Lys Val Ser Ala Asn Val Gin Asn Val 355 360 365 ACC ACT GAG GAT GTG GAG AAG GCC ACA Gπ GAC AAC AAA GAC AAA CTG 1153 Thr Thr Glu Asp Val Glu Lys Ala Thr Val Asp Asn Lys Asp Lys Leu 370 375 380 GAG GAA ACC TCT GGA CTG AAA Aπ Cπ CAA ACC GGA GTC GGG TCG AAA 1201 Glu Glu Thr Ser Gly Leu Lys He Leu Gin Thr Gly Val Gly Ser Lys 385 390 395 400 AGC AAA CTC AAG πC CTG CCT CCT CAG GCG GAG CAA GAA GAC TCC ACC 1249 Ser Lys Leu Lys Phe Leu Pro Pro Gin Ala Glu Gin Glu Asp Ser Thr 405 410 415 AAG πC ATC GCG CTC ACC CTG GTC TCC CTC GCC TGC ATC CTG GGC GTC 1297 Lys Phe He Ala Leu Thr Leu Val Ser Leu Ala Cys He Leu Gly Val 420 425 430 CTC CTG GCC TCT GGC CTC ATC TAC TGC CTC CGC CAT AGC TCT CAG CAC 1345 Leu Leu Ala Ser Gly Leu He Tyr Cys Leu Arg His Ser Ser Gin His 435 440 445 AGG CTG AAG GAG AAG CTC TCG GGA CTA GGG GGC GAC CCA GGT GCA GAT 1393 Arg Leu Lys Glu Lys Leu Ser Gly Leu Gly Gly Asp Pro Gly Ala Asp 450 455 460 GCC ACT GCC GCC TAC CAG GAG CTG TGC CGC CAG CGT ATG GCC ACG CGG 1441 Ala Thr Ala Ala Tyr Gin Glu Leu Cys Arg Gin Arg Met Ala Thr Arg 465 470 475 480 CCA CCA GAC CGA CCT GAG GGC CCG CAC ACG TCA CGC ATC AGC AGC GTC 1489 Pro Pro Asp Arg Pro Glu Gly Pro His Thr Ser Arg He Ser Ser Val 485 490 495 TCA TCC CAG πC AGC GAC GGG CCG ATC CCC AGC CCC TCC GCA CGC AGC 1537 Ser Ser Gin Phe Ser Asp Gly Pro He Pro Ser Pro Ser Ala Arg Ser 500 505 510 AGC GCC TCA TCC TGG TCC GAG GAG CCT GTG CAG TCC AAC ATG GAC ATC 1585 Ser Ala Ser Ser Trp Ser Glu Glu Pro Val Gin Ser Asn Met Asp He 515 520 525 TCC ACC GGC CAC ATG ATC CTG TCC TAC ATG GAG GAC CAC CTG AAG AAC 1633 Ser Thr Gly His Met He Leu Ser Tyr Met Glu Asp His Leu Lys Asn 530 535 540 AAG AAC CGG CTG GAG AAG GAG TGG GAA GCG CTG TGC GCC TAC CAG GCG 1681 Lys Asn Arg Leu Glu Lys Glu Trp Glu Ala Leu Cys Ala Tyr Gin Ala 545 550 555 560 GAG CCC AAC AGC TCG πC GTG GCC CAG AGG GAG GAG AAC GTG CCC AAG 1729 Glu Pro Asn Ser Ser Phe Val Ala Gin Arg Glu Glu Asn Val Pro Lys 565 570 575 AAC CGC TCC CTG GCC GTG CTG ACC TAT GAC CAC TCC CGG GTC CTG CTG 1777 Asn Arg Ser Leu Ala Val Leu Thr Tyr Asp His Ser Arg Val Leu Leu 580 585 590 AAG GCG GAG AAC AGC CAC AGC CAC TCA GAC TAC ATC AAC GCT AGC CCC 1825 Lys Ala Glu Asn Ser His Ser His Ser Asp Tyr He Asn Ala Ser Pro 595 600 605 ATC ATG GAT CAC GAC CCG AGG AAC CCC GCG TAC ATC GCC ACC CAG GGA 1873 He Met Asp His Asp Pro Arg Asn Pro Ala Tyr He Ala Thr Gin Gly 610 615 620 CCG CTG CCC GCC ACC GTG GCT GAC TTT TGG CAG ATG GTG TGG GAG AGC 1921 Pro Leu Pro Ala Thr Val Ala Asp Phe Trp Gin Met Val Trp Glu Ser 625 630 635 640 GGC TGC GTG GTG ATC GTC ATG CTG ACA CCC CTC GCG GAG AAC GGC GTC 1969 Gly Cys Val Val He Val Met Leu Thr Pro Leu Ala Glu Asn Gly Val 645 650 655 CGG CAG TGC TAC CAC TAC TGG CCG GAT GAA GGC TCC AAT CTC TAC CAC 2017 Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn Leu Tyr His 660 665 670 ATC TAT GAG GTG AAC CTG GTC TCC GAG CAC ATC TGG TGT GAG GAC πC 2065 He Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys Glu Asp Phe 675 680 685 CTG GTG AGG AGC TTC TAT CTG AAG AAC CTG CAG ACC AAC GAG ACG CGC 2113 Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn Glu Thr Arg 690 695 700 ACC GTG ACG CAG πC CAC πC CTG AGT TGG TAT GAC CGA GGA GTC CCT 2161 Thr Val Thr Gin Phe His Phe Leu Ser Trp Tyr Asp Arg Gly Val Pro 705 710 715 720 TCC TCC TCA AGG TCC CTC CTG GAC πC CGC AGA AAA GTA AAC AAG TGC 2209 Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg Arg Lys Val Asn Lys Cys 725 730 735 TAC AGG GGC CGT TCT TGT CCA ATA Aπ Gπ CAT TGC AGT GAC GGT GCA 2257 Tyr Arg Gly Arg Ser Cys Pro He He Val His Cys Ser Asp Gly Ala 740 745 750 GGC CGG AGC GGC ACC TAC GTC CTG ATC GAC ATG Gπ CTC AAC AAG ATG 2305 Gly Arg Ser Gly Thr Tyr Val Leu He Asp Met Val Leu Asn Lys Met 755 760 765 GCC AAA GGT GCT AAA GAG Aπ GAT ATC GCA GCG ACC CTG GAG CAC πG 2353 Ala Lys Gly Ala Lys Glu He Asp He Ala Ala Thr Leu Glu His Leu 770 775 780 AGG GAC CAG AGA CCC GGC ATG GTC CAG ACG AAG GAG CAG Tπ GAG πC 2401 Arg Asp Gin Arg Pro Gly Met Val Gin Thr Lys Glu Gin Phe Glu Phe 785 790 795 800 GCG CTG ACA GCC GTG GCT GAG GAG GTG AAC GCC ATC CTC AAG GCC CTG 2449 Ala Leu Thr Ala Val Ala Glu Glu Val Asn Ala He Leu Lys Ala Leu 805 810 815 CCC CAG TGAGAAπC 2464 Pro Gin (2) INFORMATION FOR SEQ ID N0:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 818 amino acids (B) TYPE amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n ) MOLECULE TYPE: protein (v) FRAGMENT TYPE internal (xi) SEQUENCE DESCRIPTION. SEQ ID N0:22 His Thr Ser Val Leu Thr Tyr Pro Pro Gly Pro Arg Thr Gin Leu His 1 5 10 15 Glu Asp Leu Leu Pro Arg Thr Leu Gly Gin Leu Gin Pro Asp Glu Leu 20 25 30 Ser Pro Lys Val Asp Ser Gly Val Asp Arg His His Leu Met Ala Ala 35 40 45 Leu Ser Ala Tyr Ala Ala Gin Arg Pro Pro Ala Pro Pro Gly Glu Gly 50 55 60 Ser Leu Glu Pro Gin Tyr Leu Leu Arg Ala Pro Ser Arg Met Pro Arg 65 70 75 80 Pro Leu Leu Ala Pro Ala Ala Pro Gin Lys Trp Pro Ser Pro Leu Gly 85 90 95 Asp Ser Glu Asp Pro Ser Ser Thr Gly Asp Gly Ala Arg He His Thr 100 105 110 Leu Leu Lys Asp Leu Gin Arg Gin Pro Ala Glu Val Arg Gly Leu Ser 115 120 125 Gly Leu Glu Leu Asp Gly Met Ala Glu Leu Met Ala Gly Leu Met Gin 130 135 140 Gly Val Asp His Gly Val Ala Arg Gly Ser Pro Gly Arg Ala Ala Leu 145 150 155 160 Gly Glu Ser Gly Glu Gin Ala Asp Gly Pro Lys Ala Thr Leu Arg Gly 165 170 175 Asp Ser Phe Pro Asp Asp Gly Val Gin Asp Asp Asp Asp Arg Leu Tyr 180 185 190 Gin Glu Val His Arg Leu Ser Ala Thr Leu Gly Gly Leu Leu Gin Asp 195 200 205 His Gly Ser Arg Leu Leu Pro Gly Ala Leu Pro Phe Ala Arg Pro Leu 210 215 220 Asp Met Glu Arg Lys Lys Ser Glu His Pro Glu Ser Ser Leu Ser Ser 225 230 235 240 Glu Glu Glu Thr Ala Gly Val Glu Asn Val Lys Ser Gin Thr Tyr Ser 245 250 255 Lys Asp Leu Leu Gly Arg Gin Pro His Ser Glu Pro Gly Ala Ala Ala 260 265 270 Phe Gly Glu Leu Gin Asn Gin Met Pro Gly Pro Ser Lys Glu Glu Gin 275 280 285 Gly Cys Val Val He Val Met Leu Thr Pro Leu Ala Glu Asn Gly Val 645 650 655 Arg Gin Cys Tyr His Tyr Trp Pro Asp Glu Gly Ser Asn Leu Tyr His 660 665 670 He Tyr Glu Val Asn Leu Val Ser Glu His He Trp Cys Glu Asp Phe 675 680 685 Leu Val Arg Ser Phe Tyr Leu Lys Asn Leu Gin Thr Asn Glu Thr Arg 690 695 700 Thr Val Thr Gin Phe His Phe Leu Ser Trp Tyr Asp Arg Gly Val Pro 705 710 715 720 Ser Ser Ser Arg Ser Leu Leu Asp Phe Arg Arg Lys Val Asn Lys Cys 725 730 735 Tyr Arg Gly Arg Ser Cys Pro He He Val His Cys Ser Asp Gly Ala 740 745 750 Gly Arg Ser Gly Thr Tyr Val Leu He Asp Met Val Leu Asn Lys Met 755 760 765 Ala Lys Gly Ala Lys Glu He Asp He Ala Ala Thr Leu Glu His Leu 770 775 780 Arg Asp Gin Arg Pro Gly Met Val Gin Thr Lys Glu Gin Phe Glu Phe 785 790 795 800 Ala Leu Thr Ala Val Ala Glu Glu Val Asn Ala He Leu Lys Ala Leu 805 810 815 Pro Gin (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2736 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23: CAGGACAGAC CCCGTGCTGA GGGTGACGAC CGCπCTCCA AGAGCATCCT GACCTATGTG 60 GCCCACACGT CTGTGCTGAC CTACCCTCCC GGGCCCCAGG CCCAGCTCCC CGAGGACCTC 120 CTGCCACGGA CCCTCAGCCA GCTCCAGCCA GACGAGCTCA GCCCTAAGGT GGACAGCAGT 180 GTGGAGAGAC ACCATCTGAT GGCAGCCCTC AGTGCCTATG CTGCCCAGAG GCCCCCAGCT 240 CCCCCTGGGA AGGGCAGCCT GGAGCCGCAG TACCπCTGC GCGCCCCGTC CAGAATGCCC 300 AGGCCCπGT TGTCGCCAGC CGTCCCCCAG AAGTGGCCπ CACCTCTGGG AGATCCTGAA 360 GACCCCCCCA GCACAGGGGA AGGAGCACGG AπCACACTC TCCTGAAGGA CCTGCAGAGG 420 CAGCCGGCTG AGGCGAGGGG CCTGAGTGAC CTGGAGCTGG ACAGCATGGC CGAGCTGATG 480 GCTGGCCTGA TGCAAGGCAT GGACCACAGA GGAGCTCTAG GCGGCCCTGG GAAAGCGGCC 540 CTGGGAGAGT CTGGAGAACA GGCGGATGGC CCCAAGGCCG CCCTCCGTGG GGAAAGCTπ 600 CCAGATGACG GAGπCAGGA CGACGATGAC AGACHTACC AAGAGGTCCA TCGTCTGAGT 660 GCCACACTCG GGGGCCTCCT GCAGGACCAC GGGTCTCGAC TCTCGCCTGG AGCCCTCCCC 720 πTGCAAAGC CCCTCAAAAT GGAGAGGAAG AAATCCGAGC GCCCTGAGGC πCCCTGTCT 780 TCAGAAGAGG AGACTGCCGG AGTGGAGAAC GTCAAGAGCC AGACGTAπC CAAAACCTGC 840 TGGGGCAGCA GCCGCAπCG GAGCCCGGGG CAGGCGCGπ TGGGGAGCTC CAAACCAGAT 900 GCCTGGGCCC TCGGAGGAGG AGCAGAGCCT TCCAGCGGGT GCTCAGGAGG CCCTCGGCGA 960 CGGCTGCAAT TGGAAGTCAA GCCπCCGAG GAAGAGGCAC GGTGCTACAT CGTGACAGAC 1020 AGAGACCCCC TGCGCCCCGA GGAAGGAAGG CAGCTGGTGG AGGACGTCGC CCGCCTCCTG 1080 CAGATGCCCA GCAGCACAπ CGCCGACGTG GAGGπCTCG GACCAGCAGT GACCπCAAA 1140 GTGGGCGCCA ATGTCCAGAA CGTGACCACT GCGGATGTGG AGAAGGCCAC AGπGACAAC 1200 AAAGACAAAC TGGAGGAAAC CTCTGGACTG AAAAπcπC AAACCGGAGT CGGGTCGAAA 1260 AGCAAACTCA AGπCCTGCC TCCTCAGGCG GAGCAAGAAG ACTCAACCAA GπCATCGCG 1320 CTCACCCTGG TCTCCCTCGC CTGCATCCTG GGCGTCCTCC TGGCCTCTGG CCTCATCTAC 1380 TGCCTACGCC ATAGCTCTCA GCACAGGCTG AAGGAGAAGC TCTCGGGACT AGGGCGCGAC 1440 CCAGGTGCAG ATGCCACCGC CGCCTACCAG GAGCTGTGCC GCCAGCGTAT GGCCACGCGG 1500 CCACCAGACC GGCCCGAGGG CCCGCACACA TCCCGCATCA GCAGCGTCTC GTCCCAGπC 1560 AGCGACGGGC CGATGCCCAG CCCCTCCGCA CGCAGCAGCG CCTCGTCCTG GTCCGAGGAG 1620 CCCGTGCAGT CCAACATGGA CATCTCCACC GGCCACATGA TCCTGTCCTA CATGGAGGAC 1680 CACCTGAAGA ACAAGAACCG GCTGGAGAAG GAGTGGGAGG CGCTGTGTGC CTACCAGGCG 1740 GAGCCCAACA GCTCACTTGT GGCCCAGAAG GAGGAGAATG TGCCCAAGAA CCGCTCCCTG 1800 GCCGTGCTGA CCTATGACCA CTCCCGGGTC CTACTGAAGG CGGAGAACAG CCACAGCCAC 1860 TCGGACTACA TCAACGCCAG CCCCATCATG GATCACGACC CGAGGAACCC CGCGTACATC 1920 GCCACCCAGG GACCGCTGCC CGCCACCGTG GCCGACHTT GGCAGATGGT GTGGGAGAGC 1980 GGCTGCGTGG TGATCGTCAT GCTGACACCC CTCACAGAGA ACGGCGTCCG GCAGTGCTAC 2040 CACTACTGGC CAGATGAAGG CTCCAACCTC TACCACATCT ATGAGGTGAA CCTGGTCTCC 2100 GAGCACATCT GGTGCGAGGA CiπCTGGTG AGGAGCπCT ATCTGAAGAA CCTGCAGACC 2160 AACGAGACGC GCACCGTGAC CCAGπCCAC πCCTGAGπ GGTATGACCG AGGAGTCCCC 2220 TCCTCCTCAA GATCCCTCCT GGACπCCGC AGAAAAGTAA ACAAGTGCTA CAGGGGCCGT 2280 TCπGTCCAA TAAπGπCA πGCAGTGAC GGTGCAGGCC GGAGCGGCAC CTACGTCCTG 2340 ATCGACATGG πCTCAACAA GATGGCCAAA GGTGCTAAAG AGAπGATAT CGCAGCAACC 2400 CTGGAGCACT TGAGGGACCA GAGACCCGGC ATGGTCCAGA CGAAGGAGCA GTπGAGπC 2460 GCGCTGACAG CCGTGGCTGA AGAGGTGAAT GCCATCCTCA AGGCCCπCC CCAGTGAGCA 2520 GCGGCCTCGG GGCCTCGGGG GAGCCCCCAC CCCCCGGATG TCGTCAGGAA TCGTGATCTG 2580 ACTTTAAπG TGTGTCπCT AπATAACTG CATAGTAATA GGGCCCπAG CTCTCCCGTA 2640 GTCAGCGCAG TπAGCAGπ AAGCAGπAA AATGTGTAπ πTGTπAAT CCAACAATAA 2700 TAAAGAGAGA πTGTGGAAA AATCCCAAAA AAAAAA 2736 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 738 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 08Z 11339919W 9V3333319339V3393191191103399V 33391W9V33193333939 02/ 39131133V19V39339V991339V3999V V999133333139V3333399V9V333913 099 91V133919V 313339V3991V9131V33V 3V9V9V991919V39V3V99199W13339 009 V3139V93V9 V339V33139 V339V31333 V993V339133133V99V93333139V333 OfrS 99V33339993331333V133V91391913193V3V33399191V133V91331V39V9V 0817 V3313113933V93V91999 V9139193333V9V3V99V393991V99333V99V33931 0Zι7 39393V9V01139V333399 V33319103099V99133113339103V3393V9331133 09ε 99W3399133391393993999V999319 V3V199V99V 9V919V39911V39V3V3W OOε W3133399V 339V33399331939W91331V399V9133V133WW3333133V9V3 0Vι2 9113W99V33V991V9191 V19V313V1V 13V91V99V399193V311199V3V39933 08T 1313VW9V39JJ .399193939133939V 39133399193339319199 V93V13933V 021 11113V991V V399331199 W9V339199 W99111919 V991V93W9191913399V 09 9331939V993913133999 V99V9313V133913999133939999333139V399339 :52 : 0N 0103S :N0IldIH0S3a 33N3H03S ( PO VN03 : 3dλl 31fl0310W ( L) J 9ULL :λ9010d01 (0) θLQ"op :SS3N03αNVyiS (3) p e OLθionu :3dλl (8) s Led θspq zze : H19N31 (V) :S3IlSiy313VαVH333N3nθ3S U) :92 : ON 01 03S yOJ NOIlVWcJOJ I (2) 8ε 91V91339913991V913 02Z 9V933991V39V3V99139V 99133V919V 91339999V9399V91399339V399V9V3 099 9133V99W91331313V3V 311V993V39 V99W9999V 3V39V3333333V9W9133 009 1V9V99913133V311339919W9V3333319339V3393191191133399V33391V 0t7S V9V3319333393939131133V19V39339V991339V3999W999133333139V33 08fr 33399V9V33391391V133919V313339 V3991V9131 V33V3V9V9V 991919V39V 02fr 3V99199W13339V3139V 93V9V339V33139V339V31333V993V339133133V9 09ε 9V93333139 V33399V33339993331333V133V91391913193V3V 33399191V1 OOε 33V91331V39V9W3313113933V93V91999V9139193333V9V3V 99V393991V 0172 99333V99V3393139393V 9V31139V333399V33319133399V9913311333913 081 3V0393V933113399W3399133391393993999V999319V3V199 V99V9V919V 021 39911V39V3 V3WW3133399V339V33399331939V V91331V399 V9133V133V 09 VW3333133 V9V39113W 99V33V991V 9191V19V313V1V13V91V 99V399193V : t72 : O 01 03S : NOUdIc.OS3α 33N3003S (PO V OO : 3dλl 3103310N (LL) eθULL :λ9010d01 (Q) 8θτ zesεo/-,6Sfi/XD-( vwtε/L β OΛA VNtP 3dλl 3103310W ( ) JB9ULL AOOlOdOl (0) θLqnop SS3Nα3αNVcllS (3) PLOP OLθLonu 3dλl (8) SJ Pd θs p q πoτ H19N31 (V) S3USIcJ313VaVH333N3D03S (L) Ll ON 0103S JOJ NOUVWyOJNI (2) 666 91V91339913991V9139 V933991V39 V3V99139V9 096 9133V919V91339999V9399V91399339V399V9V39133V99W91331313V3V3 006 11V993V39V 99W9999V3 V39V3333333V9W91331 V9V99913133V31133991 Orø 9W9V3333319339V3393191191133399V33391W 9V331933339393913113 08Z 3V19V39339 V991339V3999W999133333139V3333399V9V33391391V1339 02Z 19V313339V 3991V9131V 33V3V9V9V991919V39V3 V99199W13339V3139V9 099 3V9V339V33139V339V31333V993V339133133V99 V93333139V 33399V3333 009 9993331333 V133V91391913193V3V33399191V133V91331V39 V9W331311 Ofrg 3933V93V91999V9139193333V9V3V99V393991V99333V99V3393139393V9 087. V31139V333399V33319133399V99133113339133 V3393V933113399W339 QZP 9133391393993999V999319V3V199V 99V9V919V399JLLV39V3V 3WW31333 09ε 99V339V33399331939W 91331V399V 9133V133W W3333133V 9V39113W9 00ε 9V33V991V9191V19V313 V1V13V91V99V399193V311199V3V399331313VW 0172 9V39111399193939133939V39133399193339319199V93V13933V11113V9 081 91W399331199W9V339199W99111919V991V93 W9191913399V9331939 021 V993913133999V99V9313V133913999133939999333139V39933993V3333 09 319331931333339339133913319393 V33933913913913913V13913911913 92 ON 0103S NOIldlL∞u 33N3003S (LX) VNCP 3dλl 31fl3310W (LL) J ΘULL A9010d01 (0) ΘLqnop SS3Nα3(_NVαj.S (3) p Loe D Lθ Lonu 3dλl (8) SJLPd θs p q 666 H19N31 (V) SDIlSIHΞlOVαVHO 33N3D03S ( L) 92 ON 01 Q3S U03 NOUVWtiOJNI (2) 6 91 V91339913991V9139V933991V39V3V 006 99139V99133V919V91339999V9399V 91399339V399V9V39133 V99W91331 0t78 313V3V311V 993V39V99V V9999V3V39 V3333333V9 W91331V9V 99913133V3 6θτ reseo / -. 6 s . ι /X D[ w β ic/i β OΛV (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GCGCTCCCGC TGCTGπGCT GCTACTGCTG CTGCTGCCGC CACGCGTCCT GCCTGCCGCC 60 CCCTCGTCCG TCCCCCACGG CCGGCAGCTC CCGGGGCGCC TGGGCTGCCT ACTCGAGGAG 120 GGCCTCTGCG GAGCGTCCGA GGCCTGTGTG AACGATGGAG TGπTGGAAG GTGCCAGAAG 180 GπCCGGCAA TGGACTπTA CCGCTACGAG GTGTCGCCCG TGGCCCTGCA GCGCCTGCGC 240 GTGGCTπGC AGAAACTCTC CGGCACAGGT πCACGTGGC AGGATGACTA TACTCAGTAT 300 GTGATGGACC AGGAACπGC AGACCTCCCC AAAACCTACC TGAGGCATCC TGAAGCGTCC 360 GGCCCAGCCA GGCCCTCAAA ACACAGCAπ GGCAGTGAGA GGAGGTACAG TCGGGAGGGC 420 GGCGCTGCCC TGGCCAAGGC CπCCGACGC CACCTGCCCT TCCTGGAGGC CCTGTCCCAG 480 GCCCCAGCπ CAGACGCGCT CGCCAGGACC CGGATGGCGC AGGACAGACC CCGTGCTGAG 540 GGTGACGACC GCπCTCCAA GAGCATCCTG ACCTATGTGG CCCACACGTC TGTGCTGACC 600 TACCCTCCCG GGCCCCAGGC CCAGCTCCCC GAGGACCTCC TGCCACGGAC CCTCAGCCAG 660 CTCCAGCCAG ACGAGCTCAG CCCTAAGGTG GACAGCAGTG TGGAGAGACA CCATCTGATG 720 GCAGCCCTCA GTGCCTATGC TGCCCAGAGG CCCCCAGCTC CCCCTGGGAA GGGCAGCCTG 780 GAGCCGCAGT ACCπCTGCG CGCCCCGTCC AGAATGCCCA GGCCCπGπ GTCGCCAGCC 840 GTCCCCCAGA AGTGGCCπC ACCTCTGGGA GATCCTGAAG ACCCCCCCAG CACAGGGGAA 900 GGAGCACGGA πCACACTCT CCTGAAGGAC CTGCAGAGGC AGCCGGCTGA GGCGAGGGGC 960 CTGAGTGACC TGGAGCTGGA CAGCATGGCC GAGCTGATGG CTGGCCTGAT G 1011 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC11654 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: CGGAAπCCT CTGTGGTCCA TGCCπGC 28 (2) INFORMATION FOR SEQ ID NO:29: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC11197 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:29: AAAπAATAC GACTCACTAT AGGGAGACCG 30 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1210 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: AGTGCTGCTC ACTCTGGTGG CCCTGGCAGG TGTGGCTGGG CTGCTGGTGG CTCTGGCTGT 60 GGCTCTGTGT GTGCGGCAGC ATGCGCGGCA GCAAGACAAG GAGCGCCTGG CAGCCCTGGG 120 GCCTGAGGGG GCCCATGGTG ACACTACCπ TGAGTACCAG GACCTGTGCC GCCAGCACAT 180 GGCCACGAAG TCCπGπCA ACCGGGCAGA GGGTCCACCG GAGCCπCAC GGGTGAGCAG 240 TGTGTCCTCC CAGπCAGCG ACGCAGCCCA GGCCAGCCCC AGCTCCCACA GCAGCACCCC 300 GTCCTGGTGC GAGGAGCCGG CCCAAGCCAA CATGGACATC TCCACGGGAC ACATGAπCT 360 GGCATACATG GAGGATCACC TGCGGAACCG GGACCGCCπ GCCAAGGAGT GGCAGGCCCT 420 CTGTGCCTAC CAAGCAGAGC CAAACACCTG TGCCACCGCG CAGGGGGAGG GCAACATCAA 480 AAAGAACCGG CATCCTGACT TCCTGCCCTA TGACCATGCC CGCATAAAAC TGAAGGTGGA 540 GAGCAGCCCT TCTCGGAGCG AπACATCAA CGCCAGCCCC AπAπGAGC ATGACCCTCG 600 GATGCCAGCC TACATAGCCA CGCAGGGCCC GCTGTCCCAT ACCATCGCAG ACπCTGGCA 660 GATGGTGTGG GAGAGCGGCT GCACCGTCAT CGTCATGCTG ACCCCGCTGG TGGAGGATGG 720 TGTCAAGCAG TGTGACCGCT ACTGGCCAGA TGAGGGTGCC TCCCTCTACC ACGTATATGA 780 GGTGAACCTG GTGTCGGAGC ACATCTGGTG CGAGGACTπ CTGGTGCGGA GCπCTACCT 840 GAAGAACGTG CAGACCCAGG AGACGCGCAC GCTCACGCAG πCCACπCC TCAGCTGGCC 900 GGCAGAGGGC ACACCGGCCT CCACGCGGCC CCTGCTGGAC πCCGCAGGA AGGTGAACAA 960 GTGCTACCGG GGCCGCTCCT GCCCCATCAT CGTGCACTGC AGTGATGGTG CGGGGAGGAC 1020 CGGCACCTAC ATCCTCATCG ACATGGTCCT GAACCGCATG GCAAAAGGAG TGAAGGAGAT 1080 TGACATCGCT GCCACCCTGG AGCATGTCCG TGACCAGCGG CCTGGCCπG TCCGCTCTAA 1140 GGACCAGTπ GAATπGCCC TGACAGCCGT GGCGGAGGAA GTGAATGCCA TCCTCAAGGC 1200 CCTGCCCCAG 1210 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1263 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: TCACACGTCT GTGCTGACCT ACCCTCCCGG GCCCCGGACC CAGCTCCACG AGGACCTCCT 60 GCCACGGACC CTCGGCCAGC TCCAGCCAGA TGAGCTCAGC CCTAAGGTGG ACAGTGGTGT 120 GGACAGACAC CATCTGATGG CGGCCCTCAG TGCCTATGCT GCCCAGAGGC CCCCAGCTCC 180 CCCCGGGGAG GGCAGCCTGG AGCCACAGTA CCπCTGCGT GCACCCTCAA GAATGCCCAG 240 GCCHTGCTG GCACCAGCCG CCCCCCAGAA GTGGCCπCA CCTCTGGGAG AπCCGAAGA 300 CCCCTCTAGC ACAGGCGATG GAGCACGGAT TCATACCCTC CTGAAGGACC TGCAGAGGCA 360 GCCGGCTGAG GTGAGGGGCC TGAGTGGCCT GGAGCTGGAC GGCATGGCTG AGCTGATGGC 420 TGGCCTGATG CAAGGCGTGG ACCATGGAGT AGCTCGAGGC AGCCCTGGGA GAGCGGCCCT 480 GGGAGAGTCT GGAGAACAGG CGGATGGCCC CAAGGCCACC CTCCGTGGAG ACAGCπTCC 540 AGATGACGGA GTGCAGGACG ACGATGATAG ACπTACCAA GAGGTCCATC GTCTGAGTGC 600 CACACTCGGG GGCCTCCTGC AGGACCACGG GTCTCGACTC πACCTGGAG CCCTCCCCπ 660 TGCAAGGCCC CTCGACATGG AGAGGAAGAA GTCCGAGCAC CCTGAGTCπ CCCTGTCπC 720 AGAAGAGGAG ACTGCCGGAG TGGAGAACGT CAAGAGCCAG ACGTAπCCA AAGATCTGCT 780 GGGGCGGCAG CCGCAπCGG AGCCCGGGGC CGCTGCGTπ GGGGAGCTCC AAAACCAGAT 840 GCCTGGGCCC TCGAAGGAGG AGCAGAGCCT TCCAGCGGGT GCTCAGGAGG CCCTCAGCGA 900 CGGCCTGCAA πGGAGGTCC AGCCTTCCGA GGAAGAGGCG CGGGGCTACA TCGTGACAGA 960 CGGAGACCCC CTGCGCCCCG AGGAAGGAAG GCGGCTGGTG GAGGACGTCG CCCGCCTCCT 1020 GCAGGTGCCC AGCAGCGCGT TCGCTGACGT GGAGGπCTC GGACCAGCAG TGACCπCAA 1080 AGTGAGCGCC AATGTCCAAA ACGTGACCAC TGAGGATGTG GAGAAGGCCA CAGπGACAA 1140 CAAAGACAAA CTGGAGGAAA CCTCTGGACT GAAAAπcπ CAAACCGGAG TCGGGTCGAA 1200 AAGCAAACTC AAGπCCTGC CTCCTCAGGC GGAGCAAGAA GACTCCACCA AGπCATCGC 1260 GCA 1263 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 758 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: GAAπCGGCT TAAGGCGACG GTGGACAACA AAGACAAACT GGAGGAAACC TCTGGACTGA 60 AAAπcπCA AACCGGAGTC GGGTCGAAAA GCAAACTCAA GπCCTGCCT CCTCAGGCGG 120 AGCAAGAAGA CTCCACCAAG πCATCGCGC TCACCCTGGT CTCCCTCGCC TGCATCCTGG 180 GCGTCCTCCT GGCCTCTGGC CTCATCTACT GCCTCCGCCA TAGCTCTCAG CACAGGCTGA 240 AGGAGAAGCT CTCGGGACTA GGGGGCGACC CAGGTGCAGA TGCCACTGCC GCCTACCAGG 300 AGCTGTGCCG CCAGCGTATG GCCACGCGGC CACCAGACCG ACCTGAGGGC CCGCACACGT 360 CACGCATCAG CAGCGTCTCA TCCCAGπCA GCGACGGGCC GATCCCCAGC CCCTCCGCAC 420 GCAGCAGCGC CTCATCCTGG TCCGAGGAGC CTGTGCAGTC CAACATGGAC ATCTCCACCG 480 GCCACATGAT CCTGTCCTAC ATGGAGGACC ACCTGAAGAA CAAGAACCGG CTGGAGAAGG 540 AGTGGGAAGC GCTGTGCGCC TACCAGGCGG AGCCCAACAG CTCGπCGTG GCCCAGAGGG 600 AGGAGAACGT GCCCAAGAAC CGCTCCCTGG CCGTGCTGAC CTATGACCAC TCCCGGGTCC 660 TGCTGAAGGC GGAGAACAGC CACAGCCACT CAGACTACAT CAACGCTAGC CCCATCATGG 720 ATCACGACCC GAGGAACCCC GCGTACAAAG CCGAAπC 758 (2) INFORMATION FOR SEQ ID NO 33 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 1150 base pairs (B) TYPE nuclei c acid (C) STRANDEDNESS double (D) TOPOLOGY linear (n) MOLECULE TYPE cDNA (xi) SEQUENCE DESCRIPTION SEQ ID NO 33 AAGCπCCAC CATGCGCCAT AGCTCTCAGC ACAGGCTGAA AGAGAAGCTC TCGGGACTAG 60 GGGGCGACCC AGGTGCAGAT GCCACTGCCG CCTACCAGGA GCTGCGCCGC CAGCGTATGG 120 CCACGCGGCC ACCAGACCGA CCTGAGGGCC CGCACACGTC ACGCATCAGC AGCGTCTCAT 180 CCCAGπCAG CGACGGGCCG ATCCCCAGCC CCTCCGCACG CAGCAGCGCC TCATCCTGGT 240 CCGAGGAGCC TGTGCAGTCC AACATGGACA TCTCCACCGG CCACATGATC CTGTCCTACA 300 TGGAGGACCA CCTGAAGAAC AAGAACCGGC TGGAGAAGGA GTGGGAAGCG CTGTGCGCCT 360 ACCAGGCGGA GCCCAACAGC TCGπCGTGG CCCAGAGGGA GGAGAACGTG CCCAAGAACC 420 GCTCCCTGGC CGTGCTGACC TATGACCACT CCCGGGTCCT GCTGAAGGCG GAGAACAGCC 480 ACAGCCACTC AGACTACATC AACGCTAGCC CCATCATGGA TCACGACCCG AGGAACCCCG 540 CGTACATCGC CACCCAGGGA CCGCTGCCCG CCACCGTGGC TGACCTπGG CAGATGGTGT 600 GGGAGAGCGG CTGCGTGGTG ATCGTCATGC TGACACCCCT CGCGGAGAAC GGCGTCCGGC 660 AGTGCTACCA CTACTGGCCG GATGAAGGCT CCAATCTCTA CCACATCTAT GAGGTGAACC 720 TGGTCTCCGA GCACATCTGG TGTGAGGACT TCCTGGTGAG GAGCπCTAT CTGAAGAACC 780 TGCAGACCAA CGAGACGCGC ACCGTGACGC AGπCCACπ CCTGAGπGG TATGACCGAG 840 GAGTCCCπC CTCCTCAAGG TCCCTCCTGG ACπCCGCAG AAAAGTAAAC AAGTGCTACA 900 GGGGCCGπC πGTCCAATA AπGπCAπ GCAGTGACGG TGCAGGCCGG AGCGGCACCT 960 ACGTCCTGAT CGACATGGπ CTCAACAAGA CGGCCAAAGG TGCTAAAGAG AπGATATCG 1020 CAGCGACCCT GGAGCACπG AGGGACCAGA GACCCGGCAT GTCCAGACGA AGGAGCAGπ 1080 TGAGπCGCG CTGACAGCCG TGGCTGAGGA GGTGAACGCC ATCCTCAAGG CCCTGCCCCA 1140 GTGAGAAπC 1150 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2328 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:34: GAAπCGGCT TGAGGAACCC CGCGTACATC GCCACCCAGG GACCGCTGCC CGCCACCGTG 60 GCTGACTTπ GGCAGATGGT GTGGGAGAGC GGCTGCGTGG TGATCGTCAT GCAGACACCC 120 CTCGCGGAGA ACGGCGTCCG GCAGTGCTAC CACTACTGGC CGGATGAAGG CTCCAATCTC 180 TACCACATCT ATGAGGTGAA CCTGGTCTCC GAGCACATCT GGTGTGAGGA CπCCTGGTG 240 AGGAGCπCT ATCTGAAGAA CCTGCAGACC AACGAGACGC GCACCGTGAC GCAGπCCAC 300 πCCTGAGπ GGTπGACCG AGGAGTCCCT TCCTCCTCAA GGTCCCTCCT GGACπCCGC 360 AGAAAAGTAA ACAAGTGCTA CAGGGGCCGT TCπGTCCAA TAAπGπCA πGCAGTGAC 420 GGTGCAGGCC GGAGCGGCAC CTACGTCCTG ATCGACATGG πCTCAACAA GATGGCCAAA 480 GGTGCTAAAG AGAπGATAT CGCAGCGACC CTGGAGCACT TGAGGGACCA GAGACCCGGC 540 ATGGTCCAGA CGAAGGAGTA GTTTGAGπC GCGCTGACAG CCGTGGCTGA GGAGGTGAAC 600 GCCATCCTCA AGGCCCπCC CCAGTGAGCG GCAGCCTCAG GGGCCTCAGG GGAGCCCCCA 660 CCCCACGGAT GπGTCAGGA ATCATGATCT GACTπAAπ GTGTGTCπC TAπATAACT 720 GCATAGTAAT AGGGCCCπA GCTCTCCCGT AGTCAGCGCA GTπAGCAGT TAAAAGTGTA 780 ππTGπTA ATCAAACAAT AATAAAGAGA GATπGTGGA AAAATCCAGT TACGGGTGGA 840 GGGGAATCGG πCATCAAπ πCACπGCT TAAAAAAAAT ACTTπTCπ AAAGCACCCG 900 πCACCπCT TGGπGAAGT TGTGπAACA ATGCAGTAGC CAGCACGπC GAGGCGGπT 960 CCAGGAAGAG TGTGCπGTC ATCTGCCACT πCGGGAGGG TGGATCCACT GTGCAGGAGT 1020 GGCCGGGGAA GCTGGCAGCA CTCAGTGAGG CCGCCCGGCA CACAAGGCAC GlTTGGCAπ 1080 TCTCHTGAG AGAGπTATC AπGGGAGAA GCCGCGGGGA CAGAACTGAA CGTCCTGCAG 1140 CπCGGGGCA AGTGAGACAA TCACAGCTCC TCGCTGCGTC TCCATCAACA CTGCGCCGGG 1200 TACCATGGAC GGCCCCGTCA GCCACACCTG TCAGCCCAAG CAGAGTGAπ CAGGGGCTCC 1260 CCGGGGGCAG GCACCTGTGC ACCCCATGAG TAGTGCCCAC πGAGGCTGG CACTCCCCTG 1320 ACCTCACCπ TGCAAAGπA CAGATGCACC CCAACAπGA GATGTGTTTT TAATGπAAA 1380 ATAπGAπT CTACGπATG AAAACAGATG CCCCCGTGAA TGCπACCTG TGAGATAACC 1440 ACAACCAGGA AGAACAAATC TGGGCAπGA GCAAGCTATG AGGGTCCCCG GGAGCACACG 1500 AACCCTGCCA GGCCCCCGCT GGCTCCTCCA GGCACGTCCC GGACCTGTGG GGCCCCAGAG 1560 AGGGGACAπ TCCCTCCTGG GAGAGAAGGA GATCAGGGCA ACTCGGAGAG GGCTGCGAGC 1620 ATπCCCTCC CGGGAGAGGA GATCAGGGCG ACCTGCACGC ACTGCGTAGA GCCTGGAAGG 1680 GAAGTGAGAA ACCAGCCGAC CGGCCCTGCC CCTCπCCCG GGATCACπA ATGAACCACG 1740 TGTTTGACA TCATGTAAAC CTAAGCACGT AGAGATGAπ CGGAπTGAC AAAATAACAT 1800 πGAGTATCC GAπCGCCAT CACCCCCTAC CCCAGAAATA GGACAAπCA CπCATTGAC 1860 CAGGATGATC ACATGGAAGG CGGCGCAGAG GCAGCTGCGT GGGCTGCAGA 1TTCCTGTGT 1920 GGGGπCAGC GTAGAAAACG CACCTCCATC CCGCCCπCC CACAGCAπC CTCCATCTTA 1980 GATAGATGGT ACTCTCCAAA GGCCCTACCA GAGGGAACAC GGCCTACTGA GCGGACAGAA 2040 TGATGCCAAA ATAπGCπA TGTCTCTACA TGGTAπGTA ATGAATATCT GCπTAATAT 2100 AGCTATCAπ TCTTTTCCAA AAπACπCT CTCTATCTGG AAπTAAπA ATCGAAATGA 2160 ATπATCTGA ATATAGGAAG CATATGCCTA CπGTAAlTT CTAACTCCπ ATGHTGAAG 2220 AGAAACCTCC GGTGTGAGAT ATACAAATAT ATπAAπGT GTCATAπAA ACπCTGAπ 2280 TCACCAAAAA AAAAAAAAAA AAAAAAAAAA AAAGCGGCCG CTGAAπC 2328

Claims: CLAIMS We claim: 1. An isolated polynucleotide comprising a DNA segment encoding a mammalian islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of : a) a polypeptide of SEQ ID NO: 16 from Leu, amino acid residue 636 to Gin, amino acid residue 1012: b) a polypeptide of SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; and c) allelic variants of (a) or (b) wherein the polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM. 2. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide encodes a mammalian islet cell antigen polypeptide selected from the group consisting of : a) a polypeptide of SEQ ID NO: 16 from Phe, amino acid residue 612 to Gin, amino acid residue 1012; b) a polypeptide of SEQ ID NO: 22 from Phe, amino acid residue 418 to Gin, amino acid residue 818; and c) allelic variants of (a) or (b) . 3. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide encodes a mammalian islet cell antigen polypeptide selected from the group consisting of : a) a polypeptide of SEQ ID NO:16 from Ala, amino acid residue 1 to Gin, amino acid residue 1012; b) a polypeptide of SEQ ID NO: 22 from His, amino acid residue 1 to Gin, amino acid residue 818; and c) allelic variants of (a) or (b) . 4. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide is a DNA molecule selected from the group consisting of: a) a DNA molecule comprising the coding sequence of SEQ ID NO: 15 from nucleotide 1909 to nucleotide 3039; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1325 to nucleotide 2455; c) allelic variants of (a) or (b) ; and d) complements of polynucleotide molecules that specifically hybridize to (a) , (b) or (c) . 5. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide is a DNA molecule selected from the group consisting of: a) a DNA molecule comprising the coding sequence of SEQ ID NO:15 from nucleotide 1837 to nucleotide 3039; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 2 to nucleotide 2455; c) allelic variants of (a) or (b) ,- and d) complements of polynucleotide molecules that specifically hybridize to (a) , (b) or (c) . 6. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide is a DNA molecule selected from the group consisting of : a) a DNA molecule comprising the coding sequence of SEQ ID NO:15 from nucleotide 4 to nucleotide 3039; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1254 to nucleotide 2455; c) allelic variants of (a) or (b) ; and d) complements of polynucleotide molecules that specifically hybridize to (a) , (b) or (c) . 7. An isolated polynucleotide according to claim 1 which encodes a full length mammalian islet cell antigen polypeptide comprising the sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 8. An isolated polynucleotide comprising a DNA segment encoding a mammalian islet cell antigen polypeptide according to claim 1, wherein said mammalian islet cell antigen polypeptide is a primate islet cell antigen polypeptide. 9. A DNA construct comprising a first DNA segment encoding a human islet cell antigen polypeptide operably linked to additional DNA segments required for the expression of said first DNA segment, wherein said first DNA segment encodes a human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) wherein said mammalian islet cell antigen polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM. 10. A DNA construct according to claim 9 herein said first DNA segment comprises a nucleotide sequence selected from the group consisting of: a) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1325 to nucleotide 2455; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1253 to nucleotide 2455; c) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 2 to nucleotide 2455; d) naturally occurring allelic variants of (a) , (b) or (c) ,- and e) complements of polynucleotide molecules that specifically hybridize to (a) , (b) , (c) or (d) . 11. A DNA construct according to claim 9, wherein said first segment encodes a full length mammalian islet cell antigen comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 12. A DNA construct comprising a first DNA segment encoding a mammalian islet cell antigen according to claim 9, wherein said mammalian islet cell antigen polypeptide is a primate islet cell antigen polypeptide. 13. A host cell containing a DNA construct comprising a first DNA segment encoding a mammalian islet cell antigen polypeptide operably linked to additional DNA segments required for the expression of said first DNA segment, wherein said first DNA segment encodes a human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) wherein said mammalian islet cell antigen polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM. 14. A host cell according to claim 13, wherein said first DNA segment comprises a nucleotide sequence selected from the group consisting of: a) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1325 to nucleotide 2455; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1253 to nucleotide 2455; c) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 2 to nucleotide 2455; d) naturally occurring allelic variants of (a) , (b) or (c) ; and e) complements of polynucleotide molecules that specifically hybridize to (a) , (b) , (c) or (d) . 15. A host cell according to claim 13, wherein said first DNA segment encodes a full length mammalian islet cell antigen polypeptide comprising the sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 16. A host cell containing a DNA construct comprising a first DNA segment encoding a mammalian islet cell antigen polypeptide according to claim 13, wherein said mammalian islet cell antigen polypeptide is a primate islet cell antigen polypeptide. 17. An isolated mammalian islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of : a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) wherein said mammalian islet cell antigen polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM. 18. An isolated mammalian islet cell antigen polypeptide according to claim 17, wherein said isolated mammalian islet cell antigen polypeptide is a full length mammalian islet cell antigen polypeptide comprising the sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 19. An isolated mammalian islet cell antigen polypeptide according to claim 17, wherein said mammalian islet cell antigen polypeptide is a primate islet cell antigen polypeptide. 20. A method for producing a mammalian islet cell antigen polypeptide comprising the steps of: culturing a host cell containing a DNA construct comprising a first DNA segment operably linked to additional DNA segments required for the expression of said first DNA segment, wherein said first DNA segment encodes a human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) wherein said mammalian islet cell antigen polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM; and isolating said mammalian islet cell antigen polypeptide. 21. A method for producing a mammalian islet cell antigen polypeptide according to claim 20, wherein said first DNA segment comprises a nucleotide sequence selected from the group consisting of : a) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1325 to nucleotide 2455; b) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 1253 to nucleotide 2455; c) a DNA molecule comprising the coding sequence of SEQ ID NO:21 from nucleotide 2 to nucleotide 2455; d) naturally occurring allelic variants of (a) , (b) or (c) ; and e) complements of polynucleotide molecules that specifically hybridize to (a) , (b) , (c) or (d) . 22. A method for producing a mammalian islet cell antigen polypeptide according to claim 20, wherein said first DNA segment encodes a full length mammalian islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 23. A method for producing a human islet cell antigen polypeptide according to claim 20, wherein said host cell is a bacterial cell or a cultured human cell . 24. A method for determining the presence of an autoantibody to a human islet cell antigen polypeptide in a biological sample comprising the steps of: contacting a biological sample with a human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) , under conditions conducive to immune complex formation, and detecting the presence of immune complex formation between said human islet cell antigen polypeptide and said autoantibody to a human islet cell antigen, thereby determining the presence of an autoantibody to said human islet cell antigen in said biological sample. 25. The method of determining the presence of an autoantibody to a human islet cell antigen polypeptide according to claim 24, wherein said human islet cell antigen polypeptide is detectably labeled. 26. A method of determining the presence of an autoantibody to a human islet cell antigen polypeptide according to claim 24, wherein said human islet cell antigen polypeptide is a full length human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 27. A method for predicting the clinical course of IDDM in a patient comprising: testing a biological sample from a patient for the presence of human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) , wherein said polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM and classifying said patient for clinical course of diabetes based on the presence or absence of mammalian islet cell antigen polypeptides in said sample. 28. A method for predicting the clinical course of IDDM according to claim 27, wherein said patient is further tested for one or more additional predictive markers associated with risk of or protection from IDDM. 29. A method for predicting the clinical course of IDDM according to claim 27, wherein said predictive marker is an autoantibody to an antigen selected from the group consisting of GAD65, IA-2/ICA512, or insulin. 30. A method for predicting the clinical course of IDDM according to claim 27, wherein said predictive marker is a genotype selected from the group consisting of HLA DR and HLA DQ. 31. A method for predicting the clinical course of IDDM according to claim 27, wherein said predictive marker is a polymorphic region in the 5 ' flanking region of a human insulin gene. 32. A method of predicting the clinical course of IDDM according to claim 27, wherein said human islet cell antigen polypeptide is a full length human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 33. A human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) , that specifically binds a human islet cell antigen receptor on immature or mature T or B lymphocytes for use in preventing an autoimmune response to a human islet cell antigen polypeptide by inducing immunological tolerance. 34. A human islet cell antigen polypeptide according to claim 33, wherein said human islet cell antigen polypeptide is a full length human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 35. A probe which comprises an oligonucleotide of at least about 16 nucleotides, wherein said oligonucleotide is at least 85% identical to a sequence of the human islet cell antigen DNA sequence of SEQ ID NOs: 15 or 21. 36. An isolated antibody which specifically binds to a human islet cell antigen polypeptide, wherein said human islet cell antigen polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) . 37. An isolated antibody according to claim 36, wherein said isolated antibody is a monoclonal antibody. 38. An isolated antibody according to claim 36, wherein said human islet cell antigen polypeptide is a full length human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 39. A hybridoma which produces a monoclonal antibody which specifically binds to a human islet cell antigen polypeptide, wherein said human islet cell antigen polypeptide comprises an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) . 40. A hybridoma according to claim 39, wherein said human islet cell antigen polypeptide is a full length human islet cell antigen polypeptide comprising the amino acid sequence of SEQ ID NO:22 from Leu, amino acid residue 442 to Arg, amino acid residue 738. 41. A diagnostic kit for use in detecting an autoantibody to pancreatic β-islet cells, comprising a container containing a human islet cell antigen polypeptide wherein said human islet cell antigen polypeptide comprises an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) , wherein said polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM, and one or more containers containing additional reagents. 42. A pharmaceutical composition which comprises a human islet cell antigen polypeptide, wherein said human islet cell antigen polypeptide comprises an amino acid sequence selected from the group consisting of: a) SEQ ID NO:22 from Leu, amino acid residue 442 to Gin, amino acid residue 818; b) SEQ ID NO:22 from Phe, amino acid residue 418, to Gin, amino acid residue 818; c) a polypeptide of SEQ ID NO:22 from His, amino acid residue 1, to Gin, amino acid residue 818; and d) allelic variants of (a) , (b) or (c) , wherein said polypeptide forms an immune complex with an autoantibody from a patient at risk of or predisposed to develop IDDM in combination with a pharmaceutically acceptable carrier or vehicle. 43. A method for monitoring the disease state in a patient comprising: testing a biological sample from a patient for the presence of mammalian islet cell antigen post-translationally modified polypeptides; determining the concentration of said polypeptides; and correlating levels of said polypeptides in said sample with the disease state in a patient. 44. A method for monitoring the disease state in a patient according to claim 43 wherein said human islet cell antigen post-translationally modified polypeptide comprise the sequence of SEQ ID NO:22 from His, amino acid residue 1 to Glu, amino acid residue 227. 45. A method for monitoring the disease state in a patient according to claim 43 wherein said biological sample is plasma or serum. 46. A method for monitoring the disease state in a patient comprising: exposing T cells to islet cell antigen 1851 peptides; detecting T cell reactivity; and correlating T cell reactivity with disease state. 47. A method for monitoring the disease state according to claim 46 wherein said T cells are from peripheral blood mononuclear cells from a prediabetic patient. 48. A method for monitoring the disease state according to claim 46 wherein said disease state is conversion from prediabetes to diabetes.

Inventors: HAGOPIAN WILLIAM, JELINEK LAURA, KINDSVOGEL WAYNE, LAGASSE JAMES, SHEPPARD PAUL O, HAGOPIAN, WILLIAM, JELINEK, LAURA, KINDSVOGEL, WAYNE, LAGASSE, JAMES, SHEPPARD, PAUL, O.
Applicants: UNIV WASHINGTON, ZYMOGENETICS INC, UNIVERSITY OF WASHINGTON, ZYMOGENETICS, INC.
Application year: 1997
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N9, C12N15